DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-25-26

Baltimore, Maryland 21244-1850



State Demonstrations Group

January 13, 2025

Janet Mann
Deputy Secretary and Medicaid Director
Arkansas Department of Human Services
P.O. Box 1437
Slot S201
Little Rock, AR 72203-1437

Dear Director Mann:

Arkansas submitted the New Initiatives Implementation Plan on June 30, 2023, in accordance with special terms and conditions (STC), specifically STC 64. The Centers for Medicare and Medicaid Services is approving the Implementation Plan, as an attachment to the STCs for Arkansas's section 1115 demonstration project entitled, "Arkansas Healthy Opportunity for Me (ARHOME)" (Project No. 11-W-00365/4), effective through December 31, 2026. A copy of the approved attachment is enclosed and will be incorporated into the STCs as Attachment D.

This approval is conditioned upon compliance with the previously approved STCs, which set forth in detail the nature, character, and extent of anticipated federal involvement in the project.

We look forward to our continued partnership on the Arkansas Healthy Opportunity for Me (ARHOME) section 1115 demonstration. If you have any questions, please contact your CMS project officer, Kamia Rathore at Kamia.Rathore@cms.hhs.gov.

Sincerely,

Andrea J. Digitally signed by Andrea J. Casart -S Date: 2025.01.13 15:40:42 -05'00'

Andrea J. Casart Director Division of Eligibility and Coverage Demonstrations

Page 2 – Director Janet Mann

cc: Lee Herco, State Monitoring Lead, CMS Medicaid and CHIP Operations Group

Enclosures: Attachment D - New Initiatives Implementation Plan

CENTERS FOR MEDICARE AND MEDICAID SERVICES EXPENDITURE AUTHORITY

NUMBER: 11-W-00379/6

TITLE: Arkansas Health and Opportunity for Me Section 1115

Demonstration

AWARDEE: Arkansas Department of Human Services

Under the authority of section 1115(a)(2) of the Social Security Act (the Act), expenditures made by the state for the items identified below, which are not otherwise included as expenditures under section 1903 shall, for the period of this demonstration from January 1, 2022 through December 31, 2026, unless otherwise stated, be regarded as expenditures under the state's Title XIX plan, but are further limited by the special terms and conditions (STCs) for the Arkansas Health and Opportunity for Me (ARHOME) section 1115 demonstration.

As discussed in the Centers for Medicare & Medicaid Services' (CMS) amendment approval letter, the Secretary of Health and Human Services has determined that the ARHOME section 1115 demonstration, including the granting of the waiver and expenditure authorities described below, is likely to assist in promoting the objectives of title XIX of the Social Security Act.

- 1. Premium Assistance and Cost Sharing Reduction Payments. Expenditures for part or all of the cost of private insurance premiums in the individual market, and for payments to reduce cost sharing under such coverage for certain beneficiaries as described in these STCs.
- 2. Life360 HOMEs and Health-Related Social Needs (HRSN) Services. Effective November 1, 2022, expenditures for approved evidence-based health-related social needs services not otherwise eligible for Medicaid payment furnished to individuals who meet the qualifying criteria as described in STC 44.
- **3.** Expenditures for Life360 HOME Services Infrastructure. Effective November 1, 2022, expenditures for allowable administrative costs and infrastructure not otherwise eligible for Medicaid payment, to the extent such activities are authorized as part of the approved Infrastructure activities in STC 42.
- **4. Maternal Life360 HOME Services.** Expenditures for Maternal Life360 HOME services for up to 2 years postpartum for individuals with high risk pregnancies, as defined by their physician, who become ineligible for Medicaid coverage during their enrollment in a Maternal Life360 HOME.

Requirements Not Applicable to Expenditure Authorities:

1. Cost Effectiveness

Section 1902(a)(4) and 42 CFR 435.2025(a)(4)

Page 1 of 146

Arkansas Health and Opportunity for Me Approval Period: January 1, 2022 through December 31, 2026 Amended: January 13, 2025 To the extent necessary to permit the state to offer, with respect to beneficiaries through qualified health plans, premium assistance and cost sharing reduction payments that are determined to be cost effective using state developed tests of cost effectiveness that differ from otherwise permissible tests for cost effectiveness as described in these STCs.

2. Amount, Duration, and Scope of Services and Comparability Section 1902(a)(10)(B) and 1902(a)(17)

To the extent necessary to allow the state to offer Life360 HOME services as described in STC 40.

To the extent necessary to enable the state to provide Life360 HOME services based on systems of service that are not otherwise available to all beneficiaries in the same eligibility group.

3. Statewideness Section1902(a)(1)

To the extent necessary to enable the State to provide Life360 HOME services on a less than statewide basis.

4. Freedom of Choice

Section 1902(a)(23)(A)

To the extent necessary to enable Arkansas to limit beneficiaries' freedom of choice with respect to Life360 HOME Services to providers participating in a Life360 HOME.

CENTERS FOR MEDICARE & MEDICAID SERVICES WAIVER LIST

NUMBER: 11-W-00379/6

TITLE: Arkansas Health and Opportunity for Me Section 1115

Demonstration

AWARDEE: Arkansas Department of Human Services

All requirements of the Medicaid program expressed in law, regulation, and policy statement, not expressly waived or identified as not applicable in accompanying expenditure authorities, shall apply to the demonstration project effective January 1, 2022 through December 31, 2026. In addition, these waivers may only be implemented consistent with the approved Special Terms and Conditions (STCs).

Under the authority of section 1115(a)(1) of the Social Security Act (the Act), the following waivers of state plan requirements contained in section 1902 of the Act are granted for the ARHOME Section 1115 demonstration, subject to the STCs.

1. Freedom of Choice

Section 1902(a)(23)(A)

To the extent necessary to enable Arkansas to limit beneficiaries' freedom of choice among providers to the providers participating in the network of the beneficiary's Qualified Health Plan. No waiver of freedom of choice is authorized for family planning providers.

2. Payment to Providers

Section 1902(a)(13) and Section 1902(a)(30)

To the extent necessary to permit Arkansas to provide for payment to providers equal to the market-based rates determined by the Qualified Health Plan.

3. Prior Authorization

Section 1902(a)(54) insofar as it incorporates Section 1927(d)(5)

To permit Arkansas to require that requests for prior authorization for drugs be addressed within 72 hours, and for expedited review in exigent circumstances within 24 hours, rather than 24 hours for all circumstances as is currently required in their state policy. A 72- hour supply of the requested medication will be provided in the event of an emergency.

4. Premiums

Section 1902(a)(14) insofar as it incorporates Sections 1916 and 1916A

To the extent necessary to enable Arkansas to collect monthly premium payments, for

Page 3 of 146

Arkansas Health and Opportunity for Me Approval Period: January 1, 2022 through December 31, 2026 Amended: January 13, 2025 beneficiaries with incomes above 100 up to and including 133 percent of the federal poverty level (FPL) as described in these STCs. This waiver authority will sunset on December 31, 2022.

5. Comparability

Section 1902(a)(10)(B)

To the extent necessary to enable the state to impose targeted cost sharing on beneficiaries as described in these STCs.

6. Retroactive Eligibility

Section 1902(a)(34)

To enable the state to not provide beneficiaries in table 1 retroactive eligibility but for 30 days prior to the date of the application for coverage under the demonstration.

CENTERS FOR MEDICARE AND MEDICAID SERVICES SPECIAL TERMS AND CONDITIONS

NUMBER: 11-W-00379/6

TITLE: Arkansas Health and Opportunity for Me

AWARDEE: Arkansas Department of Human Services

I. PREFACE

The following are the Special Terms and Conditions (STCs) for the Arkansas Health and Opportunity for Me (ARHOME) section 1115(a) Medicaid demonstration (hereinafter demonstration) to enable the Arkansas Department of Human Services (state) to operate this demonstration. The Centers for Medicare & Medicaid Services (CMS) has granted waivers of requirements under section 1902(a) of the Social Security Act (Act), and expenditure authorities authorizing federal matching of demonstration costs that are not otherwise matchable, and which are separately enumerated. These STCs set forth in detail the nature, character, and extent of federal involvement in the demonstration and the state's obligations to CMS during the life of the demonstration.

These STCs are effective January 1, 2022 through December 31, 2026, unless otherwise stated.

The STCs have been arranged into the following subject areas:

- I. Preface
- II. Program Description and Objectives
- III. General Program Requirements
- IV. ARHOME Program Populations Affected
- V. ARHOME Premium Assistance Enrollment
- VI. Premium Assistance Delivery System
- VII. Benefits
- VIII. Improving Health Outcomes Through Intensive Care Coordination for Populations Most At Risk of Poor Health (Life360 HOMEs)
- IX. Premiums & Cost Sharing
- X. Fair Hearings
- XI. Monitoring and Reporting Requirements
- XII. General Financial Requirements
- XIII. Monitoring Budget Neutrality
- XIV. Evaluation of the Demonstration
- XV. Schedule of Deliverables

Attachment A: Copayment Amounts

Attachment B: Developing the Evaluation Design

Attachment C: Preparing the Interim and Summative Evaluation Reports

Page 5 of 146

Arkansas Health and Opportunity for Me Approval Period: January 1, 2022 through December 31, 2026 Amended: January 13, 2025 Attachment D: New Initiatives Implementation Plan

Attachment E: Monitoring Protocol (reserved)

Attachment F: Evaluation Design (reserved)

Attachment G: Life360 HOME Definitions and Eligibility

Attachment H: Life360 HOME Services Details (reserved)

Attachment I: Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure

Planning, and Provider Qualifications

Attachment J: Amendments to Expenditure Authorities and Special Terms and Conditions

Effective December 20, 2024

II. PROGRAM DESCRIPTION AND OBJECTIVES

Under the prior section 1115 demonstration, Arkansas Works, the state provided premium assistance to support the purchase by beneficiaries eligible under the adult group under the state plan of coverage from qualified health plans (QHPs) offered in the individual market through the Marketplace. Enrollment activities for the adult population began on October 1, 2013, for QHPs with eligibility effective January 1, 2014. Beginning in 2014, individuals eligible for coverage under the adult group are described at Section 1902(a)(10)(A)(i)(VIII) of the Social Security Act and were further specified in the state plan. The Arkansas Works demonstration terminated on December 31, 2021.

Effective January 1, 2022, the ARHOME demonstration began providing the premium assistance for the adult group.

As of November 1, 2022, the ARHOME demonstration will also provide additional supportive services to targeted populations through Life360 HOMEs, as specified in these STCs. Life360 HOMEs will provide participants with intensive care coordination to connect them to needed health services and community supports, address health-related social needs (HRSN), and actively engage them in promoting their own health. Beneficiary participation in a Life360 HOME will be voluntary and services available under a Life360 HOME will be supplemental to any medical services already covered by the beneficiary's QHP or Medicaid fee for service (FFS). ARHOME will create three types of Life360 HOMEs:

- 1. Maternal Life360 HOMEs will support individuals with high-risk pregnancies, as identified by their physician, and up to two years post-partum, even if the individual is no longer eligible for Medicaid under any other category, either through Maternal Life360 HOME's provision of evidence-based home visitation or through contracts with evidence-based home visitation programs; ¹
- 2. Rural Life360 HOMEs will support individuals with a serious mental illness (SMI) or substance use disorder (SUD) diagnosis who live in rural areas of the state through

Page 6 of 146

¹ The Maternal Life360 HOME will include leveraging the state home visiting program infrastructure that is being implemented in counties statewide and administered by the Arkansas Department of Health with Maternal, Infant and Early Childhood Home Visiting (MIECHV) program to expand current access and capacity for evidence-based home visiting for high-risk pregnant individuals. Funding authorized under this demonstration will expand access to this home visiting program and current funding levels for MIECHV will not be reduced.

- intensive care coordination provided directly or through contracts with organizations to provide care coordination; and
- 3. Success Life360 HOMEs will support young adults (ages 19-27) at high-risk for long-term poverty due to prior incarceration, involvement with the foster care system, or young adults (ages 19-24) with involvement with the juvenile justice system and veterans ages 19-30 who are at high risk of homelessness. Success Life360s will provide intensive care coordination directly or contract with organizations to provide care coordination.

Throughout the demonstration period, the state will work towards achieving several demonstration goals. These goals will inform the state's Evaluation Design hypotheses, subject to CMS approval, as described in these STCs. The demonstration's goals include, and are not limited to, the following:

- Providing continuity of coverage for individuals,
- Improving access to providers,
- Improving continuity of care across the continuum of coverage, and
- Furthering quality improvement and delivery system reform initiatives that are successful across population groups.
- Improving the health outcomes among Arkansans especially in maternal and infant health, rural health, behavioral health, and those with chronic diseases
- Providing supports to assist individuals, especially young adults in target populations, to move out of poverty; and
- Slowing the rate of growth in federal and state spending on the program so the demonstration will be financially sustainable.

Arkansas proposes that the demonstration will provide integrated coverage for low-income Arkansans, leveraging the efficiencies and experience of the private market to improve continuity, access, and quality of care for ARHOME beneficiaries that should ultimately result in lowering the rate of growth in premiums across population groups. The state proposes that the demonstration will also drive structural health care system reform and more competitive premium pricing for all individuals purchasing coverage through the Marketplace by at least doubling the size of the population enrolling in QHPs offered through the Marketplace. The state proposes to demonstrate the following key features:

Continuity of coverage and care - The demonstration will allow qualifying households to stay enrolled in the same plan regardless of whether their coverage is subsidized through Medicaid, or Advanced Premium Tax Credits (APTC).

Support equalization of provider reimbursement and improve provider access - The demonstration will support equalization of provider reimbursement across payers, toward the end of expanding provider access and eliminating the need for providers to cross-subsidize. Arkansas Medicaid provides rates of reimbursement lower than Medicare or commercial payers, causing some providers to forego participation in the program and others to "cross subsidize" their Medicaid patients by charging more to private insurers.

Integration, efficiency, quality improvement and delivery system reform - Arkansas is proposing taking an integrated and market-based approach to covering uninsured Arkansans. It is anticipated that QHPs will bring the experience of successful private sector models that can improve access to high quality services and lead delivery system reform.

III. GENERAL PROGRAM REQUIREMENTS

- 1. Compliance with Federal Non-Discrimination Statutes. The state must comply with all applicable federal statutes relating to non-discrimination. These include, but are not limited to, the Americans with Disabilities Act of 1990 (ADA), Title VI of the Civil Rights Act of 1964, Section 504 of the Rehabilitation Act of 1973 (Section 504), the Age Discrimination Act of 1975, and Section 1557 of the Affordable Care Act (Section 1557).
- 2. Compliance with Medicaid and Children's Health Insurance Program (CHIP) Law, Regulation, and Policy. All requirements of the Medicaid program and CHIP programs, expressed in federal law, regulation, and policy statement, that are not expressly waived or identified as not applicable in the waiver and expenditure authority documents (of which these terms and conditions are part), apply to the demonstration.
- 3. Changes in Medicaid and CHIP Law, Regulation, and Policy. The state must, within the timeframes specified in federal law, regulation, or policy statement, come into compliance with changes in law, regulation, or written policy affecting the Medicaid or CHIP programs that occur during this demonstration approval period, unless the provision being changed is expressly waived or identified as not applicable. In addition, CMS reserves the right to amend the STCs to reflect such changes and/or changes of as needed without requiring the state to submit an amendment to the demonstration under STC 7. CMS will notify the state 30 calendar days in advance of the expected approval date of the amended STCs to allow the state to provide comment. Changes will be considered in force upon issuance of the approval letter by CMS. The state must accept the changes in writing.

4. Impact on Demonstration of Changes in Federal Law, Regulation, and Policy.

- a. To the extent that a change in federal law, regulation, or written policy requires either a reduction or an increase in federal financial participation (FFP) for expenditures made under this demonstration, the state must adopt, subject to CMS approval, a modified budget neutrality agreement and/or a modified allotment neutrality worksheet for the demonstration as necessary to comply with such change. The modified budget neutrality and/or modified allotment neutrality agreement will be effective upon the implementation of the change. The trend rates for the budget neutrality agreement are not subject to change under this subparagraph. Further, the state may seek an amendment to the demonstration (as per STC 7 of this section) as a result of the change in FFP.
- b. If mandated changes in the federal law, regulation, or policy require state legislation, unless otherwise prescribed by the terms of the federal law, the

changes must take effect on the earlier day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the law, whichever is sooner.

- 5. State Plan Amendments. The state will not be required to submit title XIX or title XXI state plan amendments (SPAs) for changes affecting any populations made eligible solely through the demonstration. If a population eligible through the Medicaid or CHIP state plan is affected by a change to the demonstration, a conforming amendment to the appropriate state plan is required, except as otherwise noted in these STCs. In all such instances the Medicaid and CHIP state plan governs.
- 6. Changes Subject to the Amendment Process. Changes related to eligibility, enrollment, benefits, beneficiary rights, delivery systems, cost sharing, evaluation design, sources of non-federal share of funding, budget neutrality, and other comparable program elements must be submitted to CMS as amendments to the demonstration. All amendment requests are subject to approval at the discretion of the Secretary in accordance with section 1115 of the Act. The state must not implement or begin operational changes to these demonstration elements without prior approval. Amendments to the demonstration are not retroactive and no FFP of any kind, including for administrative or medical assistance expenditures, will be available for amendments to the demonstration that have not been approved through the amendment process set forth in STC 7 below, except as provided in STC 3 or as otherwise specified in the STCs.
- 7. Amendment Process. Requests to amend the demonstration must be submitted to CMS for approval no later than 120 calendar days prior to the planned date of implementation of the change and may not be implemented until approved. CMS reserves the right to deny or delay approval of a demonstration amendment based on non-compliance with these STCs, including but not limited to failure by the state to submit required elements of a complete amendment request as described in this STC, and failure by the state to submit required reports and other deliverables according to the deadlines specified herein. Amendment requests must include, but are not limited to, the following:
 - a. An explanation of the public notice process used by the state, consistent with the requirements of STC 13. Such explanation must include a summary of any public feedback received and identification of how this feedback was addressed by the state in the final amendment request submitted to CMS;
 - b. A detailed description of the amendment including impact on beneficiaries, with sufficient supporting documentation;
 - c. A data analysis worksheet which identifies the specific "with waiver" impact of the proposed amendment on the current budget neutrality agreement. Such analysis must include current total computable "with waiver" and "without waiver" status on both a summary and detailed level through the current approval period using the most recent actual expenditures, as well as summary and detailed projections of the change in the "with waiver" expenditure total as a result of the proposed amendment, which isolates (by Eligibility Group) the impact of the amendment;

- d. An up-to-date CHIP allotment neutrality worksheet, if necessary; and
- e. The state must provide updates to existing demonstration reporting and quality and evaluation plans. This includes a description of how the evaluation design and annual progress reports will be modified to incorporate the amendment provisions, as well as the oversight, monitoring and measurement of the provisions.
- **8. Extension of the Demonstration.** States that intend to request an extension of the demonstration must submit an application to CMS from the Governor of the state in accordance with the requirements of 42 CFR § 431.412(c). States that do not intend to request an extension of the demonstration beyond the period authorized in these STCs must submit a phase-out plan consistent with the requirements of STC 9.
- **9. Demonstration Phase Out.** The state may only suspend or terminate this demonstration in whole, or in part, consistent with the following requirements.
 - a. **Notification of Suspension or Termination.** The state must promptly notify CMS in writing of the reason(s) for the suspension or termination, together with the effective date and a draft transition and phase-out plan. The state must submit a notification letter and a draft plan to CMS no less than 6 months before the effective date of the demonstration's suspension or termination. Prior to submitting the draft plan to CMS, the state must publish on its website the draft transition and phase-out plan for a 30-day public comment period. In addition, the state must conduct tribal consultation in accordance with STC 13, if applicable. Once the 30-day public comment period has ended, the state must provide a summary of the issues raised by the public during the comment period and how the state considered the comments received when developing the revised transition and phase-out plan.
 - b. **Transition and Phase-out Plan Requirements**. The state must include, at a minimum, in its phase-out plan the process by which it will notify affected beneficiaries, the content of said notices (including information on the beneficiary's appeal rights), the process by which the state will conduct redeterminations of Medicaid or CHIP eligibility prior to the demonstration for the affected beneficiaries, and ensure ongoing coverage for eligible beneficiaries, as well as any community outreach activities the state will take to notify affected beneficiaries, including community resources that are available.
 - c. **Transition and Phase-out Plan Approval.** The state must obtain CMS approval of the transition and phase-out plan prior to the implementation of transition and phase-out activities. Implementation of transition and phase-out activities must begin no sooner than 14 calendar days after CMS approval of the transition and phase-out plan.
 - d. **Transition and Phase-out Procedures.** The state must redetermine eligibility for all affected beneficiaries in order to determine if they qualify for Medicaid eligibility under a different eligibility category prior to making a determination of ineligibility as required under 42 CFR 435.916(f)(1) or for children in CHIP consider eligibility for other insurance affordability programs under 42 CFR

- 457.350. For individuals determined ineligible for Medicaid and CHIP, the Commonwealth must determine potential eligibility for other insurance affordability programs and comply with the procedures set forth in 42 CFR 435.1200(e). The state must comply with all applicable notice requirements for Medicaid found in 42 CFR, part 431 subpart E, including sections 431.206 through 431.214 or for CHIP found at 42 CFR 457.340(e), including information about a right to a review consistent with 42 CFR 457.1180. In addition, the state must assure all applicable Medicaid appeal and hearing rights are afforded to Medicaid beneficiaries in the demonstration as outlined in 42 CFR, part 431 subpart E, including sections 431.220 and 431.221. If a beneficiary in the demonstration requests a hearing before the date of action, the state must maintain Medicaid benefits as required in 42 CFR §431.230.
- e. **Exemption from Public Notice Procedures 42 CFR Section 431.416(g).** CMS may expedite the federal and state public notice requirements under circumstances described in 42 CFR 431.416(g).
- f. **Enrollment Limitation during Demonstration Phase-Out.** If the state elects to suspend, terminate, or not extend this demonstration, during the last six months of the demonstration, enrollment of new individuals into the demonstration must be suspended. The limitation of enrollment into the demonstration does not impact the state's obligation to determine Medicaid eligibility in accordance with the approved Medicaid state plan.
- g. **Federal Financial Participation (FFP).** If the project is terminated or any relevant waivers are suspended by the state, FFP must be limited to normal closeout costs associated with the termination or expiration of the demonstration including services, continued benefits as a result of beneficiaries' appeals, and administrative costs of disenrolling beneficiaries.
- 10. CMS Right to Terminate or Suspend. CMS may suspend or terminate the demonstration, in whole or in part, at any time before the date of expiration, whenever it determines following a hearing that the state has materially failed to comply with the terms of the project. CMS must promptly notify the state in writing of the determination and the reasons for the suspension or termination, together with the effective date.
- 11. Withdrawal of Waiver or Expenditure Authority. CMS reserves the right to withdraw waivers and/or expenditure authorities at any time it determines that continuing the waiver or expenditure authorities would no longer be in the public interest or promote the objectives of title XIX or title XXI. CMS will promptly notify the state in writing of the determination and the reasons for the withdrawal, together with the effective date, and afford the state an opportunity to request a hearing to challenge CMS's determination prior to the effective date. If a waiver or expenditure authority is withdrawn, FFP is limited to normal closeout costs associated with terminating the waiver or expenditure authority, including services, continued benefits as a result of beneficiary appeals, and administrative costs of disenrolling beneficiaries.

- 12. Adequacy of Infrastructure. The state must ensure the availability of adequate resources for implementation and monitoring of the demonstration, including education, outreach, and enrollment; maintaining eligibility systems; compliance with cost sharing requirements; and reporting on financial and other demonstration components.
- 13. Public Notice, Tribal Consultation, and Consultation with Interested Parties. The state must comply with the state notice procedures as required in 42 CFR 431.408 prior to submitting an application to extend the demonstration. For applications to amend the demonstration, the state must comply with the state notice procedures set forth in 59 Fed. Reg. 49249 (September 27, 1994) prior to submitting such request. The state must also comply with the public notice procedures set forth in 42 CFR 447.205 for changes in statewide methods and standards for setting payment rates.

In states with federally recognized Indian tribes, consultation must be conducted in accordance with the consultation process outlined in the July 17, 2001, letter or the consultation process in the state's approved Medicaid state plan if that process is specifically applicable to consulting with tribal governments on waivers (42 CFR Section 431.408(b)(2)).

- **14. Federal Financial Participation (FFP).** No federal matching for expenditures under this demonstration, including for administrative and medical assistance expenditures, will be available until the effective date identified in the demonstration approval letter, or if later, as expressly stated within these STCs.
- 15. Administrative Authority. When there are multiple entities involved in the administration of the demonstration, the Single State Medicaid Agency must maintain authority, accountability, and oversight of the program. The State Medicaid Agency must exercise oversight of all delegated functions to operating agencies, managed care plans, and any other contracted entities. The Single State Medicaid Agency is responsible for the content and oversight of the quality strategies for the demonstration.
- 16. Common Rule Exemption. The state shall ensure that the only involvement of human subjects in research activities that may be authorized and/or required by this demonstration is for projects which are conducted by or subject to the approval of CMS, and that are designed to study, evaluate, or otherwise examine the Medicaid or CHIP program including public benefit or service programs; procedures for obtaining Medicaid or CHIP benefits or services; possible changes in or alternatives to Medicaid or CHIP programs and procedures; or possible changes in methods or levels of payment for Medicaid and CHIP benefits or services under those programs. CMS has determined that this demonstration as represented in these approved STCs meets the requirements for exemption from the human subject research provisions of the Common Rule set forth in 45 CFR 46.104(b)(5).
- IV. ARKANSAS HEALTH AND OPPORTUNITY FOR ME (ARHOME) PROGRAM POPULATIONS AFFECTED

The state will use this demonstration to ensure coverage for ARHOME eligible beneficiaries provided primarily through QHPs offered in the individual market instead of the FFS delivery system that serves the traditional Medicaid population. The state will provide premium assistance to aid ARHOME beneficiaries in enrolling in coverage through QHPs in the Marketplace.

17. Populations Affected by the ARHOME Demonstration. Except as described in STCs 18 and 19, the ARHOME demonstration affects adults aged 19 through 64 eligible under the state plan under section 1902(a)(10)(A)(i)(VIII) of the Act and 42 CFR Section 435.119 (the adult group). Eligibility and coverage for ARHOME beneficiaries are subject to all applicable Medicaid laws and regulations in accordance with the Medicaid state plan, except as expressly waived in this demonstration and as described in these STCs. Any Medicaid state plan amendments that apply to the adult group will apply to this demonstration.

Table 1. Eligibility Groups

Eligibility Group	Federal Poverty Level	Services	Funding
			Stream
Adult Group	Adults up to and including 133 percent of the	All services	Title XIX
	FPL who meet the other criteria specified in	authorized	
	Section 1902(a)(10)(A)(i)(VIII) of the Social	through the	
	Security Act	demonstration	
Maternal Life360	Individuals enrolled in a Maternal Life360	Maternal	1115
HOME non-Medicaid	HOME who become ineligible for Medicaid	Life360	demonstration
Eligible Individuals	coverage for up to two years, consistent with	Services only	
-	expenditure authority 4.		
	-		

- 18. Medically Frail Individuals. Arkansas has instituted a process to determine whether a beneficiary is medically frail. The process is described in the Alternative Benefit state plan. Beneficiaries excluded from enrolling in QHPs through the ARHOME as a result of a determination of medical frailty as defined in the Alternative Benefit Plan (ABP) state plan amendment (SPA) will have the option of receiving direct coverage through the state of either the same ABP offered to the beneficiaries or an ABP that includes all benefits otherwise available under the approved Medicaid state plan (the standard Medicaid benefit package). Direct coverage will be provided through a FFS system or the PASSE program.
- 19. American Indian/Alaska Native Individuals. Beneficiaries identified as American Indian or Alaskan Native (AI/AN) will not be required to enroll in QHPs in this demonstration, but can choose to opt into a QHP. New applicants will be subject to provisions of STC 17 and coverage will begin 30 days prior to the date an application is submitted for coverage. Beneficiaries who are AI/AN and who have not opted into a QHP will receive the ABP through a FFS system. An AI/AN beneficiary will be able to

access covered benefits through Indian Health Service (IHS), Tribal or Urban Indian Organization (collectively, I/T/U) facilities funded through the IHS. Under the Indian Health Care Improvement Act (IHCIA), I/T/U facilities are entitled to payment notwithstanding network restrictions.

20. Retroactive Eligibility. The state will only provide coverage effective 30 days prior to the date a beneficiary submits an application. All other regulations governing retroactive eligibility are otherwise consistent with the requirements of 42 CFR 435.915, for coverage for beneficiaries in table 1.

V. ARKANSAS HEALTH AND OPPORTUNITY FOR ME (ARHOME) PREMIUM ASSISTANCE ENROLLMENT

- **21. ARHOME.** For ARHOME beneficiaries, except as noted in STCs 18 and 19, enrollment in a QHP is a condition of receiving benefits.
- **QHP Selection.** The QHPs in which ARHOME beneficiaries enroll are certified through the Arkansas Insurance Department's QHP certification process. The QHPs available for selection by the beneficiary are determined by the Medicaid agency.
- 23. Auto-assignment. In the event that a beneficiary is determined eligible for coverage through the ARHOME QHP premium assistance program, but does not select a plan, the state will auto-assign the beneficiary to one of the available QHPs in the beneficiary's rating area. Beneficiaries who are auto-assigned will be notified of their assignment, and the effective date of QHP enrollment, and will be given a thirty-day period from the date of enrollment to request enrollment in another plan.
- **24. Distribution of Members Auto-assigned.** ARHOME QHP auto-assignments will be distributed among QHP issuers in good standing with the Arkansas Insurance Department offering certified silver-level QHPs certified by the Arkansas Insurance Department.
- **25. Changes to Auto-assignment Methodology.** The state will advise CMS prior to implementing a change to the auto-assignment methodology.
- **26. Disenrollment.** Beneficiaries may be disenrolled from the demonstration if they are determined to be medically frail after they were previously determined eligible.

VI. PREMIUM ASSISTANCE DELIVERY SYSTEM

- 27. Memorandum of Understanding for QHP Premium Assistance. The Arkansas Department of Human Services and the Arkansas Insurance Department have entered into a memorandum of understanding (MOU) with each QHP that enrolls beneficiaries. Areas to be addressed in the MOU include, but are not limited to:
 - a. Enrollment of beneficiaries in populations covered by the demonstration;

- b. Payment of premiums and cost sharing reductions, including the process for collecting and tracking beneficiary premiums and cost sharing, and ceasing premium collections;
- c. Reporting and data requirements necessary to monitor and evaluate the ARHOME demonstration including those referenced in STCs 65 and 66, ensuring beneficiary access to Early and Periodic Screening, Treatment and Diagnosis (EPSDT) and other covered benefits through the QHP;
- d. Requirement for QHPs to provide, consistent with federal and state laws, claims and other data as requested to support state and federal evaluations, including any corresponding state arrangements needed to disclose and share data, as required by 42 CFR 431.420(f)(2), to CMS or CMS's evaluation contractors.
- e. Noticing requirements; and
- f. Audit rights.
- **28. Qualified Health Plans.** The state will use premium assistance to support the purchase of coverage for ARHOME beneficiaries through Marketplace QHPs.
- **29. Choice of QHPs.** Each ARHOME beneficiary required to enroll in a QHP will have the option to choose between at least two silver plans covering only Essential Health Benefits (EHBs) that are offered in the individual market through the Marketplace. The state will pay the full cost of QHP premiums, less the cost of the premium paid by the beneficiary in accordance with these STCs.
 - a. ARHOME beneficiaries will be able to choose from at least two silver plans covering only EHBs that are in each rating area of the State.
 - b. ARHOME beneficiaries will be permitted to choose among all silver plans covering only EHBs that are offered in their geographic area and that meet the purchasing guidelines established by the State in that year, and thus all ARHOME beneficiaries will have a choice of at least two QHPs.
 - c. The state will comply with Essential Community Provider network requirements, as part of the QHP certification process.
 - d. ARHOME beneficiaries will have access to the same networks as other beneficiaries enrolling in QHPs through the individual Marketplace.
- **30.** Coverage Prior to Enrollment in a QHP. The state will provide coverage through FFS Medicaid from the date a beneficiary is determined eligible until the beneficiary's enrollment in the QHP becomes effective.
 - a. For beneficiaries who enroll in a QHP (whether by selecting the QHP or through auto-assignment) between the first and fifteenth day of a month, QHP coverage will become effective as of the first day of the month following QHP enrollment.
 - b. For beneficiaries who enroll in a QHP (whether by selecting the QHP or through auto-assignment) between the sixteenth and last day of a month, QHP coverage will become effective as of the first day of the second month following QHP selection (or auto-assignment).

- **31. Family Planning.** If family planning services are accessed at a facility that the QHP considers to be an out-of-network provider, the state's FFS Medicaid program will cover those services.
- **32. Non-Emergency Medical Transportation (NEMT).** Non-emergency medical transport services will be provided through the state's FFS Medicaid program. See STC 39 for further discussion of non-emergency medical transport services.
- 33. Access to Federally Qualified Health Centers (FQHC) and Rural Health Centers (RHC). ARHOME beneficiaries will have access to at least one QHP in each service area that contracts with at least one FQHC and RHC.

VII. BENEFITS

- **34. ARHOME Benefits.** Beneficiaries affected by this demonstration will receive benefits as set forth in section 1905(y)(2)(B) of the Act and codified at 42 CFR Section 433.204(a)(2). These benefits are described in the Medicaid state plan.
- **35. Alternative Benefit Plan.** The benefits provided under an alternative benefit plan for the adult group are reflected in the State ABP state plan.
- **Medicaid Wrap Benefits.** The state will provide through its FFS system wrap-around benefits that are required for the ABP but not covered by QHPs. These benefits include NEMT and EPSDT services for beneficiaries participating in the demonstration who are under age 21.
- 37. Access to Wrap Around Benefits. In addition to receiving an insurance card from the applicable QHP issuer, ARHOME beneficiaries will have a Medicaid Client Identification Number (CIN) through which providers may bill Medicaid for wrap-around benefits. The notice containing the CIN will include information about which services ARHOME beneficiaries may receive through FFS Medicaid and how to access those services. This information is also posted on Arkansas Department of Human Services' Medicaid website and will be provided through information at the Department of Human Service's call centers and through QHP issuers.
- **38.** Early and Periodic Screening, Diagnosis, and Treatment. The State must fulfill its responsibilities for coverage, outreach, and assistance with respect to EPSDT services that are described in the requirements of sections 1905(a)(4)(b) (services), 1902(a)(43) (administrative requirements), and 1905(r) (definitions).
- **39.** Access to Non-Emergency Medical Transportation. The state will establish prior authorization for NEMT in the ABP. Beneficiaries served by IHS or Tribal facilities and medically frail beneficiaries will be exempt from such requirements.

VIII. IMPROVING HEALTH OUTCOMES THROUGH INTENSIVE CARE COORDINATION FOR POPULATIONS MOST AT RISK OF POOR HEALTH (Life360 HOMEs)

- Life360 HOME Services. The state may claim FFP for the evidence-based Life360 **40.** HOME services identified in STC 41, subject to the restrictions described below and in STC 43. There are three types of Life360 HOMEs: Maternal, Success and Rural. Expenditures for some Life360 HOME services are limited to costs not otherwise covered under Title XIX, but consistent with Medicaid demonstration objectives that enable the state to continue to improve health outcomes and increase the efficiency and quality of care. To receive Life360 HOME services, individuals in the targeted populations must have a documented need for the services. Life360 HOME services must be medically appropriate for the beneficiary and based on medical appropriateness using clinical and other health-related social needs criteria. The state is required to align clinical and social risk criteria across services with other non-Medicaid support agencies, to the extent possible. The Life360 HOME services may not supplant any other available funding sources such as housing or nutrition supports available to beneficiaries through local, state or federal programs. The Life360 HOME services will be the choice of the beneficiary; beneficiaries can opt out of Life360 HOME services at any time; and Life360 HOME services do not absolve the state of their responsibility to provide required coverage for other medically necessary services. Under no circumstances will the state be permitted to condition Medicaid coverage, or coverage of any benefit or service, on receipt of Life360 HOME services. The state must submit additional details on covered Life360 HOME services to CMS as outlined in STC 41 and Attachment H.
- **41. Allowable HRSN Services**. The state may cover the following Life360 HOME services in all three Life360 HOME types:
 - a. Housing Supports, including:
 - i. Pre-tenancy and tenancy sustaining services, including tenant rights education and eviction prevention
 - ii. Housing transition navigation services
 - iii. One-time transition and moving costs (e.g., security deposits, first-month's rent, utilities activation fees, movers, and pest eradication)
 - iv. Housing deposits to secure housing, including application and inspection fees and fess to secure needed identification
 - b. Nutrition Supports
 - i. Nutrition counseling and education, including healthy meal preparation
 - c. Case management, outreach, and education including linkages to other state and federal benefit program application assistance, and benefit program application fees, as described in attachment G.

42. Life360 HOME Infrastructure.

a. The state may claim FFP in infrastructure investments in order to support the development and implementation of Life360 HOME services, subject to STC 40. This FFP will be available for the following activities:

- i. Technology- e.g., electronic referral systems, shared data platforms, EHR modifications or integrations, screening tool and/or case management systems, databases/data warehouses, data analytics and reporting, data protections and privacy, accounting and billing systems
- ii. Development of business or operational practices e.g., procurement and planning, developing policies and workflows for referral management, privacy, quality improvement, trauma-informed practices, evaluation, member navigation
- iii. Workforce development e.g., cultural competency training, trauma-informed training, community health worker certification, training staff on new policies and procedures
- iv. Outreach, education, and stakeholder convening e.g., design and production of outreach and education materials, translation, obtaining community input, investments in stakeholder convening
- v. Costs consistent with the above categories necessary for the development of crisis stabilization capacity in rural hospitals to support Rural Life360 HOMEs
- b. The state may claim FFP in Life360 HOME infrastructure expenditures for no more than the annual amounts outlined in Table 2. In the event that the state does not claim the full amount of FFP for a given demonstration year, the unspent amounts will roll over to one or more demonstration years not to exceed this demonstration period and the state may claim the remaining amount in a subsequent demonstration year.

Table 2. Annual Limits in Total Computable LIFE360 HOME Infrastructure

	DY 1	DY 2	DY 3	DY 4	DY 5
	(2022)	(2023)	(2024)	(2025)	(2026)
Total	\$0	\$2.7M	\$1.97M	\$3.0M	\$2.8M
Computable					
Expenditures					

- c. HRSN infrastructure funding must be claimed at the applicable administrative match rate, and approved HRSN Infrastructure funding will be matched at the applicable administrative match for the expenditure.
- d. This HRSN infrastructure funding is separate and distinct from the payment for delivery of Life360 HOME services. The state must ensure that Life360 HOME infrastructure expenditures are not factored into qualified health plan capitation payments, and that there is no duplication of funds.
- e. The state may not claim any FFP in Life360 HOME infrastructure expenditures until the Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure Planning, and Provider Qualifications for Life 360 HOME Services is approved, as described in STC 48. Once approved, the state can claim FFP in Life360 HOME infrastructure expenditures retrospectively to the beginning of the demonstration approval date.

- f. To the extent the state requests any additional infrastructure funding, or changes to its scope as described within this STC, it must submit an amendment to the demonstration for CMS's consideration.
- **43. Excluded Life360 HOME Services.** Excluded items, services and activities that are not covered as Life360 HOME services include, but are not limited to:
 - a. Construction costs (bricks and mortar);
 - b. Capital investments other than those as allowable as HRSN infrastructure as described in STC 42:
 - c. Room and board, except as described in STC 41;
 - d. Research grants and expenditures not related to monitoring and evaluation;
 - e. Costs for services in prisons, correctional facilities or services for people who are civilly committed and unable to leave an institutional setting;
 - f. Services provided to individuals who are not lawfully present in the United States or are undocumented;
 - g. Expenditures that supplant services and activities funded by other state and federal governmental entities;
 - h. School-based programs for children that supplant Medicaid state plan programs, or that are funded under the Department of Education and/or state or the local education agency;
 - i. General workforce activities, not specifically linked to Medicaid or Medicaid beneficiaries; and
 - j. Any other projects or activities not specifically approved by CMS as qualifying for demonstration coverage as Life360 HOME services.
 - 44. Life360 HOMEs Covered Populations. Expenditures for Life360 services may be made for the targeted populations specified below. To receive Life360 HOME services, individuals in the targeted populations must have a documented need for the services and the services must be determined medically appropriate consistent with STC 40. Medical appropriateness must be based on clinical and social risk factors. This determination must be documented in the beneficiary's care plan or medical record. A beneficiary may only participate in one Life360 HOME at a time but may participate in more than one Life360 HOME throughout the demonstration approval period, if eligible. The allowable targeted populations for each of the Life360 HOME types are:
 - a. Maternal Life360 HOMEs will support individuals with high-risk pregnancies, as diagnosed by their physician, and up to two years post-partum, even if the individual is no longer eligible for Medicaid under any other category,² either through the Maternal Life360 HOME's provision of intensive care coordination

_

² If the individual would become no longer eligible for Medicaid under any eligibility category, they would still be able to receive the benefits under the Maternal Life360 HOME,(e.g., intensive care coordination, visiting home nursing and health related social needs assessments) based on continued need. The match for services to people who are no longer eligible for the adult group would be at regular FMAP.

- and evidence-based home visitation or through contracts with evidence-based home visitation programs;³
- b. Rural Life360 HOMEs will support individuals with a serious mental illness (SMI) or substance use disorder (SUD) diagnosis who live in rural areas of the state through provision of intensive care coordination provided directly or through contracts with organizations to provide care coordination; and,
- c. Success Life360 HOMEs will support young adults (ages 19-27) most at risk of long-term poverty due to prior incarceration, involvement with the foster care system, or young adults (ages 19-24) with involvement with the juvenile justice system and veterans ages 19-30 who are at high risk of homelessness. Success Life360 HOMEs will provide intensive care coordination directly or contract with organizations to provide care coordination.
- 45. Definition of Intensive Care Coordination for Life360 HOMEs. The key function of each Life360 HOME is to provide intensive care coordination to identify HRSN and engage with the beneficiary to ensure successful connection to medical services and nonmedical supports in the community to meet the beneficiary's HRSN consistent with these STCs. Intensive Care Coordination means: a collaborative process in which a care coordinator meets regularly virtually or in person with the beneficiary and assesses, plans, implements, coordinates, monitors and evaluates the options, services and supports necessary to meet the beneficiary's health and health-related social needs. It includes advocacy on behalf of participants in health care settings, communication, and resource management and promotes quality interventions and outcomes. In addition to accessing medical services, it includes ensuring that beneficiaries attain and maintain their HRSN service goals identified in their Person-Centered Action Plan (PCAP). The Life360 will develop an individualized PCAP for each beneficiary to address their HRSN. Each beneficiary will have a care coordinator that will directly connect the beneficiary with services and supports needed to meet the goals identified in the PCAP, which should include activities beyond providing a referral. By interacting in person on a regular basis with their beneficiaries, the care coordinator will help beneficiaries develop and strengthen life skills. Maternal Life360 will provide the intensive care coordination within an evidence-based home visiting model during pregnancy and up to 2 years following childbirth.

The use of medical care typically depends on the individual's own initiative to seek care. Care coordinators will go out into the community to meet people where they live. Qualifications of care coordinators will vary depending upon the type of Life360.

Page 20 of 146

³ The Maternal Life360 HOME will include leveraging the state home visiting program infrastructure that is being implemented in counties statewide and administered by the Arkansas Department of Health with Maternal, Infant and Early Childhood Home Visiting (MIECHV) program to expand current access and capacity for evidence-based home visiting for high-risk pregnant individuals. Funding authorized under this demonstration will expand access to this home visiting program and current funding levels for MIECHV will not be reduced.

- **46. Life360 HOMEs Applicant Selection Process.** The following hospitals enrolled as a provider with the Arkansas Medicaid program and as defined as eligible in Arkansas state statute, ⁴ can apply to implement a Life360 HOME:
 - a. Maternal Life360 HOME the hospital must be a birthing facility
 - b. Rural Life360 HOME the hospital must be a rural hospital with 50 or fewer beds
 - c. Success Life360 HOME the hospital must be an acute care facility

There is no limit to the number of HOME types a hospital may establish, consistent with these STCs and subject to state review and approval.

The state must require that Life360 HOME applicants identify the target population(s) to be served (Maternal, Rural, and/or Success), service area and partners as applicable, and complete an analysis of the service area population demographics and a community resource inventory to determine the referral network/gaps and to implement data collection and sharing processes. The state must also require applicants to demonstrate they can provide, or establish contracts to provide, the required supports or model for the target population and will also need to set an annual budget and specifications for IT systems as part of their application.

- **47. Life360 HOME Program Integrity.** The state will ensure that all Life360 payments are made consistent with these STCs. Program integrity activities for Life360 HOMEs will include at a minimum:
 - a. Completing progress reporting on Life360-funded activities. All Selected Applicants will be expected to submit progress reports that document Life360 HOME-funded activities. The state will require hospitals that apply to operate a Life360 HOME and are selected by the state to do so (Selected Applicants) attest to non-duplication of funding with other federal, state, and local funds. The state must monitor for funding irregularities and potential duplication across all Life360 HOMEs.
 - b. **Participating in audit processes.** The state must conduct audits in accordance with all required policies for Medicaid funding to ensure that Life360 HOME funds are being spent on permissible uses and are being reported appropriately. The state must include results from these audits in its Annual Monitoring Reports, which are described in STC 66.
 - c. Ensuring action is taken to address noncompliance. The state will ensure that action is taken to address any identified non-compliance with Life360 HOME funding parameters. If the state determines that a Selected Applicant has failed to demonstrate appropriate performance, including enrolling an insufficient number of beneficiaries, the state may impose corrective actions that may include caps on funding, recoupment of funds, or discontinuation of Life360 HOME funding. The state may also impose corrective actions for a Selected Applicant if it determines the Life360 HOME is out of compliance with requirements set forth in the STCs

-

⁴ A.C.A. § 23-61-1010 and A.C.A. § 23-61-1003

and attachments, the agreement between the Selected Applicant and the state, and/or policy letters or guidance set forth by the state. Prior to initiating any corrective action on a Selected Applicant, the state shall provide the Selected Applicant notice and an opportunity to comment regarding the identified area of non-compliance. CMS reserves the right to require the state to return FFP associated with recoupment of funding for Selected Applicant due to noncompliance.

48. Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure Planning, and Provider Qualifications for Life360 HOMEs. Within 180 days of approval the state must complete and submit to CMS for review and approval a Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure Planning, and Provider Qualifications (Protocol) for conducting the assessment of beneficiary eligibility and needs, Life360 HOME infrastructure, and provider qualifications for Life360 HOME services. This Protocol must include a list of the Life360 HOME services and service descriptions, outlining the name and description of each proposed service, the criteria for defining when each service is medically appropriate, the process by which that criteria will be applied including care plan requirements or other documented processes, proposed uses of Life360 HOME infrastructure, and provider qualification criteria for each service. The state must resubmit an updated protocol if CMS provides feedback on the initial submission. The Protocol may be updated as details are changed or added. The state may not claim FFP for Life360 HOME service or Life360 HOME infrastructure expenditures until CMS approves the protocol. Once approved, the state can claim FFP for Life360 HOME services and Life360 HOME infrastructure expenditures retrospectively to the beginning of the amendment approval date. The approved protocol will be attached to the STCs as Attachment I.

Specifically, the Protocol must include the following information:

- a. Proposed uses of HRSN infrastructure expenditures, including the type of entities to receive funding, the intended purpose of the funding, the projected expenditure amounts, and an implementation timeline
- b. A list of the covered HRSN services (not to exceed those allowed under STC 41), with associated service descriptions and service-specific provider qualification requirements
- c. A description of the process for identifying beneficiaries with health-related social needs, including outlining beneficiary eligibility, implementation settings, screening tool selection, and rescreening approach and frequency, as applicable
- d. A description of the process by which clinical criteria will be applied, including a description of the documented process wherein a provider, using their professional judgment, may deem the service to be medically appropriate
 - i. Plan to identify medical appropriateness based on clinical and social risk factors
 - ii. Plan to publicly maintain these clinical/social risk criteria to ensure transparency for beneficiaries and stakeholders

- e. A description of the process for developing care plans based on assessment of need
 - i. Plan to initiate care plans and closed-loop referrals to social services and community providers based on the outcomes of screening
 - ii. Description of how the state will ensure that HRSN screening and service delivery are provided to beneficiaries in ways that are culturally responsive and/or trauma-informed
- **49. Sources of Non-federal Share of Funding for Life360 Expenditures.** The state shall provide permissible sources for the non-federal share of all Life360 HOME expenditures derived from state funds that do not utilize impermissible provider taxes or intergovernmental transfers (IGTs) as the source of revenue.
- **50. Compliance with Federal Requirements.** The state shall ensure Life360 HOME services are delivered in accordance with all applicable federal statute, regulation or guidance.
- 51. Person-Centered Action Plan. The state shall ensure that there is a person-centered action plan for each individual determined to be eligible for HRSN services through Life360 HOMEs. The person-centered action plan must be person-centered, identify the individual's needs and individualized strategies and interventions for meeting those needs, and be developed in consultation with the individual and the individual's chosen support network as appropriate. The person-centered action plan will be reviewed and revised upon reassessment of need at least every 12 months, when the individual's circumstances or needs change significantly, or at the request of the individual.
- 52. Conflict of Interest. The state shall ensure appropriate protections against conflicts of interest in the service planning and delivery of HRSN services though Life360 HOMEs. The state agrees that appropriate separation of assessment, service planning and service provision functions are incorporated into state and other applicable vendors' conflict of interest policies. In situations where the entity responsible for assessments is also the entity responsible for service planning, the state will ensure the individual responsible for the development of the person-centered action plan will not also be a direct service provider.
- HOME services outlined in these STCs must be submitted to CMS for review and approval at least 60 days prior to implementation. These methodologies, including but not limited to fee-for-service payment as well as non-risk payments and capitation rates in managed care delivery systems, must be included in the New Initiatives Implementation Plan. States must submit all documentation requested by CMS, including but not limited to the payment rate methodology as well as other documentation and supporting information (e.g., state responses to Medicaid non-federal share financing questions). The state must also comply with the Public Notice Procedures

- set forth in 42 CFR 447.205 for changes in statewide methods and standards for setting fee-for-service payment rates.
- 54. Maintenance of Effort (MOE). The state must maintain the level of state funding for social service programs related to housing transitions supports and nutrition supports for the duration of the demonstration. Within 90 days of approval of the Life360 amendment, the state must submit a plan to CMS as part of the New Initiatives Implementation Plan (see STC 64) that outlines how it will assess the current availability of these services throughout the state. The annual MOE will be reported and monitored as part of the Annual Monitoring Reports described in STC 66, including any justifications necessary to describe the findings.
- 55. Partnerships with State and Local Entities. The state must have in place partnerships with other state and local entities (e.g., HUD Continuum of Care Program, local housing authority, SNAP state agency, etc.) to assist beneficiaries in obtaining non-Medicaid funded housing and nutrition supports, if available, upon the conclusion of temporary Medicaid payment for such supports, in alignment with beneficiary needs identified in the person-centered plans as appropriate. The state must submit a plan to CMS as part of the New Initiatives Implementation Plan (see STC 64) that outlines how it will put into place the necessary arrangements with other state and local entities and also work with those entities to beneficiaries in obtaining available non-Medicaid funded housing and nutrition supports upon conclusion of temporary Medicaid payment as stated above. The plan must provide a timeline for the activities outlined. As part of the Quarterly Monitoring Reports described in STC 66, the state will provide the status of the state's fulfillment of its plan and progress relative to timeline, and whether and to what extent the non-Medicaid funding supports are being accessed by beneficiaries as planned. Once the state's plan is fully implemented, the state may conclude its status updates in the Quarterly Monitoring Reports.

IX. PREMIUMS & COST SHARING

- 56. Premiums & Cost Sharing. Cost sharing for ARHOME beneficiaries must be in compliance with federal requirements that are set forth in statute, regulation and policies, including requirements and limitations from cost sharing set forth in 42 CFR Section 447.50-57. Waiver authority for premiums will sunset on December 31, 2022.
- 57. **Premiums & Cost Sharing Parameters for the ARHOME Program.** With the approval of this demonstration:
 - a. Beneficiaries up to and including 20 percent of the FPL will have no cost sharing.
 - b. Beneficiaries above 20 percent of the FPL will have cost sharing consistent with Medicaid requirements beginning January 1, 2023.
 - c. Beneficiaries above 100 percent of the FPL will be required to pay monthly premiums of up to 2 percent of household income until the authority sunsets on December 31, 2022.

- d. Premiums and cost sharing will be subject to an aggregate cap of no more than 5 percent of family quarterly income.
- e. Cost sharing requirements and/or limitations described in 42 CFR 447.50-57 will be applied to all program beneficiaries.
- f. Copayment and coinsurance amounts will be consistent with federal requirements regarding Medicaid cost sharing and with the state's approved state plan; copayment and coinsurance amounts are listed in Attachment A.
- g. Medically frail individuals and American Indian/Alaska Native individuals, and individuals ages 19 and 20, will be exempt from cost sharing.
- 58. Payment Process for Payment of Cost Sharing Reduction to QHPs. Agreements with QHP issuers may provide for advance monthly cost-sharing reduction (CSR) payments to cover the costs associated with the reduced cost sharing for ARHOME beneficiaries. Such payments will be subject to reconciliation at the conclusion of the benefit year based on actual expenditures by the QHP for cost sharing reduction. If a QHP issuer's actuary determines during the benefit year that the estimated advance CSR payments are significantly different than the CSR payments the QHP issuer will be entitled to during reconciliation, the QHP issuer may ask Arkansas' Department of Human Services to adjust the advance payments. Arkansas' reconciliation process will follow 45 CFR Section 156.430 to the extent applicable.
- 59. Grace Period/Debt Collection. The grace period/debt collection process will be consistent with federal requirements regarding Medicaid cost sharing, including requirements at 42 CFR 447.55(b). ARHOME beneficiaries will have two months from the date of the payment invoice to make the required monthly premium contribution. Arkansas and/or its vendor may attempt to collect unpaid premiums and the related debt from beneficiaries, but may not report the debt to credit reporting agencies, place a lien on an individual's home, refer the case to debt collectors, file a lawsuit, or seek a court order to seize a portion of the individual's earnings for beneficiaries at any income level. The state and/or its vendor may not "sell" the debt for collection by a third party. The waiver authorizing this policy will sunset on December 31, 2022.

X. FAIR HEARINGS

60. The state will afford beneficiaries in the demonstration fair hearing rights in accordance with 42 CFR part 431 subpart E. No waiver will be granted related to fair hearings. The state must ensure compliance with all federal and state requirements related to beneficiary fair hearing rights, including compliance with the approved state plan.

XI. MONITORING AND REPORTING REQUIREMENTS

Operation 1. Deferral for Failure to Submit Timely Demonstration Deliverables. CMS may issue deferrals in accordance with 42 CFR part 430 subpart C, in the amount of \$5,000,000 per deliverable (federal share) when items required by these STCs (e.g., required data elements, analyses, reports, design documents, presentations, and other items specified in

Page 25 of 146

these STCs) (hereafter singly or collectively referred to as "deliverable(s)") are not submitted timely to CMS or found to not be consistent with the requirements approved by CMS. A deferral shall not exceed the value of the federal amount for the demonstration period. The state does not relinquish its rights provided under 42 CFR part 430 subpart C to challenge any CMS finding that the state materially failed to comply with the terms of this agreement.

The following process will be used: 1) 30 calendar days after the deliverable was due, if the state has not submitted a written request to CMS for approval of an extension as described in subsection (b) below; or 2) 30 calendar days after CMS has notified the state in writing that the deliverable was not accepted due to being inconsistent with the requirements of this agreement and the information needed to bring the deliverable into alignment with CMS requirements:

- a. CMS will issue a written notification to the state providing advance notification of a pending deferral for late or non-compliant submissions of required deliverables.
- b. For each deliverable, the state may submit to CMS a written request for an extension to submit the required deliverable. The extension request must explain the reason why the required deliverable was not submitted, the steps that the state has taken to address such issue, and state's anticipated date of submission. Should CMS agree to the state's request, a corresponding extension of the deferral process described below can be provided. CMS may agree to a corrective action as an interim step before applying the deferral, if corrective action is proposed in the state's written extension request.
- c. If CMS agrees to an interim corrective process in accordance with subsection (b), and the state fails to comply with the corrective action plan or, despite the corrective action plan, still fails to submit the overdue deliverable(s) that meets the terms of this agreement, CMS may proceed with the issuance of a deferral against the next Quarterly Statement of Expenditures reported in Medicaid Budget and Expenditure System/State Children's Health Insurance Program Budget and Expenditure System (MBES/CBES) following a written deferral notification to the state.
- d. If the CMS deferral process has been initiated for state non-compliance with the terms of this agreement for submitting deliverable(s), and the state submits the overdue deliverable(s), and such deliverable(s) are accepted by CMS as meeting the standards outlined in these STCs, the deferral(s) will be released.

As the purpose of a section 1115 demonstration is to test new methods of operation or service delivery, a state's failure to submit all required reports, evaluations and other deliverables will be considered by CMS in reviewing any application for an extension, amendment, or for a new demonstration.

62. Submission of Post-Approval Deliverables. The state must submit all deliverables as stipulated by CMS and within the timeframes outlined in these STCs.

- **63. Compliance with Federal Systems Innovation.** As federal systems continue to evolve and incorporate additional section 1115 demonstration reporting and analytics functions, the state will work with CMS to:
 - a. Revise the reporting templates and submission processes to accommodate timely compliance with the requirements of the new systems;
 - b. Ensure all section 1115, T-MSIS, and other data elements that have been agreed to for reporting and analytics are provided by the state; and
 - c. Submit deliverables to the appropriate system as directed by CMS.
- 64. New Initiatives Implementation Plan. The state is required to submit a New Initiatives Implementation Plan to cover certain key policies being tested under this demonstration, including those approved through any amendments. The Implementation Plan will contain applicable information for the following expenditure authorities: Life360 HOME HRSN Services, Life360 HOME HRSN Infrastructure. The New Initiatives Implementation Plan, at a minimum, must provide a description of the state's strategic approach to implementing the key demonstration policies, including timelines for meeting critical implementation stages or milestones, as applicable, to support successful implementation.

The state must submit the Maintenance of Effort information required by STC 54 for CMS approval no later than 90 calendar days after approval of the Life360 HOMEs amendment. All other Implementation Plan requirements outlined in this STC must be submitted for CMS approval no later than 9 months after the approval of the demonstration amendment. The state must submit any required clarifications or revisions to their Implementation Plan submission within 60 calendar days after receipt of CMS feedback. Once approved, the finalized Implementation Plan will be incorporated into the STCs as Attachment D and may be further altered only with CMS approval.

In the Implementation Plan, the state is expected only to provide additional details regarding the implementation of the demonstration policies that are not already captured in the STCs or available elsewhere publicly. Furthermore, for the state's HRSN-related authorities, the Implementation Plan does not need to repeat any information submitted to CMS in the Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure Planning, and Provider Qualifications for Life360 HOME Services (see STC 48); however, as applicable, the information provided in the two deliverables must be aligned and consistent with one another.

The Implementation Plan can be updated as necessary to align with state operations. CMS may provide the state with a template to support the state in developing and obtaining approval of the Implementation Plan.

The New Initiatives Implementation Plan must include information on, but not limited to, the following:

a. A plan for establishing and/or improving data sharing and partnerships with an array of health system and social services stakeholders to the extent those entities are vital

- to provide needed administrative and HRSN-related data on screenings, referrals, and provision of services, which are critical for understanding program implementation and conducting demonstration monitoring and evaluation
- b. Information about key partnerships related to HRSN service delivery, including plans for capacity building for community partners and for soliciting and incorporating input from impacted groups (e.g., community partners, health care delivery system partners, and beneficiaries)
- c. Plans for changes to information technology (IT) infrastructure that will support HRSN-related data exchange, including development and implementation of data systems necessary to support program implementation, monitoring, and evaluation. These existing or new data systems should, at a minimum, collect data on beneficiary characteristics, eligibility and consent, screening, referrals, and service provision.
- d. A plan for tracking and improving the share of Medicaid beneficiaries who are eligible and enrolled in the Supplemental Nutrition Assistance Program (SNAP), the Special Supplemental Nutrition Program for Women, Infants and Children (WIC), and federal and state housing assistance programs, relative to the number of total eligible beneficiaries, including establishing a timeline for reporting.
- e. An implementation timeline and evaluation considerations impacted by the timeline, such as staged rollout that can facilitate robust evaluation designs if these implementation strategies are culturally appropriate
- f. Information as required per STC 54 (MOE)
- g. Information as required per STC 55 (Partnerships with State and Local Entities)

Failure to submit a New Initiatives Implementation Plan will be considered a material failure to comply with the terms of the demonstration project as described in 42 CFR 431.420(d) and, as such, would be grounds for termination or suspension of the Life360 HOMEs programs under this demonstration.

Monitoring Protocol. The state must submit to CMS a Monitoring Protocol no later than 150 calendar days after approval of the demonstration. The state must submit a revised Monitoring Protocol within 60 days after receipt of CMS's comments. Once approved, the Monitoring Protocol will be incorporated into the STCs as Attachment E. In addition, the state must submit an updated or a separate Monitoring Protocol for any amendments to the demonstration, such as the Life 360 HOMEs, no later than 150 calendar days after the approval of the amendment. Such amendment Monitoring Protocols are subject to same requirement of revisions and CMS approval, as described above.

At a minimum, the Monitoring Protocol must affirm the state's commitment to conduct Quarterly and Annual Monitoring Reports in accordance with CMS's guidance and technical assistance and using CMS-provided reporting templates, if applicable. Any proposed deviations from CMS's guidance must be documented in the Monitoring Protocol. The Monitoring Protocol must describe the quantitative and qualitative elements on which the state will report through Quarterly and Annual Monitoring Reports. For the overall demonstration and specific policies where CMS provides states with a suite of quantitative monitoring metrics (e.g., performance metrics described in STC 66b below),

the state is required to calculate and report such metrics leveraging the technical specifications provided by CMS. CMS will provide the state with a set of required metrics, and technical specifications for data collection and metrics calculations covering reporting topics, including but not limited to, enrollment, access to care, quality of care and health outcomes, enrollment by premium payment status, and unpaid medical bills at application. The Monitoring Protocol must specify the methods of data collection and timeframes for reporting on the demonstration's progress as part of the Quarterly and Annual Monitoring Reports. In alignment with CMS guidance, the Monitoring Protocol must additionally specify the state's plans and timeline on reporting metrics data stratified by key demographic subpopulations of interest (e.g., by sex, age, race/ethnicity, English language proficiency, primary language, disability status, and geography) and demonstration component.

For the Life360 HOMEs amendment, the state can update its existing Monitoring Protocol or submit a new Monitoring Protocol within 150 days of the amendment approval. Metrics related to the Life360 HOMEs must include a selection of quality of care and health outcomes metrics and population stratifications based on CMS's upcoming guidance on the Health Equity Measure Slate, and must outline the corresponding data sources and reporting timelines. This slate of measures represents a critical set of equity-focused metrics known to be important for closing key equity gaps in Medicaid/CHIP (e.g. the National Quality Forum (NQF) "disparities-sensitive" measures) and prioritizes key outcome measures and their clinical and non-clinical (i.e. social) drivers. The Monitoring Protocol must also outline the state's planned approaches and parameters to track performance relative to the goals and milestones, as provided in the implementation plan, for the HRSN infrastructure investments.

In addition, the state must describe in the Monitoring Protocol methods to collect and analyze non-Medicaid administrative data to help calculate applicable monitoring metrics. These sources may include, but are not limited to: (1) community resource referral platforms, (2) records of social services receipt from other agencies (such as SNAP or TANF benefits, or housing assistance), (3) other data from social services organizations linked to beneficiaries (e.g., services rendered, resolution of identified need, as applicable), (4) social needs screening results from electronic health records, health plans, or other partner agencies. Across data sources, the state must make efforts and consult with relevant non-Medicaid social service agencies to collect data in ways that support analyses of data on beneficiary subgroups. The Monitoring Protocol must also outline the state's planned approaches and parameters to track performance relative to the goals and milestones, as provided in the implementation plan, for the HRSN infrastructure investments.

For the qualitative elements (e.g., operational updates as described in STC 66a below), CMS will provide the state with guidance on narrative and descriptive information which will supplement the quantitative metrics on key aspects of the demonstration policies. The quantitative and qualitative elements will comprise the state's Quarterly and Annual Monitoring Reports.

- Annual Monitoring Reports. The state must submit three Quarterly Monitoring Reports and one Annual Monitoring Report each DY. The fourth-quarter information that would ordinarily be provided in a separate report should be reported as distinct information within the Annual Monitoring Report. The Quarterly Monitoring Reports are due no later than 60 calendar days following the end of each demonstration quarter. The Annual Monitoring Report (including the fourth-quarter information) is due no later than 90 calendar days following the end of the DY. The state must submit a revised Monitoring Report within 60 calendar days after receipt of CMS's comments, if any. The reports will include all required elements as per 42 CFR 431.428, and should not direct readers to links outside the report. Additional links not referenced in the document may be listed in a Reference/Bibliography section. The Quarterly and Annual Monitoring Reports must follow the framework to be provided by CMS, which is subject to change as monitoring systems are developed/evolve, and will be provided in a structured manner that supports federal tracking and analysis.
 - a. Operational Updates. Per 42 CFR 431.428, the Monitoring Reports must document any policy or administrative difficulties in operating the demonstration. The reports must provide sufficient information to document key operational and other challenges, underlying causes of challenges, and how challenges are being addressed. The discussion should also include any issues or complaints identified by beneficiaries; lawsuits or legal actions; unusual or unanticipated trends; legislative updates; and descriptions of any public forums held. In addition, Monitoring Reports should describe key achievements, as well as the conditions and efforts to which these successes can be attributed. Monitoring Reports should also include a summary of all public comments received through post-award public forums regarding the progress of the demonstration.
 - b. Performance Metrics. The performance metrics will provide data to demonstrate how the state is progressing toward meeting the demonstration's goals including relative to their projected timelines of the demonstration's program and policy implementation and infrastructure investments, and must cover all key policies under this demonstration. Additionally, per 42 CFR 431.428, the Monitoring Reports must document the impact of the demonstration in providing insurance coverage to beneficiaries and the uninsured population, as well as outcomes of care, quality and cost of care, and access to care. This may also include the results of beneficiary satisfaction or experience of care surveys, if conducted, as well as grievances and appeals.

The demonstration's metrics reporting must cover categories including, but not limited to: enrollment and renewal, including enrollment duration, access to providers, utilization of services, enrollment by premium payment status, unpaid medical bills at application and those who experienced a gap in coverage, and quality of care and health outcomes. The state must undertake robust reporting of quality of care and health outcomes metrics aligned with the demonstration's policies and objectives, to be reported for all demonstration populations. Such reporting must also be stratified by key demographic subpopulations of interest (e.g., by sex, age, race/ethnicity, English language proficiency, primary language, disability status, and geography) and by demonstration component, to

the extent feasible. Subpopulation reporting will support identifying any existing shortcomings or disparities in quality of care and health outcomes, and help track whether the demonstration's initiatives help improve outcomes for the state's Medicaid population, including the narrowing of any identified disparities. To that end, CMS underscores the importance of the state's reporting of quality of care and health outcomes metrics known to be important for closing key equity gaps in Medicaid/CHIP (e.g. the National Quality Forum (NQF) "disparities-sensitive" measures) and prioritizing key outcome measures and their clinical and non-clinical (i.e. social) drivers of health. In coordination with CMS, the state is expected to select such measures for reporting in alignment with a critical set of equity-focused measures CMS is finalizing as part of its upcoming guidance on the Health Equity Measure Slate.

For the Life360 HOMEs amendment, in addition to reporting on the metrics described above, the state must track beneficiary participation, screening, receipt of referrals and social services over time, as well as narratively report on the adoption of information technology infrastructure to support data sharing between the state or partner entities assisting in the administration of the demonstration and social services organizations. Furthermore, the state's enrollment and renewal metrics must capture baseline data and track progress via Monitoring Reports for the percent of Medicaid renewals completed ex-party (administratively), as well as the percentage of Medicaid beneficiaries enrolled in other public benefit programs (such as, Supplemental Nutrition Assistance Program (SNAP) and Special Supplemental Nutrition Program for Women, Infants, and Children (WIC)) for which they are eligible. The Monitoring Reports must also provide status updates in accordance with the Monitoring Protocol on the implementation of infrastructure investments tied to HRSN initiatives. In addition, if the state, health plans, or health care providers will contract or partner with organizations to implement Life360 HOMEs, the state must use monitoring metrics that track the number and characteristics of contracted or participating organizations in specific demonstration programs and corresponding payment-related metrics.

- c. <u>Budget Neutrality and Financial Reporting Requirements</u>. Per 42 CFR 431.428, the Monitoring Reports must document the financial performance of the demonstration. The state must provide an updated budget neutrality workbook with every Monitoring Report that meets all the reporting requirements for monitoring budget neutrality set forth in the General Financial Requirements section of these STCs, including the submission of corrected budget neutrality data upon request. In addition, the state must report quarterly and annual expenditures associated with the populations affected by this demonstration on the Form CMS-64. Administrative costs for this demonstration should be reported separately on the CMS-64.
- d. <u>Evaluation Activities and Interim Findings</u>. Per 42 CFR 431.428, the Monitoring Reports must document any results of the demonstration to date per the evaluation hypotheses. Additionally, the state shall include a summary of the progress of evaluation activities, including key milestones accomplished, as well as challenges encountered and how they were addressed.

- 67. Corrective Action Plan Related to Monitoring. If monitoring indicates that demonstration features are not likely to assist in promoting the objectives of Medicaid, CMS reserves the right to require the state to submit a corrective action plan to CMS for approval. A state corrective action plan could include a temporary suspension of implementation of demonstration programs in circumstances where monitoring data indicate substantial and sustained directional change inconsistent with demonstration goals, such as substantial and sustained trends indicating increased difficulty accessing services. A corrective action plan may be an interim step to withdrawing waivers or expenditure authorities, as outlined in STC 11. CMS will withdraw an authority, as described in STC 11, when metrics indicate substantial and sustained directional change inconsistent with the state's demonstration goals, and the state has not implemented corrective action. CMS further has the ability to suspend implementation of the demonstration should corrective actions not effectively resolve these concerns in a timely manner.
- **68. Close-Out Report**. Within 120 calendar days after the expiration of the demonstration, the state must submit a draft Close-Out Report to CMS for comments.
 - a. The Close-Out Report must comply with the most current guidance from CMS.
 - b. In consultation with CMS, and per guidance from CMS, the state will include an evaluation of the demonstration (or demonstration components) that are to phase out or expire without extension along with the Close-Out Report. Depending on the timeline of the phase-out during the demonstration approval period, in agreement with CMS, the evaluation requirement may be satisfied through the Interim and/or Summative Evaluation Reports stipulated in STCs 104 and 105, respectively.
 - c. The state will present to and participate in a discussion with CMS on the Close-Out report.
 - d. The state must take into consideration CMS's comments for incorporation into the final Close-Out report.
 - e. A revised Close-Out report is due to CMS no later than thirty (30) calendar days after receipt of CMS's comments.
 - f. A delay in submitting the draft or final version of the Close-Out report may subject the state to penalties described in STC 61.
- 69. Monitoring Calls. CMS will convene periodic conference calls with the state.
 - a. The purpose of these calls is to discuss ongoing demonstration operation, to include (but not limited to), any significant actual or anticipated developments affecting the demonstration. Examples include implementation activities, trends in reported data on metrics and associated mid-course adjustments, enrollment and access, budget neutrality, and progress on evaluation activities.
 - b. CMS will provide updates on any pending actions, as well as federal policies and issues that may affect any aspect of the demonstration.
 - c. The state and CMS will jointly develop the agenda for the calls.

70. Post Award Forum. Pursuant to 42 CFR 431.420(c), within 6 months of the demonstration's implementation, and annually thereafter, the state must afford the public with an opportunity to provide meaningful comment on the progress of the demonstration. At least thirty (30) calendar days prior to the date of the planned public forum, the state must publish the date, time and location of the forum in a prominent location on its website. The state must also post the most recent Annual Monitoring Report on its website with the public forum announcement. Pursuant to 42 CFR 431.420(c), the state must include a summary of the public comments in the Annual Monitoring Report associated with the year in which the forum was held.

XII. GENERAL FINANCIAL REQUIREMENTS

- 71. Allowable Expenditures. This demonstration project is approved for authorized demonstration expenditures applicable to services rendered and for costs incurred during the demonstration approval period designated by CMS. CMS will provide FFP for allowable demonstration expenditures only so long as they do not exceed the pre-defined limits as specified in these STCs.
- 72. Standard Medicaid Funding Process. The standard Medicaid funding process will be used for this demonstration. The state will provide quarterly expenditure reports through the Medicaid and CHIP Budget and Expenditure System (MBES/CBES) to report total expenditures under this Medicaid section 1115 demonstration following routine CMS-37 and CMS-64 reporting instructions as outlined in section 2500 of the State Medicaid Manual. The state will estimate matchable demonstration expenditures (total computable and federal share) subject to the budget neutrality expenditure limit and separately report these expenditures by quarter for each federal fiscal year on the form CMS-37 for both the medical assistance payments (MAP) and state and local administration costs (ADM). CMS shall make federal funds available based upon the state's estimate, as approved by CMS. Within 30 days after the end of each quarter, the state shall submit form CMS-64 Quarterly Medicaid Expenditure Report, showing Medicaid expenditures made in the quarter just ended. If applicable, subject to the payment deferral process, CMS shall reconcile expenditures reported on form CMS-64 with federal funding previously made available to the state, and include the reconciling adjustment in the finalization of the grant award to the state.
- 73. Sources of Non-Federal Share. As a condition of demonstration approval, the state certifies that its funds that make up the non-federal share are obtained from permissible state and/or local funds that, unless permitted by law, are not other federal funds. The state further certifies that federal funds provided under this section 1115 demonstration must not be used as the non-federal share required under any other federal grant or contract, except as permitted by law. CMS approval of this demonstration does not constitute direct or indirect approval of any underlying source of non-federal share or associated funding mechanisms and all sources of non-federal funding must be compliant with section 1903(w) of the Act and applicable implementing regulations. CMS reserves

- the right to deny FFP in expenditures for which it determines that the sources of non-federal share are impermissible.
- a. If requested, the state must submit for CMS review and approval documentation of any sources of non-federal share that would be used to support payments under the demonstration.
- b. If CMS determines that any funding sources are not consistent with applicable federal statutes or regulations, the state must address CMS's concerns within the time frames allotted by CMS.
- c. Without limitation, CMS may request information about the non-federal share sources for any amendments that CMS determines may financially impact the demonstration.
- 74. State Certification of Funding Conditions. As a condition of demonstration approval, the state certifies that the following conditions for non-federal share financing of demonstration expenditures have been met:
 - a. If units of state or local government, including health care providers that are units of state or local government, supply any funds used as non-federal share for expenditures under the demonstration, the state must certify that state or local monies have been expended as the non-federal share of funds under the demonstration in accordance with section 1903(w) of the Act and applicable implementing regulations.
 - b. To the extent the state utilizes certified public expenditures (CPE) as the funding mechanism for the non-federal share of expenditures under the demonstration, the state must obtain CMS approval for a cost reimbursement methodology. This methodology must include a detailed explanation of the process, including any necessary cost reporting protocols, by which the state identifies those costs eligible for purposes of certifying public expenditures. The certifying unit of government that incurs costs authorized under the demonstration must certify to the state the amount of public funds allowable under 42 CFR 433.51 it has expended. The federal financial participation paid to match CPEs may not be used as the non-federal share to obtain additional federal funds, except as authorized by federal law, consistent with 42 CFR 433.51(c).
 - c. The state may use intergovernmental transfers (IGT) to the extent that the transferred funds are public funds within the meaning of 42 CFR 433.51 and are transferred by units of government within the state. Any transfers from units of government to support the non-federal share of expenditures under the demonstration must be made in an amount not to exceed the non-federal share of the expenditures under the demonstration.
 - d. Under all circumstances, health care providers must retain 100 percent of their payments for or in connection with furnishing covered services to beneficiaries. Moreover, no pre-arranged agreements (contractual, voluntary, or otherwise) may exist between health care providers and state and/or local governments, or third parties to return and/or redirect to the state any portion of the Medicaid payments in a manner inconsistent with the requirements in section 1903(w) of the Act and its implementing regulations. This confirmation of Medicaid payment retention is made with the understanding that payments that are the normal operating expenses of conducting business, such as payments related to taxes, including health care

- provider-related taxes, fees, business relationships with governments that are unrelated to Medicaid and in which there is no connection to Medicaid payments, are not considered returning and/or redirecting a Medicaid payment.
- e. The State Medicaid Director or his/her designee certifies that all state and/or local funds used as the state's share of the allowable expenditures reported on the CMS-64 for this demonstration were in accordance with all applicable federal requirements and did not lead to the duplication of any other federal funds.
- **75. Financial Integrity for Managed Care Delivery Systems.** As a condition of demonstration approval, the state attests to the following, as applicable:
 - a. All risk-based managed care organization, prepaid inpatient health plan (PIHP), and prepaid ambulatory health plan (PAHP) payments, comply with the requirements on payments in 42 CFR 438.6(b)(2), 438.6(c), 438.6(d), 438.60, and 438.74.
- **76.** Requirements for Health Care-Related Taxes and Provider Donations. As a condition of demonstration approval, the state attests to the following, as applicable:
 - a. Except as provided in paragraph (c) of this STC, all health care-related taxes as defined by section 1903(w)(3)(A) of the Act and 42 CFR 433.55 are broad-based as defined by section 1903(w)(3)(B) of the Act and 42 CFR 433.68(c).
 - b. Except as provided in paragraph (c) of this STC, all health care-related taxes are uniform as defined by section 1903(w)(3)(C) of the Act and 42 CFR 433.68(d).
 - c. If the health care-related tax is either not broad-based or not uniform, the state has applied for and received a waiver of the broad-based and/or uniformity requirements as specified by 1903(w)(3)(E)(i) of the Act and 42 CFR 433.72.
 - d. The tax does not contain a hold harmless arrangement as described by section 1903(w)(4) of the Act and 42 CFR 433.68(f).
 - e. All provider-related donations as defined by 42 CFR 433.52 are bona fide as defined by section 1903(w)(2)(B) of the Act, 42 CFR 433.66, and 42 CFR 433.54.
- 77. State Monitoring of Non-Federal Share. If any payments under the demonstration are funded in whole or in part by a locality tax, then the state must provide a report to CMS regarding payments under the demonstration no later than 60 days after demonstration approval. This deliverable is subject to the deferral as described in STC 61. This report must include:
 - a. A detailed description of and a copy of (as applicable) any agreement, written or otherwise agreed upon, regarding any arrangement among the providers including those with counties, the state or other entities relating to each locality tax or payments received that are funded by the locality tax;
 - b. Number of providers in each locality of the taxing entities for each locality tax;
 - c. Whether or not all providers in the locality will be paying the assessment for each locality tax;
 - d. The assessment rate that the providers will be paying for each locality tax;
 - e. Whether any providers that pay the assessment will not be receiving payments funded by the assessment;

- f. Number of providers that receive at least the total assessment back in the form of Medicaid payments for each locality tax;
- g. The monitoring plan for the taxing arrangement to ensure that the tax complies with section 1903(w)(4) of the Act and 42 CFR 433.68(f); and
- h. Information on whether the state will be reporting the assessment on the CMS form 64.11A as required under section 1903(w) of the Act.
- **78.** Extent of Federal Financial Participation for the Demonstration. Subject to CMS approval of the source(s) of the non-federal share of funding, CMS will provide FFP at the applicable federal matching rate for the following demonstration expenditures, subject to the budget neutrality expenditure limits described in STC 87:
 - a. Administrative costs, including those associated with the administration of the demonstration;
 - b. Net expenditures and prior period adjustments of the Medicaid program that are paid in accordance with the approved Medicaid state plan; and
 - c. Medical assistance expenditures and prior period adjustments made under section 1115 demonstration authority with dates of service during the demonstration extension period; including those made in conjunction with the demonstration, net of enrollment fees, cost sharing, pharmacy rebates, and all other types of third-party liability.
- 79. **Program Integrity.** The state must have processes in place to ensure there is no duplication of federal funding for any aspect of the demonstration. The state must also ensure that the state and any of its contractors follow standard program integrity principles and practices including retention of data. All data, financial reporting, and sources of non-federal share are subject to audit.
- **80. Medicaid Expenditure Groups**: Medicaid Expenditure Groups (MEG) are defined for the purpose of identifying categories of Medicaid or demonstration expenditures subject to budget neutrality, components of budget neutrality expenditure limit calculations, and other purposes related to monitoring and tracking expenditures under the demonstration. The Master MEG Chart Table 3 provides a master list of MEGs defined for this demonstration

Table 3: Master MEG Chart							
MEG	Which BN Test Does Applies?	WOW Per Capita	WOW Aggregate	ww	Brief Description		
Adult Group	Нуро 1	X		X	Adult Group		
HRSN Services	Capped Hypo		X	X	All expenditures for Life360 HOME HRSN services		
HRSN Infrastructure	Capped Hypo		X	X	All infrastructure expenditures related to		

.Table 3: Master MEG Chart						
MEG	Which BN Test Does Applies?	WOW Per Capita	WOW Aggregate	ww	Brief Description	
					the provision of Life360	
					HOME HRSN services	
					All additional	
					administrative costs that	
					are directly attributable to	
ADM	N/A				the demonstration and are	
					not described elsewhere	
					and are not subject to	
					budget neutrality	

BN – budget neutrality; MEG – Medicaid expenditure group; WOW – without waiver; WW – with waiver

- 81. Reporting Expenditures and Member Months. The state must report all demonstration expenditures claimed under the authority of title XIX of the Act and subject to budget neutrality each quarter on separate forms CMS-64.9 WAIVER and/or 64.9P WAIVER, identified by the demonstration project number assigned by CMS (11-W-00365/4). Separate reports must be submitted by MEG (identified by Waiver Name) and Demonstration Year (identified by the two-digit project number extension). Unless specified otherwise, expenditures must be reported by DY according to the dates of service associated with the expenditure. All MEGs identified in the Master MEG Chart as WW must be reported for expenditures, as further detailed in the MEG Detail for Expenditure and Member Month Reporting table below. To enable calculation of the budget neutrality expenditure limits, the state also must report member months of eligibility for specified MEGs.
 - a. **Cost Settlements.** The state will report any cost settlements attributable to the demonstration on the appropriate prior period adjustment schedules (forms CMS-64.9P Waiver) for the summary sheet line 10b (in lieu of lines 9 or 10c, or line 7. For any cost settlement not attributable to this demonstration, the adjustments should be reported as otherwise instructed in the State Medicaid Manual. Cost settlements must be reported by DY consistent with how the original expenditures were reported.
 - b. **Premiums and Cost Sharing Collected by the State.** The state will report any premium contributions collected by the state from demonstration enrollees quarterly on the form CMS-64 Summary Sheet line 9.D, columns A and B. In order to assure that these collections are properly credited to the demonstration, quarterly premium collections (both total computable and federal share) should also be reported separately by demonstration year on the form CMS-64 Narrative, and on the Total Adjustments tab in the Budget Neutrality Monitoring Tool. In the annual calculation of expenditures subject to the budget neutrality expenditure limit, premiums collected in the demonstration year will be offset against

- expenditures incurred in the demonstration year for determination of the state's compliance with the budget neutrality limits.
- c. **Pharmacy Rebates.** Because pharmacy rebates are not included in the base expenditures used to determine the budget neutrality expenditure limit, pharmacy rebates are not included for calculating net expenditures subject to budget neutrality. The state will report pharmacy rebates on form CMS-64.9 BASE, and not allocate them to any form 64.9 or 64.9P WAIVER.
- d. **Administrative Costs.** The state will separately track and report additional administrative costs that are directly attributable to the demonstration. All administrative costs must be identified on the forms CMS-64.10 WAIVER and/or 64.10P WAIVER. Unless indicated otherwise on the MEG Charts and in the STCs in section XII, administrative costs are not counted in the budget neutrality tests; however, these costs are subject to monitoring by CMS.
- e. **Member Months.** As part of the Quarterly and Annual Monitoring Reports described in section IX, the state must report the actual number of "eligible member months" for all demonstration enrollees for all MEGs identified as WOW Per Capita in the Master MEG Chart table above, and as also indicated in the MEG Detail for Expenditure and Member Month Reporting table below. The term "eligible member months" refers to the number of months in which persons enrolled in the demonstration are eligible to receive services. For example, a person who is eligible for three months contributes three eligible member months to the total. Two individuals who are eligible for two months, each contribute two eligible member months per person, for a total of four eligible member months. The state must submit a statement accompanying the annual report certifying the accuracy of this information.
- f. Budget Neutrality Specifications Manual. The state will create and maintain a Budget Neutrality Specifications Manual that describes in detail how the state will compile data on actual expenditures related to budget neutrality, including methods used to extract and compile data from the state's Medicaid Management Information System, eligibility system, and accounting systems for reporting on the CMS-64, consistent with the terms of the demonstration. The Budget Neutrality Specifications Manual will also describe how the state compiles counts of Medicaid member months. The Budget Neutrality Specifications Manual must be made available to CMS on request.

Table 4. MEG Detail for Expenditure and Member Month Reporting								
MEG (Waiver Name)	Detailed Description	Exclusions	CMS-64.9 or 64.10 Line(s) To Use	How Expend. Are Assigned to DY	MAP or ADM	Report Member Months (Y/N)	MEG Start Date	MEG End Date
Adult Group	Report all medical assistance expenditures for eligible adult group individuals enrolled in ARHOME		Follow standard CMS 64.9 Category of Service Definition	Date of service	MAP	Y	1/1/202	12/31/20 26
HRSN Services	Report all expenditures for approved HRSN initiatives, excluding infrastructure	See STC# 41	Follow standard CMS 64.9 or CMS 64.10 Category of Service Definitions	Date of service/Date of payment	MAP/A DM	N	11/1/22	12/31/26
HRSN Infrastructure	Report all infrastructure expenditures for approved HRSN initiatives	See STC# 42	Follow standard CMS 64.10 Category of Service Definitions	Date of payment	ADM	N	11/1/22	12/31/26
ADM	Report all additional administrative costs that are directly attributable to the demonstration and are not described elsewhere and are not subject to budget neutrality		Follow standard CMS 64.10 Category of Service Definitions	Date of Payment	ADM	N	1/1/22	12/31/26

ADM – administration; DY – demonstration year; MAP – medical assistance payments; MEG – Medicaid expenditure group;

82. Demonstration Years. The Demonstration Years (DY) for this demonstration are defined in Table 5.

Table 5. Demonstration Populations

Demonstration Year 1 (DY1)	January 1, 2022	12 months
Demonstration Year 2 (DY2)	January 1, 2023	12 months
Demonstration Year 3 (DY3)	January 1, 2024	12 months
Demonstration Year 4 (DY4)	January 1, 2025	12 months
Demonstration Year 5 (DY5)	January 1, 2026	12 months

- 83. Budget Neutrality Monitoring Tool. The state must provide CMS with quarterly budget neutrality status updates, including established baseline and member months data, using the Budget Neutrality Monitoring Tool provided through the performance metrics database and analytics (PMDA) system. The tool incorporates the "Schedule C Report" for comparing the demonstration's actual expenditures to the budget neutrality expenditure limits described in section XII. CMS will provide technical assistance, upon request.⁵
- 84. Claiming Period. The state will report all claims for expenditures subject to the budget neutrality agreement (including any cost settlements) within two years after the calendar quarter in which the state made the expenditures. All claims for services during the demonstration period (including any cost settlements) must be made within two years after the conclusion or termination of the demonstration. During the latter two-year period, the state will continue to identify separately net expenditures related to dates of service during the operation of the demonstration on the CMS-64 waiver forms in order to properly account for these expenditures in determining budget neutrality.
- **85. Future Adjustments to Budget Neutrality.** CMS reserves the right to adjust the budget neutrality expenditure limit:

Page 40 of 146

⁵ Per 42 CFR 431.420(a)(2), that states must comply with the terms and conditions of the agreement between the Secretary (or designee) and the state to implement a demonstration project, and 431.420(b)(1) states that the terms and conditions will provide that the state will perform periodic reviews of the implementation of the demonstration. CMS's current approach is to include language in STCs requiring, as a condition of demonstration approval, that states provide, as part of their periodic reviews, regular reports of the actual costs which are subject to the budget neutrality limit. CMS has obtained Office of Management and Budget (OMB) approval of the monitoring tool under the Paperwork Reduction Act (OMB Control No. 0938 – 1148) and states agree to use the tool as a condition of demonstration approval.

- a. To be consistent with enforcement of laws and policy statements, including regulations and guidance, regarding impermissible provider payments, health care related taxes, or other payments. CMS reserves the right to make adjustments to the budget neutrality limit if any health care related tax that was in effect during the base year, or provider-related donation that occurred during the base year, is determined by CMS to be in violation of the provider donation and health care related tax provisions of section 1903(w) of the Act. Adjustments to annual budget targets will reflect the phase out of impermissible provider payments by law or regulation, where applicable.
- b. To the extent that a change in federal law, regulation, or policy requires either a reduction or an increase in FFP for expenditures made under this demonstration. In this circumstance, the state must adopt, subject to CMS approval, a modified budget neutrality agreement as necessary to comply with such change. The modified agreement will be effective upon the implementation of the change. The trend rates for the budget neutrality agreement are not subject to change under this STC. The state agrees that if mandated changes in the federal law require state legislation, the changes shall take effect on the day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the federal law.

The state certifies that the data it provided to establish the budget neutrality expenditure limit are accurate based on the state's accounting of recorded historical expenditures or the next best available data, that the data are allowable in accordance with applicable federal, state, and local statutes, regulations, and policies, and that the data are correct to the best of the state's knowledge and belief. The data supplied by the state to set the budget neutrality expenditure limit are subject to review and audit, and if found to be inaccurate, will result in a modified budget neutrality expenditure limit.

- 86. Budget Neutrality Mid-Course Correction Adjustment Request. No more than once per demonstration year, the state may request that CMS make an adjustment to its budget neutrality agreement based on changes to the state's Medicaid expenditures that are unrelated to the demonstration and/or outside the state's control, and/or that result from a new expenditure that is not a new demonstration-covered service or population and that is likely to further strengthen access to care.
 - a. Contents of Request and Process. In its request, the state must provide a description of the expenditure changes that led to the request, together with applicable expenditure data demonstrating that due to these expenditures, the state's actual costs have exceeded the budget neutrality cost limits established at demonstration approval. The state must also submit the budget neutrality update described in STC 86.c. If approved, an adjustment could be applied retrospectively to when the state began incurring the relevant expenditures, if appropriate. Within 120 days of acknowledging receipt of the request, CMS will determine whether the state needs to submit an amendment pursuant to STC 6. CMS will evaluate each request based on its merit and will approve requests when the state establishes that an adjustment to its budget neutrality agreement is necessary due to changes to the state's Medicaid expenditures that are unrelated to the demonstration, are outside of the state's control, and/or that result from a new

- expenditure that is not a new demonstration-covered service or population and that is likely to further strengthen access to care.
- b. **Types of Allowable Changes.** Adjustments will be made only for actual costs as reported in expenditure data. CMS will not approve mid-demonstration adjustments for anticipated factors not yet reflected in such expenditure data. Examples of the types of mid-course adjustments CMS may consider allowable include the following:
 - i. Provider rate increases that are anticipated to further strengthen access to care:
 - ii. CMS or State technical errors in the original budget neutrality formulation applied retrospectively, including, but not limited to the following: mathematical errors (such as not aging data correctly) or unintended omission of certain applicable costs of services for individual MEGs;
 - iii. Changes in federal statute or regulations, not directly associated with Medicaid, that impact expenditures;
 - iv. State legislated or regulatory change to Medicaid that significantly affects the costs of medical assistance;
 - v. When not already accounted for under Emergency Medicaid 1115 demonstrations, cost impacts from public health emergencies;
 - vi. High cost innovative medical treatments that states are required to cover; or,
 - vii. Corrections to coverage/service estimates where there is no prior state experience (e.g., SUD) or small populations where expenditures may vary widely.
- c. **Budget Neutrality Update.** The state must submit an updated budget neutrality analysis with its adjustment request, which includes the following elements:
 - i. Projected without waiver and with waiver expenditures, estimated member months, and annual limits for each DY through the end of the approval period; and,
 - ii. Description of the rationale for the mid-course correction, including an explanation of why the request is based on changes to the state's Medicaid expenditures that are unrelated to the demonstration and/or outside of the state's control, and/or is due to a new expenditure that is not a new demonstration-covered service or population and that is likely to further strengthen access to care.

XIII. MONITORING BUDGET NEUTRALITY

Medicaid funding the state may receive over the course of the demonstration approval. The budget neutrality expenditure limits are based on projections of the amount of FFP that the state would likely have received in the absence of the demonstration. The limit consists of a Hypothetical Budget Neutrality Test and a Capped Hypothetical Budget Neutrality Test, as described below. CMS's assessment of the state's compliance with these tests will be based on the Schedule C CMS-64 Waiver Expenditure Report, which

Page 42 of 146

summarizes the expenditures reported by the state on the CMS-64 that pertain to the demonstration.

- 88. Risk. The budget neutrality expenditure limits are determined on either a per capita or aggregate basis as described in Table 3. Master MEG Chart, and Table 4, MEG Detail for Expenditure and Member Month Reporting. If a per capita method is used, the state is at risk for the per capita cost of state plan and hypothetical populations, but not for the number of participants in the demonstration population By providing FFP without regard to enrollment in the demonstration for all demonstration populations, CMS will not place the state at risk for changing economic conditions, however, by placing the state at risk for the per capita costs of the demonstration populations, CMS assures that the demonstration expenditures do not exceed the levels that would have been realized had there been no demonstration. If an aggregate method is used, the state accepts risk for both enrollment and per capita costs.
- 89. Calculation of the Budget Neutrality Limits and How They Are Applied. To calculate the budget neutrality limits for the demonstration, separate annual budget limits are determined for each DY on a total computable basis. Each annual budget limit is the sum of one or more components: per capita components, which are calculated as a projected without-waiver PMPM cost times the corresponding actual number of member months, and aggregate components, which project fixed total computable dollar expenditure amounts. The annual limits for all DYs are then added together to obtain a budget neutrality limit for the entire demonstration period. The federal share of this limit will represent the maximum amount of FFP that the state may receive during the demonstration period for the types of demonstration expenditures described below. The federal share will be calculated by multiplying the total computable budget neutrality expenditure limit by the appropriate Composite Federal Share.
- 90. Main Budget Neutrality Test. This demonstration does not include a Main Budget Neutrality Test. Budget neutrality will consist entirely of Hypothetical and Capped Hypothetical Budget Neutrality Tests. If the state exceeds the budget neutrality limits under the Hypothetical or Capped Hypothetical Budget Neutrality Tests it must return the excess FFP to CMS.
- 91. Hypothetical Budget Neutrality. When expenditure authority is provided for coverage of populations or services that the state could have otherwise provided through its Medicaid state plan or other title XIX authority (such as a waiver under section 1915 of the Act), or when a WOW spending baseline for certain WW expenditures is difficult to estimate due to variable and volatile cost data resulting in anomalous trend rates, CMS considers these expenditures to be "hypothetical," such that the expenditures are treated as if the state could have received FFP for them absent the demonstration. For these hypothetical expenditures, CMS makes adjustments to the budget neutrality test which effectively treats these expenditures as if they were for approved Medicaid state plan services. Hypothetical expenditures, therefore, do not necessitate savings to offset the expenditures on those services. When evaluating budget neutrality, CMS does not offset

non-hypothetical expenditures with projected or accrued savings from hypothetical expenditures; that is, savings are not generated from a hypothetical population or service. To allow for hypothetical expenditures, while preventing them from resulting in savings, CMS currently applies separate, independent Hypothetical Budget Neutrality Tests, which subject hypothetical expenditures to pre-determined limits to which the state and CMS agree, and that CMS approves, as a part of this demonstration approval. If the state's WW hypothetical spending exceeds the Hypothetical Budget Neutrality Test's expenditure limit, the state agrees (as a condition of CMS approval) to offset that excess spending through savings elsewhere in the demonstration (if available) or to refund the FFP to CMS.

92. Hypothetical Budget Neutrality Test 1: The table below identifies the MEGs that are used for Hypothetical Budget Neutrality Test 1. MEGs that are designated "WOW Only" or "Both" are the components used to calculate the budget neutrality expenditure limit. The Composite Federal Share for the Hypothetical Budget Neutrality Test is calculated based on all MEGs indicated as "WW Only" or "Both." MEGs that are indicated as "WW Only" or "Both" are counted as expenditures against this budget neutrality expenditure limit.

	Table 6. Hypothetical Budget Neutrality Test 1								
MEG	PC or Agg	WOW Only, WW Only, or Both	Base Year	Trend Rate	DY 01	DY 02	DY 03	DY 04	DY 05
Adult Group	PC	Both	2019	5.8%	\$717.25	\$758.85	\$802.86	\$849.43	\$898.69

93. Capped Hypothetical Budget Neutrality for Evidence-Based HRSN Initiatives.

When expenditure authority is provided for specified HRSN initiatives in the demonstration (in this approval, as specified in STC 41), CMS considers these expenditures to be "capped hypothetical" expenditures; that is, the expenditures are eligible to receive FFP up to a specific aggregate spending cap per demonstration year, based on the state's expected expenditures. States can also receive FFP for capacity-building, infrastructure, and operational costs for the HRSN initiatives (per STC 42); this FFP is limited by a sub-cap of the aggregate spending cap and is determined by CMS based on the amount the state expects to spend. Like all hypothetical expenditures, capped hypothetical expenditures do not need to be offset by savings, and cannot produce savings; however, unspent expenditure authority allocated for HRSN infrastructure in a given demonstration year can be applied to HRSN services in the same demonstration year. Any unspent HRSN services expenditure authority may not be used to fund HRSN infrastructure. To allow for capped hypothetical expenditures and to prevent them from

resulting in savings that would apply to the rest of the demonstration, CMS currently applies a separate, independent Capped Hypothetical Budget Neutrality Test, which subjects capped hypothetical expenditures to pre-determined aggregate limits to which the state and CMS agree, and that CMS approves, as a part of this demonstration approval. If actual HRSN initiative spending is less than the Capped Hypothetical Budget Neutrality Test's expenditure limit for a given demonstration year, the difference is not considered demonstration savings. Unspent HRSN expenditure authority under the cap for each demonstration year can be carried, shifted, or transferred across future demonstration years. However, unspent HRSN expenditure authority cannot roll over to the next demonstration approval period. If the state's capped hypothetical spending exceeds the Capped Hypothetical Budget Neutrality Test's expenditure limit, the state agrees (as a condition of CMS approval) to refund any FFP in excess of the cap to CMS.

94. Capped Hypothetical Budget Neutrality Test: HRSN. Table 7 identifies the MEGs that are used for the Capped Hypothetical Budget Neutrality Test. MEGs that are designated "WOW Only" or "Both" are the components used to calculate the budget neutrality expenditure limit. The Composite Federal Share for the Capped Hypothetical Budget Neutrality Test is calculated based on all MEGs indicated as "WW Only" or "Both." MEGs that are indicated as "WW Only" or "Both" are counted as expenditures against this budget neutrality expenditure limit. Any expenditures in excess of the limit from the Capped Hypothetical Budget Neutrality Test cannot be offset by savings under the Hypothetical Budget Neutrality Test.

Table 7. Capped Hypothetical Budget Neutrality Test								
MEG	PC or Agg	WOW Only, WW Only, or Both	DY01	DY02	DY03	DY04	DY05	
HRSN services	Agg	Both	\$0	\$8.4M	\$19.5M	\$25.8M	\$31.1M	
HRSN Infrastructure	Agg	Both	\$0	\$2.7M	\$1.97M	\$3.0M	\$2.8M	

95. Composite Federal Share. The Composite Federal Share is the ratio that will be used to convert the total computable budget neutrality limit to federal share. The Composite Federal Share is the ratio calculated by dividing the sum total of FFP received by the state on actual demonstration expenditures during the approval period by total computable demonstration expenditures for the same period, as reported through the MBES/CBES

and summarized on Schedule C. Since the actual final Composite Federal Share will not be known until the end of the demonstration's approval period, for the purpose of interim monitoring of budget neutrality, a reasonable estimate of Composite Federal Share may be developed and used through the same process or through an alternative mutually agreed to method. Each Budget Neutrality Test has its own Composite Federal Share, as defined in the paragraph pertaining to each particular test.

- 96. Exceeding Budget Neutrality. CMS will enforce the budget neutrality agreement over the demonstration period, which extends from January 1, 2022 to December 31, 2026. If at the end of the demonstration approval period a Hypothetical or Capped Hypothetical Budget Neutrality Test has been exceeded, the excess federal funds will be returned to CMS. If the demonstration is terminated prior to the end of the budget neutrality agreement, the budget neutrality test shall be based on the time elapsed through the termination date.
- 97. Corrective Action Plan. If at any time during the demonstration approval period CMS determines that the demonstration is on course to exceed its budget neutrality expenditure limit, CMS will require the state to submit a corrective action plan for CMS review and approval. CMS will use the threshold levels in the tables below as a guide for determining when corrective action is required.

Table 8. Budget Neutrality Test Corrective Action Plan Calculation					
Demonstration Year	Percentage				
DY 1	Cumulative budget neutrality limit plus:	2.0 percent			
DY 1 through DY 2	Cumulative budget neutrality limit plus:	1.5 percent			
.DY 1 through DY 3	Cumulative budget neutrality limit plus:	1.0 percent			
DY 1 through DY 4	Cumulative budget neutrality limit plus:	.0.5 percent			
.DY 1 through DY 5	Cumulative budget neutrality limit plus:	0.0 percent			

XIV. EVALUATION OF THE DEMONSTRATION

98. Cooperation with Federal Evaluators and Learning Collaborative. As required under 42 CFR 431.420(f), the state must cooperate fully and timely with CMS and its contractors in any federal evaluation of the demonstration or any component of the

Page 46 of 146

demonstration. This includes, but is not limited to, commenting on design and other federal evaluation documents and providing data and analytic files to CMS, including entering into a data use agreement that explains how the data and data files will be exchanged, and providing a technical point of contact to support specification of the data and files to be disclosed, as well as relevant data dictionaries and record layouts. The state must include in its contracts with entities that collect, produce or maintain data and files for the demonstration, that they make data available for the federal evaluation as is required under 42 CFR 431.420(f) to support federal evaluation. This may also include the state's participation – including representation from the state's contractors, independent evaluators, and organizations associated with the demonstration operations, as applicable – in a federal learning collaborative aimed at cross-state technical assistance, and identification of lessons learned and best practices for demonstration measurement, data development, implementation, monitoring and evaluation. The state may claim administrative match for these activities. Failure to comply with this STC may result in a deferral being issued as outlined in STC 61.

- 99. Independent Evaluator. The state must use an independent party to conduct an evaluation of the demonstration to ensure that the necessary data is collected at the level of detail needed to research the approved hypotheses. The independent party must sign an agreement to conduct the demonstration evaluation in an independent manner in accordance with the CMS-approved Evaluation Design. When conducting analyses and developing the evaluation reports, every effort should be made to follow the approved methodology. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances.
- draft Evaluation Design no later than 180 days after the approval of the demonstration. The Evaluation Design must be drafted in accordance with Attachment A (Developing the Evaluation Design) of these STCs, and any applicable CMS evaluation guidance and technical assistance for the demonstration's policy components. The Evaluation Design must also be developed in alignment with CMS guidance on applying robust evaluation approaches, such as quasi-experimental methods like difference-in-differences and interrupted time series, as well as establishing valid comparison groups and assuring causal inferences in demonstration evaluations. In addition to these requirements, if determined culturally appropriate for the communities impacted by the demonstration, the state is encouraged to consider implementation approaches involving randomized control trials and staged rollout (for example, across geographic areas, by service setting, or by beneficiary characteristic)—as these implementation strategies help create strong comparison groups and facilitate robust evaluation.

The state is strongly encouraged to use the expertise of the independent party in the development of the draft Evaluation Design. The draft Evaluation Design also must include a timeline for key evaluation activities, including the deliverables outlined in STCs 104 and 104.

For any amendment to the demonstration, the state will be required to update the approved Evaluation Design or submit a new Evaluation Design to accommodate the amendment component. The amended Evaluation Design must be submitted to CMS for review no later than 180 calendar days after CMS's approval of the demonstration amendment. Depending on the scope and timing of the amendment, in consultation with CMS, the state may provide the details on necessary modifications to the approved Evaluation Design via the monitoring reports. The amendment Evaluation Design must also be reflected in the state's Interim and Summative Evaluation Reports, described below.

- Evaluation Design Approval and Updates. The state must submit a revised draft Evaluation Design within 60 calendar days after receipt of CMS's comments, if any. Upon CMS approval of the Evaluation Design, the document will be included as an attachment to these STCs. Per 42 CFR 431.424(c), the state will publish to its website the approved Evaluation Design within 30 days of CMS approval. The state must implement the Evaluation Design and submit a description of its evaluation progress in each of the Quarterly and Annual Monitoring Reports. Once CMS approves the Evaluation Design, if the state wishes to make changes, the state must submit a revised Evaluation Design to CMS for approval if the changes are substantial in scope; otherwise, in consultation with CMS, the state may include updates to the Evaluation Design in Monitoring Reports.
- 102. Evaluation Questions and Hypotheses. Consistent with Attachments B and C (Developing the Evaluation Design and Preparing the Interim and Summative Evaluation Reports) of these STCs, the evaluation deliverables must include a discussion of the evaluation questions and hypotheses that the state intends to test. In alignment with applicable CMS evaluation guidance and technical assistance, the evaluation must outline and address well-crafted hypotheses and research questions for all key demonstration policy components that support understanding the demonstration's impact and its effectiveness in achieving the goals.

The hypothesis testing should include, where possible, assessment of both process and outcome measures. The evaluation must study outcomes, such as likelihood of enrollment and enrollment continuity, and various measures of access, utilization, and health outcomes, as appropriate and in alignment with applicable CMS evaluation guidance and technical assistance, for the demonstration policy components. Proposed measures should be selected from nationally-recognized sources and national measures sets, where possible. Measures sets could include CMS's Core Set of Health Care Quality Measures for Children in Medicaid and CHIP, Consumer Assessment of Health Care Providers and Systems (CAHPS), the Core Set of Health Care Quality Measures for Medicaid-Eligible Adults, the Behavioral Risk Factor Surveillance System (BRFSS) survey, and/or measures endorsed by National Quality Forum (NQF).

CMS underscores the importance of the state undertaking a well-designed beneficiary survey and/or interviews to assess, for instance, beneficiary understanding of and

experience with the various demonstration policy components, including the Life360 components, and waiver of retroactive eligibility, beneficiary experiences with access to and quality of care, as well as changes in incidence of beneficiary medical debt. In addition, the state is strongly encouraged to evaluate the implementation of the demonstration programs in order to better understand whether implementation of certain key demonstration policies happened as envisioned during the demonstration design process and whether specific factors acted as facilitators of—or barriers to—successful implementation. Implementation research questions can also focus on beneficiary and provider experience with the demonstration. The implementation evaluation can inform the state's crafting and selection of testable hypotheses and research questions for the demonstration's outcome and impact evaluations and provide context for interpreting the findings.

Specifically, hypotheses for the demonstration's program component authorizing premium assistance and cost-sharing reduction payments for beneficiaries in QHPs must focus on outcomes such as beneficiary enrollment, take-up rates, access and health outcomes, and unmet need for care. Hypotheses for the waiver of retroactive eligibility must relate to (but are not limited to) the following outcomes: likelihood of enrollment and enrollment continuity, enrollment when people are healthy, health status, and financial status. The state must also include descriptive research questions and hypotheses related to trends in enrollment, disenrollment, and reenrollment, beneficiary outreach, and challenges encountered during the premium policy phase out process.

With respect to the Life360 HOMEs amendment, evaluation hypotheses must focus on areas such as assessing the effectiveness of the HRSN services in mitigating identified needs of beneficiaries. Such assessment is expected to use applicable demonstration monitoring and other data on the prevalence and severity of beneficiaries' HRSNs and the provision of and beneficiary utilization of HRSN services. Furthermore, the HRSN evaluation must include an analysis of how the initiatives affect utilization of preventive and routine care, utilization of and costs associated with potentially avoidable, highacuity health care, and beneficiary physical and mental health outcomes. More specifically, the evaluation must analyze—among other outcomes—maternal and infant health outcomes for participants in the Maternal Life360 HOMEs; utilization of behavioral health and substance use disorder treatments for individuals with relevant diagnoses in Rural Life360 HOMEs; and the impact of incentives and supports to assist individuals in Success Life360 HOMES. Given the populations of focus and the program designs of the Life360 HOMEs, the state must also outline goals on how the demonstration may reduce inequities in health care access, quality of care, or health outcomes at the individual and/or community level, and include corresponding research questions and hypotheses focused on understanding the impact of the demonstration on health quality, including through the reduction of health disparities. For example, by assessing the effects of the initiatives in reducing disparities in health care access, quality of care, or health outcomes at the individual, population, and/or community level.

The evaluation must also assess the effectiveness of the infrastructure investments authorized through the demonstration to support the development and implementation of the HRSN initiatives. The state must also examine whether and how state and local investments in housing, nutrition and any other type of allowable HRSN services change over time in concert with new Medicaid funding toward those services. In addition, in light of how demonstration HRSN expenditures are being treated for purposes of budget neutrality, the evaluation of the HRSN initiative must include a cost analysis to support developing comprehensive and accurate cost estimates of providing such services. It also is required to include a robust assessment of potential improvements in the quality and effectiveness of downstream services that can be provided under the state plan authority, and associated cost implications.

Additionally, as part of its evaluation efforts, the state must also conduct a demonstration cost assessment to include, but not be limited to: administrative costs of demonstration implementation and operation, Medicaid health service expenditures, and provider uncompensated care costs. The state must analyze the budgetary effects of the HRSN services, and the overall Medicaid health medical assistance service expenditures. In addition, the state must use findings from hypothesis tests aligned with other demonstration goals and cost analyses together to assess the demonstration's effects on the fiscal sustainability of the state's Medicaid program.

The state must collect data to support analyses stratified by key subpopulations of interest (e.g., by sex, age, race/ethnicity, English language proficiency, primary language, disability status, and geography). Such stratified data analyses will provide a fuller understanding of existing disparities in access to and quality of care and health outcomes, and help inform how the demonstration's various policies might support reducing such disparities.

- 103. Evaluation Budget. A budget for the evaluation must be provided with the draft Evaluation Design. It will include the total estimated cost, as well as a breakdown of estimated staff, administrative and other costs for all aspects of the evaluation such as any survey and measurement development, quantitative and qualitative data collection and cleaning, analyses, and report generation. A justification of the costs may be required by CMS if the estimates provided do not appear to sufficiently cover the costs of the design or if CMS finds that the design is not sufficiently developed, or if the estimates appear to be excessive.
- **104. Interim Evaluation Report.** The state must submit an Interim Evaluation Report for the completed years of the demonstration, and for each subsequent extension of the demonstration, as outlined in 42 CFR 431.412(c)(2)(vi). When submitting an application for extension, the Interim Evaluation Report should be posted to the state's website with the application for public comment.
 - a. The Interim Evaluation Report will discuss evaluation progress and present findings to date as per the approved Evaluation Design. In this report, the state

- must also describe its findings related to unwinding the state's premium policies, and any potential lessons thereof.
- b. For demonstration authority or any components within the demonstration that expire prior to the overall demonstration's expiration date, and depending on the timeline of expiration/phase-out, the Interim Evaluation Report may include an evaluation of the authority, to be collaboratively determined by CMS and the state.
- c. If the state is seeking to extend the demonstration, the draft Interim Evaluation Report is due when the application for extension is submitted, or one year prior to the end of the demonstration, whichever is sooner. If the state is not requesting an extension for the demonstration, an Interim Evaluation Report is due one year prior to the end of the demonstration.
- d. The state must submit a revised Interim Evaluation Report within 60 days of receiving CMS's comments on the draft Interim Evaluation Report, if any. Once approved by CMS, the state must post the final Interim Evaluation Report to the state's Medicaid website within 30 calendar days.
- e. The Interim Evaluation Report must comply with Attachment C (Preparing the Interim and Summative Evaluation Reports) of these STCs.
- 105. Summative Evaluation Report. The state must submit a draft Summative Evaluation Report for the demonstration's current approval period within 18 months of the end of the approval period represented by these STCs. The draft Summative Evaluation Report must be developed in accordance with Attachment C (Preparing the Interim and Summative Evaluation Reports) of these STCs, and in alignment with the approved Evaluation Design.
 - a. The state must submit a revised Summative Evaluation Report within 60 calendar days of receiving comments from CMS on the draft.
 - b. Once approved by CMS, the state must post the final Summative Evaluation Report to the state's Medicaid website within 30 calendar days.
- 106. Corrective Action Plan Related to Evaluation. If evaluation findings indicate that demonstration features are not likely to assist in promoting the objectives of Medicaid, CMS reserves the right to require the state to submit a corrective action plan to CMS for approval. These discussions may also occur as part of an extension process when associated with the state's Interim Evaluation Report, or as part of the review of the Summative Evaluation Report. A corrective action plan could include a temporary suspension of implementation of demonstration programs, in circumstances where evaluation findings indicate substantial and sustained directional change inconsistent with demonstration goals, such as substantial and sustained trends indicating increased difficulty accessing services. A corrective action plan may be an interim step to withdrawing waivers or expenditure authorities, as outlined in STC 11. CMS further has the ability to suspend implementation of the demonstration should corrective actions not effectively resolve these concerns in a timely manner.

- **107. State Presentations for CMS.** CMS reserves the right to request that the state present and participate in a discussion with CMS on the Evaluation Design, the Interim Evaluation Report, and/or the Summative Evaluation Report.
- **108. Public Access.** The state shall post the final documents (e.g., Implementation Plans, Monitoring Protocol, Monitoring Reports, Close-Out Report, approved Evaluation Design, Interim Evaluation Report, and Summative Evaluation Report) on the state's Medicaid website within 30 calendar days of approval by CMS.
- 109. Additional Publications and Presentations. For a period of 12 months following CMS's approval of deliverables, CMS will be notified prior to presentation of these reports or their findings, including in related publications (e.g., journal articles), by the state, contractor or any other third party directly connected to the demonstration over which the state has control. Prior to release of these reports, articles and other documents, CMS will be provided a copy including any associated press materials. CMS will be given 10 business days to review and comment on publications before they are released. CMS may choose to decline to comment or review some or all of these notifications and reviews. This requirement does not apply to the release or presentation of these materials to state or local government officials.

XV. SCHEDULE OF DELIVERABLES

The state is held to all reporting requirements as outlined in the STCs; this schedule of deliverables should serve only as a tool for informational purposes only.

Date – Specific	Deliverable	Section Reference
Within 9 months of Life360 HOME amendment approval; Maintenance of Effort component is required within 90 days of Life360 HOME amendment approval	New Initiatives Implementation Plan	STC 64
Within 60 days of receiving CMS comments	Revised New Initiatives Implementation Plan	STC 64
Within 150 days of approval date	Monitoring Protocol	STC 65
Within 60 days of receiving CMS comments	Revised Monitoring Protocol	STC 65
Within 180 calendar days from approval date	Draft Evaluation Design	STC 100
Within 180 calendar days from approval date	Amended Evaluation Design	STC 100
Within 60 days of receiving CMS comments	Revised Evaluation Design	STC 101

Date – Specific	Deliverable	Section Reference
One year prior to demonstration expiration or with extension application	Draft Interim Evaluation Report	STC 104
Within 60 days of receiving CMS comments	Revised Interim Evaluation Report	STC 104
Within 18 months after the expiration of this demonstration period	Draft Summative Evaluation Report	STC 105
Within 60 days of receiving CMS comments	Revised Summative Evaluation Report	STC 105
Within 120 days after the end of the demonstration	Draft Close-Out Report	STC 68
Within 30 days after receiving CMS comments	Revised Close-Out Report	STC 68
Within 180 days of Life360 HOME amendment approval	Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure Planning, and Provider Qualifications for Life360 HOMEs	STC 50
	Annually	
90 days after the end of each DY	Annual Monitoring Report (including Q4 monitoring information and budget neutrality)	STC 66, 81
Within 60 days of receiving CMS	Revised Annual Monitoring	STC 66
comments	Report Quarterly	
60 days following the end of the	Quarterly Monitoring Reports	STC 64
quarter	Quarterly Monitoring Reports	510 04
30 days following the end of the quarter	Quarterly Expenditure Reports	STC 72
60 days following the end of the quarter, except for Q4 which is submitted with Annual Report	Quarterly Budget Neutrality Report	STC 66, 81, 83, 84

Attachment A Copayment Amounts

General Service Description	Cost Sharing for Beneficiaries with Incomes >20% FPL
Behavioral Health - Inpatient	\$0
Behavioral Health - Outpatient	\$4.70
Behavioral Health -	\$4.70
Professional	
Durable Medical Equipment	\$4.70
Emergency Room Services	\$0
FQHC	\$4.70
Inpatient	\$0
Lab and Radiology	\$4.70
Skilled Nursing Facility	\$0
Other	\$4.70
Other Medical Professionals	\$4.70
Outpatient Facility	\$4.70
Primary Care Physician	\$4.70
Specialty Physician	\$4.70
Pharmacy - Generics	\$4.70
Pharmacy - Preferred Brand	\$4.70
Drugs	
Pharmacy - Non-Preferred	\$9.40
Brand Drugs, including	
specialty drugs	

No copayments for individuals at or below 20% FPL.

Attachment B Developing the Evaluation Design

Introduction

Both state and federal governments need rigorous quantitative and qualitative evidence to inform policy decisions. To that end, for states that are testing new approaches and flexibilities in their Medicaid programs through section 1115 demonstrations, evaluations are crucial to understand and disseminate information about these policies. The evaluations of new initiatives seek to produce new knowledge and direction for programs and inform Medicaid policy for the future. While a narrative about what happened during a demonstration provides important information, the principal focus of the evaluation of a section 1115 demonstration should be obtaining and analyzing data. Evaluations should include findings about the process (e.g., whether the demonstration is being implemented as intended), outcomes (e.g., whether the demonstration is having the intended effects on the population of focus), and impacts of the demonstration (e.g., whether the outcomes observed in the population of focus differ from outcomes in similar populations not affected by the demonstration).

Submission Timelines

There is a specified timeline for the state's submission of its draft Evaluation Design and subsequent evaluation reports. The graphic below depicts an example of this timeline for a 5-year demonstration. In addition, the state should be aware that section 1115 evaluation documents are public records. The state is required to publish the Evaluation Design to the state's website within 30 calendar days of CMS approval, as per 42 CFR 431.424(e). CMS will also publish a copy to the Medicaid.gov website.



Expectations for Evaluation Designs

CMS expects Evaluation Designs to be rigorous, incorporate baseline and comparison group assessments, as well as statistical significance testing. Technical assistance resources for constructing comparison groups and identifying causal inferences are available on Medicaid.gov: https://www.medicaid.gov/medicaid/section-1115-demonstration-1115-demonstration-nonitoring-evaluation/1115-demonstration-state-monitoring-evaluation-resources/index.html. If

the state needs technical assistance using this outline or developing the Evaluation Design, the state should contact its demonstration team.

All states with section 1115 demonstrations are required to conduct Interim and Summative Evaluation Reports, and the Evaluation Design is the roadmap for conducting these evaluations. The roadmap begins with the stated goals for the demonstration, followed by the measurable evaluation questions and quantifiable hypotheses, all to support a determination of the extent to which the demonstration has achieved its goals. When conducting analyses and developing the evaluation reports, every effort should be made to follow the approved methodology. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances.

The format for the Evaluation Design is as follows:

- A. General Background Information;
- B. Evaluation Questions and Hypotheses;
- **C.** Methodology;
- **D.** Methodological Limitations;
- E. Attachments.
- **A. General Background Information** In this section, the state should include basic information about the demonstration, such as:
 - 1. The issue/s that the state is trying to address with its section 1115 demonstration and/or expenditure authorities, the potential magnitude of the issue/s, and why the state selected this course of action to address the issue/s (e.g., a narrative on why the state submitted an 1115 demonstration proposal).
 - 2. The name of the demonstration, approval date of the demonstration, and period of time covered by the evaluation.
 - 3. A description of the population groups impacted by the demonstration.
 - 4. A brief description of the demonstration and history of its implementation, and whether the draft Evaluation Design applies to an amendment, extension, or expansion of, the demonstration.
 - 5. For extensions, amendments, and major operational changes: a description of any changes to the demonstration during the approval period; the primary reason or reasons for the change; and how the Evaluation Design was altered or augmented to address these changes.
- **B.** Evaluation Questions and Hypotheses In this section, the state should:

- 1. Identify the state's hypotheses about the outcomes of the demonstration, and discuss how the evaluation questions align with the hypotheses and the goals of the demonstration.
- 2. Address how the hypotheses and research questions promote the objectives of Titles XIX and/or XXI.
- 3. Describe how the state's demonstration goals are translated into quantifiable targets for improvement, so that the performance of the demonstration in achieving these targets can be measured.
- 4. Include a Logic Model or Driver Diagram to visually aid readers in understanding the rationale behind the cause and effect of the variants behind the demonstration features and intended outcomes. A driver diagram, which includes information about the goals and features of the demonstration, is a particularly effective modeling tool when working to improve health and health care through specific interventions. A driver diagram depicts the relationship between the goal, the primary drivers that contribute directly to achieving the goal, and the secondary drivers that are necessary to achieve the primary drivers for the demonstration. For an example and more information on driver diagrams: https://innovation.cms.gov/files/x/hciatwoaimsdrvrs.pdf.
- 5. Include implementation evaluation questions to inform the state's crafting and selection of testable hypotheses and research questions for the demonstration's outcome and impact evaluations and provide context for interpreting the findings. Implementation evaluation research questions can focus on barriers, facilitators, beneficiary and provider experience with the demonstration, the extent to which demonstration components were implemented as planned, and the extent to which implementation of demonstration components varied by setting.
- C. Methodology In this section, the state is to describe in detail the proposed research methodology. The focus is on showing that the evaluation meets the prevailing standards of scientific and academic rigor, that the results are statistically valid and reliable, and that it builds upon other published research, using references where appropriate. The evaluation approach should also consider principles of equitable evaluation, and involve partners such as community groups, beneficiaries, health plans, health care providers, social service agencies and providers, and others impacted by the demonstration who understand the cultural context in developing an evaluation approach. The state's Request for Proposal for an independent evaluator, for example, could encourage research teams to partner with impacted groups.

This section also provides evidence that the demonstration evaluation will use the best available data. The state should report on, control for, and make appropriate adjustments for the limitations of the data and their effects on results, and discuss the generalizability of results. This section should provide enough transparency to explain what will be measured and how, in sufficient detail so that another party could replicate the results. Table A below

is an example of how the state might want to articulate the analytic methods for each research question and measure.

Specifically, this section establishes:

- 1. *Methodological Design* Provide information on how the evaluation will be designed. For example, whether the evaluation will utilize pre/post data comparisons, pre-test or post-test only assessments. If qualitative analysis methods will be used, they must be described in detail.
- 2. Focus and Comparison Populations Describe the characteristics of the focus and comparison populations, incorporating the inclusion and exclusion criteria. Include information about the level of analysis (beneficiary, provider, or program level), and if populations will be stratified into subgroups. Additionally, discuss the sampling methodology for the populations, as well as support that a statistically reliable sample size is available.
- 3. Evaluation Period Describe the time periods for which data will be included.
- 4. Evaluation Measures List all measures that will be calculated to evaluate the demonstration. The state also should include information about how it will define the numerators and denominators. Furthermore, the state should ensure the measures contain assessments of both process and outcomes to evaluate the effects of the demonstration during the period of approval. When selecting metrics, the state shall identify opportunities for improving quality of care and health outcomes, and controlling cost of care. The state also should incorporate benchmarking and comparisons to national and state standards, where appropriate.

Include the measure stewards (i.e., the organization(s) responsible for the evaluation data elements/sets by "owning", defining, validating, securing, and submitting for endorsement, etc.) Proposed health measures could include CMS's Core Set of Health Care Quality Measures for Children in Medicaid and CHIP, Consumer Assessment of Health Care Providers and Systems (CAHPS), the Core Set of Health Care Quality Measures for Medicaid-Eligible Adults, metrics drawn from the Behavioral Risk Factor Surveillance System (BRFSS) survey, and/or measures endorsed by National Quality Forum. Proposed performance metrics can be selected from nationally recognized metrics, for example from sets developed by the Center for Medicare and Medicaid Innovation or for meaningful use under Health Information Technology.

5. Data Sources – Explain from where the data will be obtained, describe any efforts to validate and clean the data, and discuss the quality and limitations of the data sources. If the state plans to collect primary data (i.e., data collected specifically for the evaluation), include the methods by which the data will be collected, the source of the proposed questions and responses, and the frequency and timing of data collection. Additionally,

- copies of any proposed surveys must be provided to CMS for approval before implementation.
- 6. *Analytic Methods* This section includes the details of the selected quantitative and/or qualitative analysis measures that will adequately assess the effectiveness of the demonstration. This section should:
 - a. Identify the specific statistical testing which will be undertaken for each measure (e.g., t-tests, chi-square, odds ratio, ANOVA, regression).
 - b. Explain how the state will isolate the effects of the demonstration from other initiatives occurring in the state at the same time (e.g., through the use of comparison groups).
 - c. Include a discussion of how propensity score matching and difference-indifferences designs may be used to adjust for differences in comparison populations over time, if applicable.
 - d. Consider the application of sensitivity analyses, as appropriate.
- 7. *Other Additions* The state may provide any other information pertinent to the Evaluation Design for the demonstration.

Table A. Example Design Table for the Evaluation of the Demonstration

Table 11. Exam	ipic Design Table io	i the Evaluation of the	Demonstration	
Research Question	Outcome measures used to address the research question	Sample or population subgroups to be compared	Data Sources	Analytic Methods
Hypothesis 1				
Research question 1a	-Measure 1 -Measure 2 -Measure 3	-Sample e.g. All attributed Medicaid beneficiaries -Beneficiaries with diabetes diagnosis	-Medicaid fee- for-service and encounter claims records	-Interrupted time series
Research question 1b	-Measure 1 -Measure 2 -Measure 3 -Measure 4	-Sample, e.g., PPS patients who meet survey selection requirements (used services within the last 6 months)	-Patient survey	Descriptive statistics
Hypothesis 2				
Research question 2a	-Measure 1 -Measure 2	-Sample, e.g., PPS administrators	-Key informants	Qualitative analysis of interview material

D. Methodological Limitations – This section provides more detailed information about the limitations of the evaluation. This could include limitations about the design, the data sources or collection process, or analytic methods. The state should also identify any efforts to minimize these limitations. Additionally, this section should include any information about features of the demonstration that effectively present methodological constraints that the state would like CMS to take into consideration in its review.

CMS also recognizes that there may be certain instances where a state cannot meet the rigor of an evaluation as expected by CMS. In these instances, the state should document for CMS why it is not able to incorporate key components of a rigorous evaluation, including comparison groups and baseline data analyses. For example, if a demonstration is long-standing, it may be difficult for the state to include baseline data because any pre-test data points may not be relevant or comparable. Other examples of considerations include:

- 1. When the demonstration is:
 - a. Non-complex, unchanged, or has previously been rigorously evaluated and found to be successful; or
 - b. Could now be considered standard Medicaid policy (CMS published regulations or guidance).

- 2. When the demonstration is also considered successful without issues or concerns that would require more regular reporting, such as:
 - a. Operating smoothly without administrative changes;
 - b. No or minimal appeals and grievances;
 - c. No state issues with CMS-64 reporting or budget neutrality; and
 - d. No Corrective Action Plans for the demonstration.

E. Attachments

- 1. **Independent Evaluator.** This includes a discussion of the state's process for obtaining an independent entity to conduct the evaluation, including a description of the qualifications that the selected entity must possess, and how the state will assure no conflict of interest. Explain how the state will assure that the Independent Evaluator will conduct a fair and impartial evaluation and prepare objective Evaluation Reports. The Evaluation Design should include a "No Conflict of Interest" statement signed by the independent evaluator.
- 2. **Evaluation Budget.** A budget for implementing the evaluation shall be provided with the draft Evaluation Design. It will include the total estimated costs, as well as a breakdown of estimated staff, administrative, and other costs for all aspects of the evaluation. Examples include, but are not limited to: the development of all survey and measurement instruments; quantitative and qualitative data collection; data cleaning and analyses; and reports generation. A justification of the costs may be required by CMS if the estimates provided do not appear to sufficiently cover the costs of the draft Evaluation Design, if CMS finds that the draft Evaluation Design is not sufficiently developed, or if the estimates appear to be excessive.
- 3. **Timeline and Major Milestones.** Describe the timeline for conducting the various evaluation activities, including dates for evaluation-related milestones, including those related to procurement of an outside contractor, if applicable, and deliverables. The final Evaluation Design shall incorporate milestones for the development and submission of the Interim and Summative Evaluation Reports. Pursuant to 42 CFR 431.424(c)(v), this timeline should also include the date by which the Final Summative Evaluation Report is due.


Attachment C Preparing the Interim and Summative Evaluation Reports

Introduction

Both state and federal governments need rigorous quantitative and qualitative evidence to inform policy decisions. To that end, for states that are testing new approaches and flexibilities in their Medicaid programs through section 1115 demonstrations, evaluations are crucial to understand and disseminate information about these policies. The evaluations of new initiatives seek to produce new knowledge and direction for programs and inform Medicaid policy for the future. While a narrative about what happened during a demonstration provides important information, the principal focus of the evaluation of a section 1115 demonstration should be obtaining and analyzing data. Evaluations should include findings about the process (e.g., whether the demonstration is being implemented as intended), outcomes (e.g., whether the demonstration is having the intended effects on the population of focus), and impacts of the demonstration (e.g., whether the outcomes observed in the population of focus differ from outcomes in similar populations not affected by the demonstration).

Submission Timelines

There is a specified timeline for the state's submission of Evaluation Designs and Evaluation Reports. These dates are specified in the demonstration Special Terms and Conditions (STCs). The graphic below depicts an example of a deliverables timeline for a 5-year demonstration. In addition, the state should be aware that section 1115 evaluation documents are public records. In order to assure the dissemination of the evaluation findings, lessons learned, and recommendations, the state is required to publish the Interim and Summative Evaluation Reports to the state's website within 30 calendar days of CMS approval, as per 42 CFR 431.424(d). CMS will also publish a copy to the Medicaid.gov website.



Expectations for Evaluation Reports

All states with Medicaid section 1115 demonstrations are required to conduct evaluations that are valid (the extent to which the evaluation measures what it is intended to measure), and reliable (the extent to which the evaluation could produce the same results when used repeatedly). The already-approved Evaluation Design is a map that begins with the demonstration goals, then transitions to the evaluation questions, and to the specific hypotheses, which will be used to investigate whether the demonstration has achieved its goals. When

conducting analyses and developing the evaluation reports, every effort should be made to follow the methodology outlined in the approved Evaluation Design. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances.

When submitting an application for renewal, the Interim Evaluation Report should be posted on the state's website with the application for public comment. Additionally, the Interim Evaluation Report must be included in its entirety with the application submitted to CMS.

CMS expects Interim and Summative Evaluation Reports to be rigorous, incorporate baseline and comparison group assessments, as well as statistical significance testing. Technical assistance resources for constructing comparison groups and identifying causal inferences are available on Medicaid.gov: https://www.medicaid.gov/medicaid/section-1115-demonstration-state-monitoring-evaluation-resources/index.html. If the state needs technical assistance using this outline or developing the evaluation reports, the state should contact its demonstration team.

Intent of this Attachment

Title XIX of the Social Security Act (the Act) requires an evaluation of every section 1115 demonstration. In order to fulfill this requirement, the state's evaluation report submissions must provide comprehensive written presentations of all key components of the demonstration, and include all required elements specified in the approved Evaluation Design. This Attachment is intended to assist states with organizing the required information in a standardized format and understanding the criteria that CMS will use in reviewing the submitted Interim and Summative Evaluation Reports.

Required Core Components of Interim and Summative Evaluation Reports

The Interim and Summative Evaluation Reports present research and findings about the section 1115 demonstration. It is important that the reports incorporate a discussion about the structure of the Evaluation Design to explain the goals and objectives of the demonstration, the hypotheses related to the demonstration, and the methodology for the evaluation. The evaluation reports should present the relevant data and an interpretation of the findings; assess the outcomes (what worked and what did not work); explain the limitations of the design, data, and analyses; offer recommendations regarding what (in hindsight) the state would further advance, or do differently, and why; and discuss the implications on future Medicaid policy.

The format for the Interim and Summative Evaluation reports is as follows:

- A. Executive Summary;
- B. General Background Information;
- C. Evaluation Questions and Hypotheses;
- D. Methodology;
- E. Methodological Limitations;
- F. Results;
- G. Conclusions;
- H. Interpretations, and Policy Implications and Interactions with Other State Initiatives;

- I. Lessons Learned and Recommendations; and,
- J. Attachment(s).
- **A.** Executive Summary A summary of the demonstration, the principal results, interpretations, and recommendations of the evaluation.
- **B.** General Background Information about the Demonstration In this section, the state should include basic information about the demonstration, such as:
 - 1. The issue/s that the state is trying to address with its section 1115 demonstration and/or expenditure authorities, how the state became aware of the issue, the potential magnitude of the issue, and why the state selected this course of action to address the issues.
 - 2. The name of the demonstration, approval date of the demonstration, and period of time covered by the evaluation.
 - 3. A description of the population groups impacted by the demonstration.
 - 4. A brief description of the demonstration and history of the implementation, and if the evaluation is for an amendment, extension, or expansion of, the demonstration.
 - 5. For extensions, amendments, and major operational changes: A description of any changes to the demonstration during the approval period; whether the motivation for change was due to political, economic, and fiscal factors at the state and/or federal level; whether the programmatic changes were implemented to improve beneficiary health, provider/health plan performance, or administrative efficiency; and how the Evaluation Design was altered or augmented to address these changes. Additionally, the state should explain how this Evaluation Report builds upon and expands earlier demonstration evaluation findings (if applicable).
- C. Evaluation Questions and Hypotheses In this section, the state should:
 - 1. Identify the state's hypotheses about the outcomes of the demonstration, and discuss how the goals of the demonstration align with the evaluation questions and hypotheses.
 - 2. Address how the research questions / hypotheses of this demonstration promote the objectives of Titles XIX and XXI.
 - 3. Describe how the state's demonstration goals were translated into quantifiable targets for improvement, so that the performance of the demonstration in achieving these targets could be measured.
 - 4. The inclusion of a Logic Model or Driver Diagram in the Evaluation Report is highly encouraged, as the visual can aid readers in understanding the rationale behind the demonstration features and intended outcomes.
- **D.** Methodology In this section, the state is to provide an overview of the research that was conducted to evaluate the section 1115 demonstration, consistent with the approved Evaluation Design. The Evaluation Design should also be included as an attachment to the report. The focus is on showing that the evaluation builds upon other published research, (using references), meets the prevailing standards of scientific and academic rigor, and the results are statistically valid and reliable.

An Interim Evaluation Report should provide any available data to date, including both quantitative and qualitative assessments. The Evaluation Design should assure there is appropriate data development and collection in a timely manner to support developing an Interim Evaluation Report.

This section provides the evidence that the demonstration evaluation used the best available data and describes why potential alternative data sources were not used. The state also should report on, control for, and make appropriate adjustments for the limitations of the data and their effects on results, and discusses the generalizability of results. This section should provide enough transparency to explain what was measured and how, in sufficient detail so that another party could replicate the results. Specifically, this section establishes that the approved Evaluation Design was followed by describing:

- 1. *Methodological Design* Whether the evaluation included an assessment of pre/post or post-only data, with or without comparison groups, etc.
- 2. Focus and Comparison Populations Describe the focus and comparison populations, describing inclusion and exclusion criteria.
- 3. *Evaluation Period* Describe the time periods for which data will be collected.
- 4. *Evaluation Measures* List the measures used to evaluate the demonstration and their respective measure stewards.
- 5. *Data Sources* Explain from where the data were obtained, and efforts to validate and clean the data.
- 6. *Analytic Methods* Identify specific statistical testing which was undertaken for each measure (t-tests, chi-square, odds ratio, ANOVA, regression, etc.).
- 7. *Other Additions* The state may provide any other information pertinent to the evaluation of the demonstration.
- **E. Methodological Limitations** This section provides sufficient information for discerning the strengths and weaknesses of the study design, data sources/collection, and analyses.
- **F. Results** In this section, the state presents and uses the quantitative and qualitative data to demonstrate whether and to what degree the evaluation questions and hypotheses of the demonstration were addressed. The findings should visually depict the demonstration results, using tables, charts, and graphs, where appropriate. This section should include findings from the statistical tests conducted.

- **G. Conclusions** In this section, the state will present the conclusions about the evaluation results. Based on the findings, discuss the outcomes and impacts of the demonstration and identify the opportunities for improvements. Specifically, the state should answer the following questions:
 - 1. In general, did the results show that the demonstration was/was not effective in achieving the goals and objectives established at the beginning of the demonstration?
 - a. If the state did not fully achieve its intended goals, why not?
 - b. What could be done in the future that would better enable such an effort to more fully achieve those purposes, aims, objectives, and goals?
- H. Interpretations, Policy Implications and Interactions with Other State Initiatives In this section, the state will discuss the section 1115 demonstration within an overall Medicaid context and long-range planning. This should include interrelations of the demonstration with other aspects of the state's Medicaid program, interactions with other Medicaid demonstrations, and other federal awards affecting service delivery, health outcomes and the cost of care under Medicaid. This section provides the state with an opportunity to provide interpretations of the data using evaluative reasoning to make judgments about the demonstration. This section should also include a discussion of the implications of the findings at both the state and national levels. Interpreting the implications of evaluation findings should include involving partners, such as community groups, beneficiaries, health plans, health care providers, social service agencies and providers, and others impacted by the demonstration who understand the cultural context in which the demonstration was implemented.
- I. Lessons Learned and Recommendations This section of the evaluation report involves the transfer of knowledge. Specifically, it should include potential "opportunities" for future or revised demonstrations to inform Medicaid policymakers, advocates, and stakeholders. Recommendations for improvement can be just as significant as identifying current successful strategies. Based on the evaluation results, the state should address the following questions:
 - 1. What lessons were learned as a result of the demonstration?
 - 2. What would you recommend to other states which may be interested in implementing a similar approach?

Attachment D New Initiatives Implementation Plan

State of Arkansas

Arkansas Health and Opportunity for Me (ARHOME) Section 1115 Medicaid Demonstration Waiver

New Initiatives Implementation Plan

July 1, 2023

ARHOME New Initiatives Implementation Plan July 1, 2023

The New Initiatives Implementation Plan, at a minimum, must provide a description of the state's strategic approach to implementing the key demonstration policies, including timelines for meeting critical implementation stages or milestones, as applicable, to support successful implementation.

Medicaid Waiver STC 64. The New Initiatives Implementation Plan must include information on, but not limited to, the following:

A plan for establishing and/or improving data sharing and partnerships with an array of health system and social services stakeholders to the extent those entities are vital to provide needed administrative and HRSN-related data on screenings, referrals, and provision of services, which are critical for understanding program implementation and conducting demonstration monitoring and evaluation

DHS is partnering with an array of groups across the state to collaboratively address Health-Related Social Needs (HRSN) and reduce silos between state agencies. Specifically, DHS is partnering on efforts to implement collaborative and consistent HRSN screening, social service community resource directories and data sharing across agencies to streamline access to services.

HRSN screening

DHS is working with a group of health care providers and the state's Health Information Exchange, the Arkansas State Health Alliance for Records Exchange (SHARE), to develop a shared approach to HRSN screening and referrals. The group meets bi-monthly and includes insurance carriers, hospital systems, medical groups, and behavioral health providers. The partnership's goal is to map the current landscape of HRSN screening and referrals and increase capacity across healthcare and related providers to standardized coding for SDOH screening and referrals. Health care providers report that the most significant barriers to conducting HRSN screens are 1) a lack of reimbursement for administering screens and 2) a lack of resources to address needs identified through the screens. The Life360 HOME program addresses those issues by reducing the provider's burden to screen and refer. Instead, the Life360 HOME program will administer HRSN screening for program participants and, with the beneficiary's consent, provide the results to their care providers. The Life360 HOME will be responsible for making service referrals and following up, and the provider will receive the screening results to better inform treatment plans.

Community resource directories

To understand potential community resource platforms available for Life360 HOME's closed loop services tracking, DHS reviewed several community resource platforms used by state agencies, health care providers and local social service organizations. DHS anticipates developing or acquiring its own resource platform if CMS approves the state's Opportunities for Success Initiative waiver amendment, and DHS intends to make its chosen platform available for use by Life360 HOMEs. DHS has reviewed Unite US, Find Help, 211, HARK-USA, Good Grid, and the VA's Camp Kiosk, as well as the state's own web-based resource directories developed by DHS, the Arkansas Department of Education (ADE), the Arkansas

Page 68 of 146

⁶ Submitted June 1, 2023 and available at this link: <u>Request to Amend the ARHOME Section 1115 Demonstration</u> <u>Project (medicaid.gov)</u>

Department of Health (ADH) and others. DHS is currently assessing each platform's robustness in maintaining accurate resources and its usefulness in capturing data on closed loop referrals and assisting with identifying local community needs that may be contributing to individual HRSN barriers.

Data sharing

DHS is working with the Division of Information Systems (DIS) to share data across state agencies, including employment, education, and workforce training data. DIS already maintains the Arkansas Statewide Longitudinal Data System (SLDS), which links state data across sources and over time to answer critical questions about education, workforce, social programs, and the economy. DIS has already matched ARHOME enrollee data with data in the SLDS to better understand the proportion of the ARHOME population who are employed or enrolled in school or workforce training programs or have been previously incarcerated. DHS anticipates future data sharing through the state's data infrastructure will provide Life360 HOMEs information about beneficiaries' education level, employment, and previous incarceration status, and Life360 HOMEs could also share their data with other entities who may request it.

Partnerships for referrals

DHS expects Life360 HOME programs to develop robust relationships with health care providers and community organizations to develop beneficiary referral networks. To support those beneficiary referral resources, DHS has also developed partnerships internally and across state agencies to ensure eligible individuals are referred to Life360 HOME programs and receive services as timely as possible. DHS is developing a process with the Arkansas Department of Corrections (DOC) to help transition incarcerated individuals back into the community. The process will include referrals to Success or Rural Life360 HOME programs for eligible beneficiaries when a program is available in their area.

DHS also has developed internal partnerships with the DHS Division of Youth Services (DYS) and the Division of Children and Family Services (DCFS) to develop referral processes to the Success Life360 HOME program for eligible beneficiaries upon their exit from foster care or the juvenile justice system.

DHS has begun discussions with the Arkansas Veterans Administration and the Central Arkansas Veterans Healthcare System to encourage referrals to the Success or Rural Life360 HOME program when veterans move into Arkansas and for former military service men and women who may not be receiving veteran's benefits. Developing an accurate picture of our veteran population with the ARHOME program has been a challenge due to restrictions on veterans' personal information at the federal level. However, DHS's Medicaid application captures voluntary identification of veteran status, and we expect Success Life360 HOME to partner with veterans' organizations in their community to encourage referrals. DHS will ensure that each Life360 HOME is familiar with the Veterans liaison for its area through the Arkansas Department of Veteran Affairs. The Veterans Liaison can help connect beneficiaries to local and regional veterans support organizations. Also, DHS has connected with individuals involved in the Governor's Challenge on Suicide Prevention Among Service Members, Veterans and their Families. Through this partnership we've shared information on Life360 HOME implementation to organizations such as the Central Arkansas Veterans Healthcare System and community-based organizations in Northwest and Central Arkansas as well as other areas of the state. We will facilitate the Life360 HOMEs connecting with these VA providers to identify eligible veterans for Life360 HOME services.

The Life360 HOME services can help improve participants' health outcomes and the QHPs' quality metrics (i.e., percentage of births that are preterm) and will not be an expense for the QHPs. QHPs will be expected to identify beneficiaries eligible for Life360 HOME programs and refer them for services, specifically, women with high-risk pregnancies for referrals to Maternal Life360 Homes and individuals in rural areas with SMI or SUD for Rural Life360 Homes.

Maternal Home Visiting Partnerships

DHS has developed partnerships with state home visiting program partners to support Maternal Life360 HOME implementation. The Arkansas Department of Health (ADH) receives the federal Maternal Infant and Early Childhood Home Visiting (MIECHV) funding. ADH oversees implementation of the Nurse Family Partnership (NFP) program and, through a professional services contract with Arkansas Children's Hospital (ACH), provides funding for the Arkansas Home Visiting Network (AHVN). The AHVN oversees several dozen home-visiting providers and provides training, technical assistance, data collection and evaluation for these providers and others across the state. DHS has developed relationships with ADH NFP, AHVN, and the local home visiting sites to learn about their programming and identify opportunities to collaborate. ADH NFP and AVHN have also worked closely with DHS to support outreach to local programs to provide input and identify capacity and interest in partnering with hospitals for the Maternal Life360 program. AHVN's service provider directory was also used to create a county-by-county map of the evidence-based home visiting programs eligible to partner with a hospital. This map along with a contact list of the home visiting providers by model and location that meet the Maternal Life360 criteria can be shared with hospitals as needed and is available on our website.

AHVN through the contract with ADH and as required for the MIECHV program must tracks required program data, including screening other aspects of services. This data will help DHS verify eligible Maternal Life360 beneficiaries are not already being served in a MIECHV or other evidence-based home visiting program. The AHVN data also may be useful to link data on HRSN screening and referrals and other data metrics. In addition to the programs AHVN oversees, the ADH program also collects and reports MIECHV required data for NFP. DHS will work with the NFP program to ensure services are not duplicated with Maternal Life360 programs. A few local Early Head Start (EHS) programs receive direct federal funding to provide home visits to EHS eligible individuals who are pregnant. The MaternalLife360 programs will work directly with any of these sites as well to avoid duplication.

DHS is also part of the Pritzker Foundation-funded Excel by Eight statewide collaborative that includes multiple state and community services providers and advocates and that promotes policy to address maternal health and early childhood development in Arkansas. This group focuses specifically on improving availability of home visiting services from prenatal to age three and other supports such as quality childcare for low-income families. Its local partnership sites have also worked with DHS to identify potential partners to apply to implement Life360 HOMEs, including one for Maternal Life360.

Information about key partnerships related to HRSN service delivery, including plans for capacity building for community partners and for soliciting and incorporating input from impacted groups (e.g., community partners, health care delivery system partners, and beneficiaries)

One of the foundational principles of the Life360 HOME programs is ensuring Life360 hospitals connect with their community resource providers, such as food banks, shelters, and veterans' organizations. The state expects Life360 HOMEs to develop relationships with organizations in their community that

Page 70 of 146

connect beneficiaries to needed services, but that also serve as a referral network to the Life360 HOME. For example, developing a relationship between the Life360 HOME Hospital and the local food bank will lead to the food bank referring potential beneficiaries to the Life360 HOME.

When applying to become a Life360 HOME, hospitals will be required to provide a community needs assessment and a plan for developing relationships with social service organizations in their service area. In their application, they will identify available community resource providers for each type of HRSN and describe their referral processes for connecting participants to those providers. During the readiness review, DHS will confirm the process the program will use to ensure the development of a consistent approach for tracking referrals and services provided. If needed, DHS may support standardized referral agreement language and provide technical assistance on available resource platforms at the state and local level. Life360 HOMEs will be required to reassess available community resources and services annually, providing feedback to DHS on needed resources in short supply and communities that have developed service delivery models that could be replicated in other parts of the state. DHS will facilitate learning opportunities based on the needs and interests of the Life360 HOME providers as well as its monitoring/technical assistance (TA). DHS's approach could include providing information or contacts directly through TA/monitoring conversations or connecting Life360 HOME providers with innovative practices to other Life360 HOME providers. DHS may also distribute information via e-mail for all providers or host webinars for interested Life360 HOMEs on a specific topic or program based on the interest/needs of the providers and feature a Life360 HOME program, or other outside programs implementing successful approaches.

The state is also supplementing these foundational community-level relationships with extensive partnerships at the state level.

Leading up to the implementation of Life360 HOMEs, DHS met with several dozen home visiting providers, ADH Nurse Family Partnership, multiple behavioral health providers, Early Head Start providers, FQHCs, community mental health centers, housing providers and CoCs as well as the Association for Community Health Workers, Arkansas Department of Corrections, Arkansas Rural Health Partnership, Central Arkansas Veterans Health Services and other regional service providers/collaboratives such as Baptist health System, Mercy Health, and the Northwest Arkansas Healthcare Transformation collaborative as well as key policymakers. We have also engaged the ARHOME Advisory Panel which consists of key policymakers and state agency partners. Through these meetings and presentations, DHS has been able to assess capacity for service delivery, learn about community barriers and obtain input on implementation of the program. DHS also compiled data on the number of eligible beneficiaries in each county and the hospitals that are eligible for each type of Life360 HOME and posted it on the Life360 HOME website. The data are displayed on a map that is posted on the Life360 HOME website.

DHS has been able to connect with some beneficiaries directly through stakeholder outreach, and through public forums in different parts of the state. DHS will also leverage the Medicaid Client Voice Council's feedback. The Council is a body of individual Medicaid beneficiaries representing different regions of the state that advises DHS on Medicaid services. The Life360 HOME website includes a page for beneficiaries and also accepts feedback from those beneficiaries. Finally, the Waiver demonstration evaluation will conduct beneficiary surveys to assess satisfaction with Life360 HOME services.

At the request of DHS Secretary Kristi Putnam, Arkansas is receiving pro-bono technical assistance from Data Labs, a collaboration between the National Governors Association and Georgetown University. The technical assistance will focus on improving access to and administration of state and federal programs such as Medicaid, Supplemental Nutrition Assistance Program (SNAP), and Special Supplemental Nutrition Program for Women, Infants, and Children (WIC). The assistance will focus on developing an integrated service delivery or "no wrong door" approach to delivering intergovernmental services, encouraging partners to develop and share a common vision that connects citizens with the full range of services available in their communities and facilitating coordination of services to align resources and maximize outcomes for our citizens, employers, and the economy. The vision for the project is to support Governor Sarah Huckabee Sanders's Workforce Cabinet in the development of a strategic plan for data-driven supports to integrate services, increase operational efficiency and improve citizen outcomes.

In conjunction with the Data Labs technical assistance, DHS is working with the state Division of Information Systems in its partnership with the Google.org philanthropy to implement CiviForm, an online portal to allow citizens to find and apply for community services. The portal will allow information to be used across state agency program enrollment forms, reducing application time and improving data consistency, and it will notify applicants when new programs are added, or eligibility requirements change.

DHS will work with the U.S. Department of Housing and Urban Development's five local HUD Continuum of Care organizations (COCs), including Balance of the State CoC, Central Arkansas CoC, Southeast Arkansas CoC, Fayetteville/Northwest AR CoC, and Fort Smith CoC. The use of coordinated entry systems and HMIS for referrals is still emergent, or not yet in place, for most of the CoCs. Therefore, referrals for housing are made to each individual housing provider, and services are available on a first come, first serve basis. Life360 HOMEs will make housing referrals when a need is identified and will document if the referral cannot be accepted to monitor for community affordable housing availability. DHS's capacity building plan includes helping Life360 HOMEs collect and analyze their referral data to identify gaps. It also includes helping the Life360 HOMEs and partner housing organizations use referral data in their service planning and funding requests. DHS also will use the data to identify service gaps for state and federal policymakers. This information could assist policymakers better understand where in the state a lack of affordable housing may be inhibiting employment and consider policy changes to address it.

Hospitals will submit a community resource network inventory with their Life360 Home application identifying housing service providers and describing their existing referral process through the CoC or local housing providers. Life360 HOMEs will utilize available resource platforms and develop partnerships/referral arrangements with housing service providers during the startup phase and establish how they will track services. As outlined in the state's *Protocol for Assessment of Beneficiary Need, Infrastructure Planning and Provider Qualifications,* Life360 HOMEs will document HRSN services needed, service referrals made and outcomes of services rendered in the person-centered action plan (PCAP). DHS will provide a standardized PCAP template to providers during the startup period to capture these data elements. DHS also is collaborating with the Arkansas Division of Information Services and health care provider groups to coordinate and leverage state resources to develop and avoid duplication of HRSN screenings, resources referrals and education/workforce connections data. Life360 HOMEs will work with the PHAs, which cover more than 100 jurisdictions around the State, to submit applications/make referrals for eligible beneficiaries. DHS will also ensure the CoCs/PHAs are familiar

with the Life360 HOME program and support Life360 HOMEs to build strong partnerships with the local housing providers.

Life360 HOMEs must demonstrate in the readiness review how they intend to work with HRSN service partners to address housing and other needs. In the startup phase, DHS will review and provide feedback on the development of the Life360 HOMEs' referral processes and/or referral agreements through the regular TA meetings. Through TA, DHS will identify progress and challenges to building these partnerships and provide recommendations as needed and additional support connect with area service providers. DHS will also ensure Life360 HOMEs are able to make referrals to DHS programs including Emergency Services Grant (ESG) program, TANF emergency assistance, foster care programs, and others when needed. DHS will provide program information and contacts for the grant organizations DHS funds to the Life360 HOMEs. We will also share resources available through state partners such as McKinney Vento (Arkansas Department of Education), Arkansas-Department of Corrections transitional housing for formerly incarcerated, foster care transitional housing (AR-DHS Division of Children and Family Services), affordable housing and domestic violence programs overseen by Department of Finance Administration, and the Department of Veteran's housing.

In addition to connecting Life360 HOME beneficiaries to social services, the state is also developing partnerships to connect beneficiaries to education, workforce training and employment. Secretary Putnam was appointed to the Governor's Workforce Cabinet (the Cabinet) along with the Secretaries of five other state agencies. The Cabinet's mission is to strategically align state agencies and organizations to drive workforce, education and economic development. The Cabinet will review and make recommendations on the coordinated use of funds and services to maximize the state's workforce outcomes. One component of this effort is the development of an online tool to help people connect to meaningful employment openings, explore career paths, and find educational opportunities. In coordination with DHS, DIS and the Arkansas Division of Workforce Services (DWS) are developing an online tool to use government administrative data to deliver personalized career recommendations in growing industries and match residents to best-fit available job opportunities. The tool will be available to Life360 HOMEs to help enrolled beneficiaries explore their career potential and engage in education or workforce opportunities when appropriate.

Referrals will be tracked by either local resources platforms or processes developed by the service providers and Life360 HOMEs and must be documented in the beneficiary's PCAP.

Plans for changes to information technology (IT) infrastructure that will support HRSN-related data exchange, including development and implementation of data systems necessary to support program implementation, monitoring, and evaluation. These existing or new data systems should, at a minimum, collect data on beneficiary characteristics, eligibility and consent, screening, referrals, and service provision.

Enrollment Data System Infrastructure

DHS has implemented changes to its MMIS system to process beneficiary eligibility, collect consent forms and process program enrollment. These changes created the necessary infrastructure for Life360 HOME provider enrollment and payment, for providers to submit a beneficiary enrollment request to confirm eligibility for Life360 services and gather required enrollment documentation, including signed consent forms, required medical documentation, such as a medical referral for high-risk pregnancy or verification

of veteran status. The required beneficiary consent form will include with whom their data will be shared and how it will be used for monitoring, evaluation and service provision. The MMIS system changes establish a program enrollment record for Life360 that allows for data collection on beneficiary characteristics through its connection to the beneficiary's Medicaid enrollment record. As of June 2023, system testing is completed and the changes are operational. Once Life360 providers are approved, we will provide training on how to use MMIS for these processes and will work with providers and our MMIS team continuously to improve the system and process.

Program Report Portal

Beyond beneficiary enrollment, a program reporting portal will be developed. The new portal will have similar functionality to our current Patient-Centered Medical Home (PCMH) portal used by primary care providers that tracks quality of care metrics. Life360 HOME providers will upload or enter their program data into the system, and DHS will monitor and track their progress on different performance metrics. Through the portal, the Life360 Homes will report beneficiary visits, Person-Centered Action Plan (PCAP) milestones and other required beneficiary metrics (e.g., HRSN screenings completed, prenatal care visits, education enrollment, etc.) on at least a quarterly basis. Eventually, the portal will link Medicaid and administrative data related to healthcare services metrics, health outcomes and other state funded services and benefits available that are needed for the Waiver demonstration reporting and Life360 performance metrics.

We anticipate the portal development will begin after the vendor agreement is reviewed by the legislature in July. The timeline for completion is expected to be 3 to 4 months. While we anticipate the portal will be in place in some initial form in time for implementation of services, if necessary, we will gather the required data directly from each provider securely through a Move it account created for our program. We are also assessing any other beneficial tools that would support secure reporting.

A plan for tracking and improving the share of Medicaid beneficiaries who are eligible and enrolled in the Supplemental Nutrition Assistance Program (SNAP), the Special Supplemental Nutrition Program for Women, Infants and Children (WIC), and federal and state housing assistance programs, relative to the number of total eligible beneficiaries, including establishing a timeline for reporting.

Plan for WIC

DHS has established a data sharing agreement with the Arkansas Department of Health's WIC program to establish for the baseline of Medicaid beneficiaries enrolled in WIC and to track progress of the percentage of Medicaid beneficiaries who are eligible for WIC and who are enrolled. Generally, most Medicaid eligible individuals are eligible for WIC as the WIC income limit is higher than most Medicaid eligibility limits.. DHS and ADH initiated the first data exchange in June 2023 and DHS and are currently analyzing results. DHS will periodically examine the number of Life360 HOME beneficiaries enrolled in WIC and monitor changes in dual participation in the programs. DHS will work with ADH to identify any strategies needed to improve participation and streamline enrollment in both programs for those who are eligible.

Plan for SNAP

Page 74 of 146

DHS houses both the state's Medicaid program and the state's SNAP program. Recent data matches of beneficiaries indicate that about 12% of the ARHOME population is also enrolled in the SNAP program. As with the WIC program, DHS will examine at least annually the number of ARHOME enrollees that are enrolled in SNAP and monitor changes in dual participation in the programs and work with its sister division, the Division of County Operations, which is responsible for administration of the SNAP program, to identify any improvements needed. Because DHS uses an integrated eligibility system (ARIES), beneficiaries who are enrolled in either program are simultaneously assessed for eligibility in both programs at renewal.

Plan for Housing and Other Services

When an individual applies for Medicaid, they are asked about their housing status. DHS will review this data to develop an estimate of housing needs among beneficiaries served in the Life360 HOME program in addition to the data captured by the Life360 HOME during HRSN screening and through any other state and local partners.

The Life360 HOME program and DHS will work to track referrals using the Homeless Management Information System (HMIS) in the service areas that use it. However, a majority of the state's service areas do not use the HMIS at this time. For those that don't, DHS and the Life360 HOME will rely on the Life360's resource directory platform or other available tool. If HMIS or a resource platform cannot be used, Life360 HOMEs will gather the data directly from their local housing referral partner(s). During the application process, the Life360 HOME will identify HRSN screening tools, referral agreements, and data systems tracking that will be utilized, and DHS will review and provide any feedback during the readiness review. As DHS works on data sharing with state partners to improve service connections and data collection as described in this implementation plan, opportunities to gather data on existing housing programs and other services will be reviewed, and Life360 HOMEs will track any services that may be received through these specific programs.

An implementation timeline and evaluation considerations impacted by the timeline, such as staged rollout that can facilitate robust evaluation designs if these implementation strategies are culturally appropriate.

DHS has completed work on its MMIS system to allow hospitals to enroll as Life360 HOMEs and to allow beneficiaries to enroll as Life360 Home participants. As of June 2023, the state has received ten letters of intent (the first step in the application process) from hospitals that would like to enroll as Life360 providers (one has since withdrawn) and three applications (the next step). Nine of the letters of intent received were for Maternal Life360, and one is for Rural Life360. All approved Life360 HOME providers must successfully complete a readiness review before they can begin enrolling beneficiaries and up to six months is allowed to complete readiness. DHS anticipates no hospital will complete readiness review before the end of the third quarter of 2023. This may result in delayed data collection for the Life360 HOME evaluation to the start of 2024, which is Demonstration Year Three.

DHS anticipates administering the program in a portal that is connected to MMIS but is separate. The portal will be designed to populate enrollment data from MMIS and allow Life360 HOMEs to enter required monthly individual programmatic data and expenditure data. The portal will be designed to capture data necessary for the interim and summative evaluations of the Life360 HOME program.

However, we do not believe perfect alignment between the start of the first Life360 HOME program and the portal's final completion are likely, nor is alignment required to allow for necessary evaluation activities. DHS will develop manual data collection processes to ensure a complete evaluation can be conducted.

Maintenance of Effort (MOE)

Under ARHOME Special Terms and Condition #54, Arkansas must maintain the level of state funding for social service programs related to housing transitions supports and nutrition supports for the duration of the demonstration. STC #54 requires the state to submit a plan to CMS that outlines how it will assess the current availability of these services throughout the State. The annual MOE will be reported and monitored as part of the Annual Monitoring Reports described in STC #66, including any justifications necessary to describe the findings.

The total Maintenance of Effort calculation of the state investment in social service programs related to nutrition supports is \$43,370,669.

For housing supports, the total state investment for housing for persons and households experiencing domestic violence is \$435,000, of which \$350,000 is fee generated and can fluctuate. The state's spending for housing related services for foster care youth is \$2,459,410.

Nutritional Supports

Women Infants and Children (WIC)

USDA provides federal grants to states to provide supplemental foods, health care referrals, and nutrition education for low-income pregnant, breastfeeding, and non-breastfeeding postpartum women, and to infants and children up to age 5 who are found to be at nutritional risk.

In Arkansas pregnant women and their children are eligible for WIC if they are under 185% of the federal poverty level. All pregnant women in ARHOME and most pregnant women in other Medicaid eligibility categories are eligible for WIC.

This program in Arkansas is administered by the Arkansas Department of Health.

Benefits are available statewide. On average, 56,000 people in Arkansas are served by this program each month, including 14,200 women (5,800 of whom are pregnant) and 16,700 infants. Through the WIC program, Arkansas spends about \$22.8 million a year in nutritional supports and administrative costs.⁷

No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding. However, a Life360 HOME program goal is to increase beneficiaries' connections to health-related social needs, including WIC services beneficiaries. We have begun the process of matching Medicaid beneficiary data to WIC recipient data to determine the percentage of Medicaid-enrolled pregnant women and their eligible children who are receiving WIC and the percentage who are eligible for the WIC program but are not currently being served. An important goal of the Life360 HOME program—particularly the Maternal Life360 HOME —is to ensure appropriate

Page 77 of 146

⁷ https://view.officeapps.live.com/op/view.aspx?src=https%3A%2F%2Ffns-prod.azureedge.us%2Fsites%2Fdefault%2Ffiles%2Fresource-files%2FWICAgencies2022ytd-1.xlsx&wdOrigin=BROWSELINK

enrollments are being made. We will monitor these data for Life360 HOME beneficiaries on a quarterly basis and for the entire Medicaid population on at least an annual basis.

Supplemental Nutritional Assistance Program

SNAP provides funding to assist low-income individuals and families with the purchase of food in grocery stores and other food venues. Households containing an individual with disability or a member age 60 or older are eligible for SNAP if they meet all program requirements and have a net income at or below 100% of the federal poverty guidelines. All other households must have both a gross income at or below 130% of the federal poverty guidelines and a net income at or below 100% of the federal poverty guidelines.

In Arkansas, this program is administered by the Arkansas Department of Human Services.

Benefits are available statewide. In state fiscal year 2022, 462,877 people received SNAP benefit assistance totaling \$585,107,157. SNAP benefit assistance is entirely federally funded; however, SNAP administrative expenses are shared 50% by the state and 50% by the USDA. In federal fiscal year 2022, the state's share of SNAP administrative expenses totaled \$42,706,250. We will monitor and report state expenditures to CMS on an annual basis with an explanation of any decreases in state administrative expenditures outside of the Life360 HOME's control. A goal of the Life360 HOME program is to increase participants' connections to health-related social needs, including SNAP benefits for eligible beneficiaries. As a result, we don't anticipate decreases in funding for this program.

Child and Adult Care Food Program

The Child and Adult Care Food Program provides funding for meals for eligible children and adults who enrolled in child and adult day care centers or afterschool programs, children in emergency shelters, and adults who are over 60 or disabled and enrolled in day care programs.

In Arkansas, this program is administered by the Arkansas Department of Education. In federal fiscal year 2022, the program had an average daily attendance of 45,080 with cash payment of more than \$47 million.⁸ No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding.

Summer Food Service Program

The Summer Food Service Program reimburses program operators who serve free healthy meals and snacks to children and teens in low-income areas.

In Arkansas, this program is administered by the Arkansas Department of Education.

In federal fiscal year 2022, the program had an average daily attendance of 9,873 people in Arkansas with cash payments of more than \$2 million. No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding.

Page 78 of 146

⁸ Child Nutrition Tables | Food and Nutrition Service (usda.gov)

⁹ Child Nutrition Tables | Food and Nutrition Service (usda.gov)

The Emergency Food Assistance Program

The Emergency Food Assistance Program provides emergency food assistance. The state provides commodity foods to selected local agencies, usually food banks and Casualty Assistance Program agencies, which in turn distribute the food to local organizations, such as food pantries, mass distribution sites and soup kitchens. These local organizations distribute the donated commodities to eligible recipients for home consumption or use the commodities to prepare and serve meals in a congregate setting. In Arkansas, recipients of food for home use must be at or below 130% of the federal poverty level.

In Arkansas, this program is administered by the Arkansas Department of Human Services. In state fiscal year 2022, the Emergency Food Assistance Program spent \$664,419 in state funding. We will monitor and report those expenditures to CMS on an annual basis with an explanation of any decreases in state administrative expenditures beyond the control of the Life360 HOME. One of the goals of the Life360 HOMEs is to increase connections to health-related social needs, including Emergency Food Assistance, when needed for eligible beneficiaries.

Other Nutritional Support Program

The state also administers the Commodity Supplemental Food Program and the National School Lunch Program. Both of these programs serve beneficiaries outside the age range served by the Life360 HOMEs and will not be included in the annual MOE reporting on state funding.

Additional Nutrition Assistance Funding under American Rescue Plan Act (ARPA)

Arkansas used about \$585,000 of its federal ARPA funding for the Arkansas Alliance of Boys & Girls Clubs nutrition program. The funding helped Boys & Girls Clubs provide food, weekend backpacks, nutrition instruction, supplies and transportation of food to communities in need. This federal funding will not be included in the annual MOE reporting.¹⁰

Housing Supports

A major goal of the Life360 HOME program is to connect beneficiaries to health-related social needs, including housing services. The following provides information about housing services and assistance programs available in Arkansas.

Continuum of Care (CoC)

The Continuum of Care (CoC) program provides funding for efforts by nonprofit providers and state and local governments to quickly rehouse homeless individuals and families including those who are fleeing domestic violence. The program promotes access to and utilization of mainstream programs by those being served and optimizes self-sufficiency among individuals and families experiencing homelessness.

In Arkansas, this program is administered by local entities funded directly by the U.S. Housing and Urban Development agency. The four (4) CoCs include Little Rock/Central Arkansas, Fayetteville/Northwest Arkansas, Southeast Arkansas, and Arkansas Balance of the State (includes portions of Southwest and Northeast Arkansas). Each CoC distributes funding and supports a range of housing programs through

_

¹⁰ SLFRF-Recovery Plan.pdf (arkansas.gov)

local partners including emergency and transitional shelters, rapid re-housing, and permanent supportive housing. CoCs also lead planning and evaluation of the overall programs and services needed to address homelessness.

The CoCs received \$4.2 M in FY 2021. No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding. A goal of the Life360 HOME program is to increase participants' connections to health-related social needs, including housing when needed for eligible beneficiaries.

Emergency Solutions Grant

The Emergency Solutions Grant (ESG) Program is designed to end homelessness by providing funding to eligible non-profit organizations or general units of local government. Covered services include four different areas: outreach to engage individuals who are homeless and not staying in a shelter or other housing; rental assistance and other supports for those who are at risk of becoming homeless to stay housed or relocate; help finding and paying for housing for those who are experiencing homelessness and case management during the transition to stability; and support for emergency shelter operations along with critical services such as child care, skills training, and transportation assistance.

In Arkansas, ESG is administered by the Arkansas Department of Human Services (DHS), Division of County Operations, which distributes ESG funding to community-based service providers and local government across the state. The program assists more than 2,000 individuals and families annually. The state received a total of \$2.2M in ESG funding in FY 2022. No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding.

Tenant Based Rental Assistance (TBRA)

The Tenant-Based Rental Assistance Program (TBRA), administered through Arkansas Development Finance Authority (ADFA), is designed to provide temporary assistance to participants awaiting a permanent subsidy through the Housing Choice Voucher program. The program provides short-term rental or housing assistance payments and utility payments to landlords to prevent homelessness for up to 24 months. On average 260 households annually receive support through this program.

ADFA funds public housing authorities (PHAs) to supplement Section 8 vouchers and to agencies in the community that lack rental assistance to address housing cost burden. TBRA is included in the state's larger HOME Investment Partnership program grant that promotes the development of affordable housing units for low-income families. The state received approximately \$11M in HOME funding in FY 2022, and five metropolitan PHAs each received HOME allocations from \$240,000 to \$845,000.

No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding.

Affordable Housing Programs

ADFA also administers and monitors affordable housing programs that support affordable housing for more than 20,000 Arkansans in 450 units. These programs' total annual average funding include Low Income Housing Credit Tax (\$8.5 million), as well as the HOME Investment Partnerships Act and National Housing Trust Fund (\$6.5 million).

No state funding is used in these programs, so they will not be included in the annual MOE reporting.

Programs for specific populations

Incarcerated Individuals— The Arkansas Department of Corrections (DOC) Transitional Housing program serves individuals who have been transferred or paroled from the Division of Corrections or Division of Community Corrections. Transitional housing services are provided through community transitional housing facilities with funding from the AR-DOC for up to 120 days. Transitional housing providers must provide meals and assist with identifying stable housing in the community and ensure access to substance abuse treatment and recovery services. This program is funded through state resources at \$1.8M in FY 2023.

This funding is state funding and will be included in the annual MOE reporting.

<u>Victims of Domestic Violence</u> - Administered by the Arkansas Department of Finance and Administration (DFA), the Arkansas Domestic Violence Shelter Grant Program is designed to assist in the funding of domestic violence shelters in Arkansas. The Domestic Violence Shelter Fund (DVSF) was created by Arkansas Act 583 of 2017 to provide a method of helping support domestic violence shelters and programs through grants funded by special revenues under A.C.A. § 9-15-202(d) and A.C.A. § 16-10-305(h). This program provides services including food, housing, advice, counseling and assistance to victims of domestic abuse and their dependents. The DVSF provided \$2,833 per shelter to 30 shelters in FY 2023, approximately \$85,000 overall. Each shelter may use the funds differently, for food purchases, or maintenance for the facility, but is towards the overall operations of the shelter. This funding will be included in the annual MOE reporting.

The Domestic Peace Fund managed by the Domestic Violence Coalition receives the funding generated through fees charged in criminal cases. The amount fluctuates based on fees collected. Currently, there are 30 Coalition-affiliated shelters that receive about \$11,000 annually from this fund, approximately \$350,000 total in the current year budget.

Since this program is also state funded, we will include it in the annual MOE reporting, though as noted, this amount may change year to year. DHS will provide this amount separately.

Federal grant funds are awarded to the State of Arkansas through DHS to support programs and projects statewide that establish, maintain and expand programs and projects to prevent family violence and provide immediate shelter and related assistance for victims of family violence and their dependents. This domestic violence (DV) shelter program receives a total of \$144,959 divided among 10 shelters in five regions for bed nights for adult participants. The funds can be used for any shelter needs. Each region receives a different amount divided between two shelters per region.

The DHS DV shelter program is federally funded and will not be part of the MOE.

<u>Former Foster Care Youth</u> – The Division of Children and Family Services (DCFS) Extended Foster Care Program provides money and support to assist former foster youth in making a successful transition to adulthood, including help enrolling in and attending school (including college), getting job training, and finding a place to live. To be eligible for Extended Foster Care, youth must either be enrolled in school, working at least 80 hours per month, enrolled in a program designed to remove barriers from

Page 81 of 146

employment, or have a documented medical condition that prevents them from participating in any of the required activities. Youth ages 18 to 21 who elect to participate in the Extended Foster Care Program receive a monthly board payment. The board payment amount is based on the youth's specific budget, including any income the youth may earn, and averages around \$750 per month. Typically, the board payment is paid directly to the youth's selected Transitional Youth Services (TYS) Sponsor who helps the youth to manage his or her board payment and serves as the youth's mentor and coach.

Youth in Extended Foster Care are also eligible for other supplemental, one-time financial supports, such as the following:

- \$1,000 in start-up funding, which can be used for an apartment deposit, furnishings or other items needed for an apartment, groceries, etc.
- Car repairs in the amount of \$500, and
- \$200 toward the cost of a cell phone or phone minutes.

Board payments are funded by a mix of Title IV-E dollars as well as State General Revenue (SGR). The remaining one-time financial benefits through Extended Foster Care are supported by federal Chafee funds.

DCFS has placement contracts throughout the state for Supervised Independent Living (SIL) for youth ages 18 to 21 to help youth transition to adulthood. These providers provide an apartment or shared housing placement for youth and case management services in addition to the services from the assigned DCFS caseworker. As of June 2023, a total of 41 youth in Extended Foster Care are placed with an SIL provider. The funds for these contracts are blended from federal Title IV-E funds, federal Chafee funds, and State General Revenue. The total amount of SGR expended on the Extended Foster Care Program between board payments and SIL contracts in state fiscal year 2022 was \$2,459,410. This funding will be tracked for the MOE.

DCFS also has an agreement with local housing authorities for the Foster Youth to Independence (FYI) Housing Choice Vouchers. Young adults ages 18 to 24 who are no longer in foster care, or who will leave foster care within 90 days may qualify if living in a participating county. FYI vouchers may be used to provide housing assistance for a maximum of 36 months. DCFS has MOUs with 7 counties for this program and as of June 2023, a total of 17 youth was placed in housing with an FYI voucher, 3 had a pending application, 6 had applied and were pending paperwork, and 3 had voluntarily left the program. For youth who age out of foster care at 18 and choose not to participate in the Extended Foster Care Program, Aftercare funding is available to help pay for school or job training programs, housing, insurance, transportation, or utility bills/setup. Funds are paid directly to the goods or services provider or to the youth on a reimbursement basis. Up to \$2,000 can be provided, though typically not more than \$500 is spent per month. Aftercare funds come out of federal Chafee funding and will not be included in the MOE.

DCFS also partners with the Arkansas Department of Workforce Services (DWS). Through this partnership, DWS provides Temporary Assistance for Needy Families (TANF) funds to support Immerse Arkansas's LifeBase Program. which provides in-home, two-generational coaching and case management, including ongoing assessment to promote progress for those in a resource home or teens who were adopted from foster care. This program currently operates in Pulaski County and Faulkner County with a focus on supporting teens adopted from foster care and their adoptive families with a range of supports. LifeBase:

Page 82 of 146

- Focuses on safe and stable housing by:
 - empowering and guiding youth and families to create a home atmosphere that has physical and psychological safety
 - increasing placement stability through appropriately identifying and addressing the needs of youth and families
 - empowering youth and families through building resiliency, implementing protective factors, and strengthening developmental assets
 - o assisting in the development and implementation of a plan towards independent housing when appropriate
- Provides 24/7 crisis intervention and support and equipping youth and families with resources and tools for educational and employment stability and growth.
- Provides a therapeutic component including individual scheduled therapy, evidence-based treatment including long-term therapy for the youth and families, and immediate counseling onsite

In addition, DCFS also contracts with Youth Villages to provide the LifeSet Program to youth ages 17 to 21 in foster care. LifeSet is an individualized, evidence-informed intensive community-based program. Specialists help young people build healthy relationships, obtain safe housing, education and employment through weekly meetings and other contacts. All Specialists receive weekly clinical supervision and can provide 24/7 crisis intervention and support. LifeSet is offered in DCFS Areas 1 and 2 (Northwest AR) and will launch in Areas 8 and 9 (Northeast AR) in July 2023.

On average, a little over 300 youth are participating in the Extended Foster Care Program at any given time. In state fiscal year 2022, 26 youth received After Care funding in some amount. In state fiscal year 2022, 101 youth received ETV awards.

Title IV-E is an entitlement program so there is not a set amount of those funds designated for youth in Extended Foster Care. The Chafee and ETV awards run on a two-year cycle. The current federal Chafee award (cycle 10/1/21-9/30/23) amount is \$1,348,638. The current ETV award amount is \$447,434. These amounts are federal funds and will not be included in the MOE.

TANF Assistance

Arkansas' TANF program, known as Temporary Employment Assistance (TEA), provides one-time assistance to address emergency housing needs that may hinder employment. The program also supports childcare assistance for qualified children up to 2 years for persons receiving and/or transitioning from TEA. On average, the state serves 3,000 individuals in TEA each year.

The total federal funding for this program in FY 2022 was \$56.5M. The state's MOE for the TEA program in FY 2022 was \$33,464,340.

Additional Housing Assistance Funding under American Rescue Plan Act (ARPA)

Emergency Solutions Grants-CARES Act (ESG-CV) and Emergency Housing Vouchers (EHV)

ESG programs as well as other community development programs received substantial funding through ARPA. This funding was applied more flexibly or expanded existing services to address urgent needs during the pandemic. The Emergency Housing Voucher (EHV) program provided \$4.7M to local Public Housing Authorities (PHAs), and 355 households have been able to secure permanent housing through the program. Since the funding was intended for one-time use and is federal funds only, it will not be included in the MOE reporting.

HOME Investment Partnerships American Rescue Plan Program (HOME-ARP)

Once approved by U.S. Department of Housing and Urban Development, ADFA will be responsible for administering and overseeing the \$37.5M in planned projects and services in its HOME-ARP plan completed in September 2022. States can use this funding to support activities including acquisition and development of shelter, supportive services, tenant based rental assistance, HOME-ARP rental housing, planning and administration, and nonprofit operating and capacity building. (A portion of funds must assist qualifying populations, including those experiencing homelessness). The state's plan will prioritize supportive services and the acquisition and development of shelter and related non-profit operations capacity and supportive services to address needs identified through the state's planning process. This funding approach will complement the state's existing plans to add more than 1,500 affordable housing units. The proposed services funding will leverage Medicaid, CoC and other supportive resources, including behavioral health services to strengthen services needed to transition to housing.

No state funding is used in this program, so this program will not be included in the annual MOE reporting on state funding.

The state must have in place partnerships with other state and local entities (e.g., HUD Continuum of Care Program, local housing authority, SNAP state agency, etc.) to assist beneficiaries in obtaining non-Medicaid funded housing and nutrition supports, if available, upon the conclusion of temporary Medicaid payment for such supports, in alignment with beneficiary needs identified in the personcentered plans as appropriate. The state must submit a plan to CMS as part of the New Initiatives Implementation Plan (see STC 64) that outlines how it will put into place the necessary arrangements with other state and local entities and also work with those entities to beneficiaries in obtaining available non-Medicaid funded housing and nutrition supports upon conclusion of temporary Medicaid payment as stated above. The plan must provide a timeline for the activities outlined.

As mentioned previously in this implementation plan, DHS is partnering with an array of organizations and agencies across the state to collaboratively address Health-Related Social Needs (HRSN) and reduce silos between state agencies.

Partnerships for Housing Supports

DHS will work with the U.S. Department of Housing and Urban Development's five local HUD Continuum of Care organizations (COCs), including Balance of the State CoC, Central Arkansas CoC, Southeast Arkansas CoC, Fayetteville/Northwest AR CoC, and Fort Smith CoC. The use of coordinated entry systems and HMIS for referrals is still emergent or not yet in place for most of the CoCs. Therefore, referrals to housing are made to each individual housing provider, and services are available on a first come, first serve basis.

DHS will also ensure the CoCs/PHAs are familiar with the Life360 HOMEs and will support Life360s to build strong partnerships with the local housing providers included in the CoC. DHS will also provide feedback on referral processes and/or agreements outlined by the partners and will ensure that Life360 HOMEs connect individuals with housing needs who would meet criteria for housing resources through our state partners. These partners include TANF housing and childcare (Arkansas Division of Workforce Services), McKinney Vento (Arkansas Department of Education), Arkansas Department of Corrections transitional housing for formerly incarcerated, foster care transitional housing (DHS Division of Children and Family Services), affordable housing programs overseen by Department of Finance Administration, and the Department of Veteran's housing.

Partnerships for Nutritional Supports

Most Medicaid eligible pregnant or postpartum women in Arkansas are eligible for WIC, so DHS has begun developing a relationship with the Arkansas Department of Health's WIC program. DHS has established a data sharing agreement with the Arkansas Department of Health's WIC program to establish baseline data for Medicaid beneficiaries enrolled in WIC, as well as those who are not but could be eligible, and to track progress in the percentage of Medicaid beneficiaries who are eligible for WIC and who are enrolled. Through this partnership, DHS plans to provide Life360 HOMEs with information about participants who are not enrolled in WIC but are eligible for the program and expects the Life360 HOME program to encourage and assist participants in enrolling.

Beyond the Life360 HOME program, DHS anticipates the partnership with ADH's WIC program will lead to more communication between the two agencies, greater understanding of one another's programs and ultimately efficiency in enrolling individuals eligible for both Medicaid and WIC.

DHS houses both the state's Medicaid program and the state's SNAP program. Recent data matches of beneficiaries indicate that about 12% of the ARHOME population is enrolled in the SNAP program. As with the WIC program, DHS will periodically examine the number of ARHOME enrollees enrolled in SNAP and monitor changes in membership with dual participation in the programs. Because DHS uses an integrated eligibility system (ARIES), beneficiaries who are enrolled in either program are assessed for eligibility in both programs. This ensures that all Medicaid beneficiaries are easily enrolled in SNAP if they are eligible.

Appendix C: Rate Methodology STC 53

On June 30, 2023, DHS submitted the Rate Methodology to CMS.

Attachment E Monitoring Protocol (RESERVED)

Attachment F Evaluation Design (RESERVED)

Attachment G Life360 HOME Definitions & Eligibility

Life360 HOME	Services Definition	Eligibility	Duration	Settings and Referrals
Maternal Life360 HOME	Beneficiaries will receive intensive care coordination through home visitation services based on one of the models that has demonstrated effectiveness as assessed by the U.S. Department of Health and Human Services and linkages to community resources and supports. The Life360 HOME hospital will incorporate screening that includes health and social-related needs (HSRN) as well as any other required health screenings, which will help inform the supports to be delivered to improve outcomes in each of the following domains: • Maternal Health • Child Health • Family Economic Self-Sufficiency • Positive Parenting Practices Referral to community supports to address identified HRSN as	An individual is eligible for the Maternal Life360 HOME if: • Lives in the Maternal Life360 identified service area; and Is pregnant with a high-risk pregnancy diagnosis High-risk pregnancy may be determined by the Maternal Life360 HOME if not already documented through a medical provider.	Services begin during pregnancy and continue up to two years after birth of the baby even if the individual is no longer eligible for Medicaid under any eligibility category. 11 based upon continued need of home visiting support.	Intensive Care Coordination will be delivered primarily in the home setting but could also be delivered in community or clinic settings. Maternal Life360 HOMEs will accept referrals for Maternal Life360 HOME Services from a diverse array of health and social service organizations, medical providers, and non- medical supports in the community through formal and informal agreements.

¹¹ If the individual would become no longer eligible for Medicaid under any eligibility category, they would still be able to receive the benefits under the Maternal Life360, based upon continued need, e.g., intensive care coordination, visiting home nursing and health related social needs assessments. The match for services to people who are no longer eligible for the adult group would be at regular FMAP.

Life360 HOME	Services Definition	Eligibility	Duration	Settings and Referrals
	permitted under these STCs			
Rural Life360 HOME	 Screening for HRSN using a standardized tool Referral to community supports to address identified HRSN as permitted under these STCs In addition to the services above, individuals with a mental health or substance use disorder and identified HRSN needs will receive Intensive Care Coordination services which will include: Conducting an in-depth 1:1 interview to determine the HRSN, any unmet needs related to medical services and nonmedical supports, and system involvement such as criminal justice if applicable. Developing an individualized Person-Centered Action Plan (PCAP) reflecting the beneficiary 's preferences for addressing the needs identified. Goals may include but are not limited to establishing and maintaining regular 	All individuals living in the Rural Life360 HOME identified service area are eligible to receive a HRSN Screening and referrals to needed community supports regardless of Medicaid eligibility. An individual is eligible for Rural Life360 HOME intensive care coordination if the individual: • Is eligible for the ARHOME program; • Lives in the Rural Life360 identified service area; • Has a mental health or substance use disorder diagnosis; and • Has at least one HRSN need identified through a HRSN screen.	Intensive Care Coordination can be received as long as the individual is eligible for the ARHOME demonstration and resides in the service area.	Intensive Care Coordination will be delivered primarily in the home setting but could also be delivered in community, medical clinic, behavioral health clinic, or hospital settings. Hospitals will accept referrals for Rural Life360 services from a diverse array of health and social service organizations, medical providers and non- medical supports in the community through formal and informal agreements. It is expected that most referrals will come from mental health or substance used disorder treatment providers.

Life360 HOME	Services Definition	Eligibility	Duration	Settings and Referrals
	care for behavioral health and medical needs; strengthening life and family skills; emotional and mental wellness; and obtaining or sustaining safe housing. • Working directly with the beneficiary to improve their skills to be healthy and thrive in their community and connecting them to identified medical services and nonmedical supports. • Documenting care coordination activities including new goals and barriers/successes experienced by beneficiary			
Success Life360 HOME	Beneficiaries will receive Intensive Care Coordination services, which will include: • Screening for HRSN using a standardized tool as prescribed by the program model • Conducting in-depth 1:1 interview to determine the HRSN, any unmet needs related to medical services and nonmedical supports, and system involvement such as	An individual is eligible for Success Life360 intensive care coordination if the individual: • Lives in the Success Life360 identified service area; • Has a chronic health condition; and • Meets the criteria for at least one of the following categories: • Between nineteen (19) and twentyfour (24) years of age and has been previously placed	Length of time to receive intensive care coordination based upon obtainment of PCAP goals and is expected to be completed in 24 months or less. Services may remain in place at lesser intensity for longer than 24 months if PCAP goals	Intensive Care Coordination will be delivered primarily in the home or shelter setting but could also be delivered in community, educational or job training settings. Hospitals will accept referrals for Success Life360 services from a diverse array of health and social service organizations, medical providers and non- medical supports in the community through

Life360	Services Definition	Eligibility	Duration	Settings and Referrals
HOME	criminal justice if applicable. Developing an individualized PCAP reflecting the beneficiary 's preferences for addressing the needs identified. Goals may include but are not limited to establishing and maintaining regular care for behavioral health and/or medical needs; strengthening life skills; emotional and mental wellness; support applying for job training or education programs offered through the provider or other organizations; and obtaining or sustaining safe housing. Working directly with the beneficiary to improve their skills to be healthy and thrive in their community and connecting them to identified medical services and nonmedical supports. Documenting care coordination activities including new goals and barriers/ successes experienced by the beneficiary.	under the supervision of the Division of Youth Services as verified by Arkansas Department of Human Services Between nineteen (19) and twentyfour (24) years of age and has been previously placed under the supervision of the Arkansas Department of Correction, as verified by the Arkansas Department of Correction Between nineteen (19) and twentyseven (27) years of age and has been previously placed under the supervision of the Division of Children and Family Services; as verified by Arkansas Department of Human Services. Between nineteen (19) and thirty (30) years of age and is a veteran verified by Arkansas Veterans Administration.	have not been completed and the individual remains eligible for Medicaid.	formal and informal agreements. A large portion of referrals will come from the state agencies that serve eligible beneficiaries.

Attachment H Life360 HOME Service Details (RESERVED)

Attachment I

Protocol for Assessment of Beneficiary Eligibility and Needs, Infrastructure Planning, and Provider Qualifications for Life360 HOMEs

Overview

As part of the new Arkansas Health and Opportunity for Me (ARHOME) program, Arkansas is creating a Life360 HOME program to create Community Bridge Organizations (CBOs), known as Life360 HOMEs, for ARHOME beneficiaries most at-risk of long-term poverty and poor health outcomes. The state will contract with hospitals to become Life360 HOMEs and address the health-related social needs (HRSN) of eligible beneficiaries. A central component of the program is screening beneficiaries enrolled in the program for HRSN and referring them to needed resources. There are three types of Life360 HOMEs:

Maternal Life360 HOMEs: The goal of the Maternal Life360 HOME is to improve state maternal health and child health outcomes, particularly birth outcomes, by providing evidence-based home visiting services to women with high-risk pregnancies.

Rural Life360 HOMEs: Rural hospitals approved to be Rural Life360 HOMEs will provide care coordination services to beneficiaries with serious mental illness or substance use disorder. Rural Life360s will also provide HRSN screenings to general community members and refer to needed resources and Life360s will operate an acute crisis unit in the hospital.

Success Life360 HOMEs: Acute care hospitals approved to become Success Life360 HOMEs will provide services to enhance life skills (e.g., resume writing, obtaining a driver's license) for young adults (ages 19-30) who are veterans or who were previously incarcerated, in the juvenile justice system, or in foster care. (As part of a separate waiver amendment application, the state is requesting to expand beneficiary eligibility to adults up to age 59. As of May 2024, this application is still pending approval.)

This Protocol must include:

- a list of the Life360 HOME services and service descriptions, outlining the name and description of each proposed service,
- the criteria for defining when each service is medically appropriate,
- the process by which that criteria will be applied including care plan requirements or other documented processes,
- proposed uses of Life360 HOME infrastructure, and
- provider qualification criteria for each service.

Identifying Beneficiaries with HRSN

A description of the process for identifying beneficiaries with health-related social needs, including

- outlining beneficiary eligibility,
- implementation settings,
- screening tool selection, and
- rescreening approach and frequency.

Life360 HOME Beneficiary Eligibility

All Life360 HOMEs enroll eligible beneficiaries into the program based on the eligibility criteria outlined below for each type of Life360 HOME. If more than one type of Life360 HOME is available and a beneficiary is eligible for both, they may choose the Life360 that best fits their needs. The Life360 HOME will either enroll the beneficiary or provide linkage to the other Life360 based on the enrollee's request. Each Life360 HOME hospital will be responsible for entering enrollment requests with the required documentation for each type of Life360 HOME to the Medicaid provider portal. Maternal and Rural Life360 HOME eligibility requires a medical diagnosis for enrollment, but referral for potential program participation may be initiated by community partners, such as homeless shelters, churches, or food banks. Clients may even selfrefer based on knowledge of the program or state and community outreach efforts. Eligibility will be verified through an enrollment program reviewing each enrollment request. As part of the enrollment request, each beneficiary will submit a consent form indicating their agreement to participate in the program and their consent to have their data shared with program partners. Participation in Life360 services is voluntary for the beneficiary; the beneficiary is not required to enroll in Life360 HOME program to continue Medicaid eligibility. Those participating in Life360 may end services at any time by informing the enrollment broker or Life360 provider.

To be eligible for Life360 HOME participation, the beneficiary must live in the service area defined by the Life360 HOME provider. Residence can be determined by the person's geographic residence, shelter or other temporary residence, such as a health facility. If no current residence exists, job history, school/childcare enrollment, or legal documents can help establish whether the beneficiary meets the residency requirements. The chart below describes the criteria beneficiaries must meet to be eligible to receive Life360 HOME services. It also describes the implementation settings for Life360 activities.

Life360 HOME	Beneficiary Eligibility for Services	Implementation Settings
Maternal Life360 HOME	Individuals are eligible to enroll in the Maternal Life360 HOME program if they: 1. Clinical criteria: Are either currently pregnant with a high-risk pregnancy or were pregnant with a high-risk pregnancy when they originally enrolled in the Maternal Life360 program. High-risk pregnancy is defined as having a diagnosis of needing supervision for high-risk pregnancy. High-risk pregnancy must be verified through a completed referral form from the beneficiary's physician that includes the most current clinical note.	Home visiting services will mostly be delivered in the beneficiary's home. The services may also be delivered in the community partner organization facility, medical clinic, behavioral health clinic, shelter, or hospital settings. Video or phone-supported visits also may be appropriate for beneficiaries being served in remote areas or experiencing
	Are currently enrolled in Arkansas Medicaid or were enrolled in ARHOME while participating in the Maternal Life360	contagious illness. Maternal Life360s will accept referrals for services from a diverse array of health and social service

Life360 HOME	Beneficiary Eligibility for Services	Implementation Settings
	program. Women who were enrolled in ARHOME at the time of the child's birth are eligible to remain in the program for up to two years after the baby's birth, even if they lose Medicaid eligibility. Women who were in another Arkansas Medicaid program while enrolled in the program are eligible to participate for one year after the baby's birth but cannot continue to receive services if they lose Medicaid eligibility. 3. Are not currently receiving state- or federally funded home visiting services through a provider whose services cover pregnancy or the first two (2) years of a baby's life.	organizations, medical providers, and non-medical supports in the community through formal and informal agreements. For persons receiving intensive care coordination, the care coordinator will communicate with partners and the individual to ensure resources are obtained to meet their needs. The Maternal Life360 HOME will document resources through either formal or informal partner agreements received in the enrollees' PCAP.
	To specifically qualify for housing supports (not including helping with connections to housing supports), individuals must be considered homeless or at risk of becoming homeless, as defined by the U.S. Department of Housing and Urban Development (HUD) in 24 CFR 91.5.	
	To specifically qualify for nutritional supports (not including helping with connections to nutritional supports), individuals must be identified as meeting the <u>USDA definition</u> of low food security or very low food security. Further detail on the available housing or	
	nutrition supports is available in the HRSN Services section below.	
Rural Life360 HOME	Community HRSN Screening: All individuals living in the Rural Life360 service area are eligible for HRSN screening and referrals to needed community supports. These individuals will not be enrolled in the Rural Life360 HOME program through the enrollment	Community HRSN screening and referrals will occur in settings identified by the Life360 hospital that ensures space for confidential communication, including but not limited to the following:

Life360 HOME	Beneficiary Eligibility for Services	Implementation Settings
	process described above but will receive HRSN screenings and referrals if they agree to be screened.	 Hospital facilities Medical and behavioral health clinics
	Intensive Care Coordination To be eligible for intensive care coordination, an individual must:	 Health fairs Local health units Shelters and transitional housing Food banks and pantries
	 Be enrolled in ARHOME; Have a mental health and/or substance use disorder diagnosis as verified by a qualified provider; and Not be enrolled in the Provider-led Arkansas Shared Services Entity (PASSE) program, a managed care program that provides care coordination, medical care and other supports for persons with mental health or intellectual or developmental disability who meet the PASSE's established assessment criteria. 	DHS will review any proposed formal agreements with other service providers during the application and the readiness stage to confirm provider's ability (i.e., having funding and experience with a particular HRSN) to provide that service and that the scope of services complies with the approved HRSN in the STCs and the Life360 provider manual
	To specifically qualify for housing supports (not including helping with connections to housing supports), individuals must be considered homeless or at risk of becoming homeless, as defined by the U.S. Department of Housing and Urban Development (HUD) in 24 CFR 91.5. To specifically qualify for nutritional	requirements. Intensive care coordination can be delivered in the community partner organization facility, medical clinic, behavioral health clinic, hospital, or the beneficiary's home, shelter, or transitional
	supports (not including helping with connections to nutritional supports), individuals must be identified as meeting the <u>USDA definition</u> of low food security or very low food security.	housing. Video supported visits also may be appropriate for beneficiaries, particularly those in remote areas or experiencing
	Further detail on the available housing or nutrition supports is available in the HRSN Services section below.	contagious illness.
Success Life360 HOME	Individuals are eligible for Success Life360 intensive care coordination if they meet the following criteria:	Intensive care coordination will be delivered primarily in the facility of the community

Life360 HOME	Beneficiary Eligibility for Services	Implementation Settings
Life360 HOME	 Are enrolled in ARHOME; Are not enrolled in the Provider-led Arkansas Shared Services Entity (PASSE) program; Have a chronic health condition as verified by participating hospitals. Meet the criteria for at least one of the following categories: Is between nineteen (19) and twenty-four (24) years of age and has been previously placed under the supervision of the DHS Division of Youth Services as verified by DHS. Is between nineteen (19) and twenty-four (24) years of age and has been previously placed under the supervision of the Arkansas Department of Corrections (DOC), as verified by the DOC. 	Implementation Settings partner organization but may also be delivered in the beneficiary's home, shelter or transitional housing facility. Video supported visits also may be appropriate for beneficiaries, particularly those in remote areas or experiencing contagious illness.
	 Is between nineteen (19) and twenty-seven (27) years of age and has been previously placed under the supervision of the DHS Division of Children and Family Services; as verified by DHS. Is between nineteen (19) and thirty (30) years of age and is a veteran as verified by DD214 Certificate of Release or Discharge from Active Duty. To specifically qualify for financial supports for housing (not including helping with connections to housing supports), individuals must be considered homeless or at risk of becoming homeless, as defined by the U.S. Department of Housing and Urban Development (HUD) in 24 CFR 91.5. To specifically qualify for financial 	
	nutritional supports (not including helping with connections to nutritional supports),	

Life360 HOME	Beneficiary Eligibility for Services	Implementation Settings
	individuals must be identified as meeting the <u>USDA definition</u> of low food security or very low food security.	
	Further detail on the available financial supports for housing or nutrition is available in the HRSN Services section below.	

HRSN Screening

The process for identifying beneficiaries' HRSN starts with an HRSN screening. All Life360 HOMEs will be expected to screen all enrolled beneficiaries to determine any needs or barriers a beneficiary may experience. These HRSN screenings will be expected to occur routine and must identify several required elements encompassing primary social determinants of health, including, at a minimum, housing instability, food insecurity, utility needs, interpersonal safety, transportation needs, financial strain, employment, family and community support, education, physical activity, substance use, mental health, and disabilities. Information gathered through HRSN screenings will be used to help inform care coordination plans and referrals to community services and supports.

HRSN will also be identified through the development and monitoring of the patient-centered action plan, or PCAP, as described in this protocol and included in the Life360 HOME provider manual.

• Screening tool selection, and rescreening approach and frequency

The Life360 HOME program will not specify a single HRSN screening tool providers must use, but Life360 HOME providers must use a DHS-approved HRSN screening tool. Life360 provider applicants must submit their screening tool during at application and DHS will verify use of the tool during readiness review prior to service implementation. While a specific HRSN tool will not be required, each Life360 must incorporate a tool that screens across a set of required domains, is written in accessible language, conducted by staff trained to use the tool, and is coordinated with any additional screening and assessment that may be part of the program. Providers must complete necessary staff training to administer the tool, have a platform for capturing results, and a process for linking beneficiaries to resources and monitoring the receipt of those referrals.

At readiness review and prior to starting services, DHS will ensure each Life360 and/or its partner has met each of these requirements. DHS may provide feedback on the tools and require revisions to ensure alignment with program goals. If a Life360 changes its HRSN screening tool, it must submit its new tool to DHS for approval before making the change.

HRSN screens will be conducted with every enrolled Life360 beneficiary within fifteen (15) calendar days of enrollment and every six (6) months during program participation.

Medical Appropriateness

A description of the process by which clinical criteria will be applied, including:

- 1. A description of the documented process wherein a provider, using their professional judgment, may deem the service to be medically appropriate
- 2. Plan to identify medical appropriateness based on clinical and social risk factors

For Maternal Life360, the clinical criteria applied for receiving home visiting services is a medical diagnosis of needing supervision for high-risk pregnancy which includes medical and social risk. This diagnosis must be verified through a completed referral form from the beneficiary's medical provider, including PCP, specialist or advanced nurse practitioner that includes the most current clinical note. See Appendix A for diagnosis codes that beneficiaries must have to be eligible for Life360 home visiting services.

Individuals living in the Rural Life360 service area are eligible for HRSN screening and referrals to needed community supports. To be eligible for Rural Life360 Home intensive care coordination HRSN supports, the individual must have a mental health and/or substance use disorder diagnosis verified by any qualified clinical provider in the beneficiary's QHP or Medicaid FFS for those enrolled in the Medically Frail ARHOME. Generally this includes a licensed clinician or PCP providing care to the beneficiary who meets the QHP or Medicaid program criteria. See Appendix A for diagnosis codes that beneficiaries must have to be eligible for Life360 care coordination services.

Success Life360 eligibility criteria are based on age, as well as social risk factors, including former foster care services or any supervision by the DHS children and family welfare division, juvenile justice system involvement, former incarceration, or veteran status. Success Life360 HOMEs will verify that potential enrollees have a chronic condition to be eligible for Success Life360 HOME services. DHS will develop a list of eligible chronic conditions and will require Success Life 360 hospitals to verify the client has one of the listed chronic conditions prior to enrollment.

For all three Life360 types, receipt of HRSN supports will be informed by the needs identified through the HRSN screening and as well as other documented concerns in coordination with the community referral network partners and PCP.

Life360 enrollees will continue to receive all medical care through the existing network of medical and clinical providers. Identification of appropriateness for any medical or clinical services after Life360 referrals will be determined by licensed treatment providers. Treatment services will be covered through the ARHOME or other Medicaid/insurance plan based on each plan's medical criteria.

Identification of appropriateness for social supports obtained through Life360 referrals will be determined by HRSN screening, availability of community resources and available program eligibility parameters (for example income requirements, disability, household composition, and/or other defined risk criteria).

Plan to publicly maintain these clinical/social risk criteria to ensure transparency for beneficiaries and stakeholders

DHS will post on its website the Life360 HOMEs provider manual, which describes beneficiary eligibility for Life360 services, the description of services and other information helpful to beneficiaries. The Life360 Beneficiary webpage has already been established and will be updated with Life360 HOME locations and any changes related to eligibility or services. DHS will also develop and distribute beneficiary flyers for each type of Life360 HOMES that include the eligibility criteria and other information about the program. The information will be distributed as part of community outreach by Life360s, DHS partners, and community stakeholders. The website and flyers will be available in English, Spanish and Marshallese. Flyers needed in other languages will be provided as requested by Life360 HOME providers or program enrollees and DHS will post them for availability on the agency's website.

Life360s and their partners will be responsible for outreach to ensure entities that will make referrals based on an eligible diagnosis (e.g., obstetricians and behavioral health providers) are aware of Life360 services and the referral process. Life360s and their partners will also be responsible for general community outreach and awareness activities directed at the target population as well as key community groups that have direct contact with and are trusted by the Life360 target population (e.g., veterans groups, shelters, local health units, etc.).

Care Plan Development

A description of the process for developing care plans based on assessment of need

Plan to initiate care plans and closed-loop referrals to social services and community providers based on the outcomes of screening

Life360 HOMEs beneficiaries will develop with their Life360 care coordination coach an individualized person-centered action plan (PCAP) to address health needs and HRSN . DHS's requirements for documentation of the beneficiary's PCAP include documenting the HRSN screening results, services needed, including health care service needs, or explored with client; referrals made, and outcomes of services rendered. Client goals and milestones and the date(s) of the initial PCAP and changes or updates must also be documented. The PCAP will be updated regularly to reflect goals met and new circumstances or needs. At a minimum, the PCAP will be updated annually. These PCAP requirements are intended to align with the existing person-centered planning requirements that apply to the provision of Home and Community-Based Services in Medicaid. The PCAP must describe the beneficiary's strengths, preferences, including language or disability accommodation, and HRSN, as identified by the HRSN screen, as well as needs for connections to medical providers. The plan must include short-term (less than 6 months) goals, a crisis plan, if necessary, and longer-term goals (more than 6 months).

Page 102 of 146

Each PCAP must include goals and barriers in areas identified through screening and ongoing interaction with the beneficiary, including but not limited to:

- Safe housing including utilities, if necessary
- Food security and nutrition
- Employment and/or education
- Financial stability and any needed social services
- Health and emotional wellness
- Establishing a relationship with a primary care provider and all other needed healthcare providers for preventative care (and to avoid non-emergent emergency department visits)
- Criminal justice involvement, if applicable
- Transportation

Providers must have a PCAP template developed and approved by DHS prior to starting services and a plan for initiating and updating the PCAP regularly, at a minimum annually. Life360s will conduct in-depth personal interview with the individual to identify HRSN needs and potential barriers to addressing them. The Life360 will develop or determine the tools and care coordination services provided for each target population and will coordinate with other services providers. Maternal Life360s will implement the care plan development approach of the evidence-based model selected that utilize best practices and tools for quality and effectiveness of home visits and to document observations and assessments of maternal/child health and any other family outcomes included. Therefore, a separate PCAP will not be required.

Each Life360 will identify their processes for referring individuals to community resources as part of their application, and DHS will review that process as part of the readiness review. To support referrals, each Life360 must have in place a community resource network and include a description of their plan for this network in their application. For example, Life360 hospitals will complete an assessment of the service area population demographics and a community resource inventory to determine the available community resources and gaps to develop referrals to HRSN. This inventory will include community medical providers, community service organizations, and social service providers to whom the Life360 can refer beneficiaries for appropriate services and supports. Life360s will also execute community partner agreements for their referral network prior to starting services, establish agreements if needed for health information data exchange and a process for communication and tracking of referrals. The above required components of Life360 are outlined in DHS's provider manual, and specifics are outlined in DHS's executed agreements with each Life360 provider. DHS will monitor the implementation of the requirements through the program reports.

DHS is working with Arkansas Division of Information Services (DIS) and health care provider groups to coordinate and leverage state resources to develop (and avoid duplication of) HRSN screenings, resource referral platforms, state program applications and education and workforce connections. DHS is working with these groups to ensure the tools and technology currently under development support Life360s' care coordination for care planning and documentation of services provided. A component of this project will streamline and improve applications for public benefits such as Medicaid, TANF and SNAP, as well as the process for claiming federal income tax credits through an open-source tool that integrates applications for public benefits.

Page 103 of 146

DIS houses an array of federal and state employment, workforce training/education and other data. DIS has been awarded philanthropic support to continue its technical support of improvements to the state's workforce and career education platform. Additionally, DHS serves on the Governor's Workforce Cabinet along with other key state agencies. DHS will rely on data matching across DIS (workforce, incarceration) and DHS (FPL, dependents, SNAP, etc.) to develop a basic profile and also translating HRSN screening results to standardized codes that can be reported back to MMIS/Life360 portal. The available HRSN and employment/education screening and intake information will help identify beneficiary activities, characteristics and eligibility across state Workforce programs, DHS TANF/SNAP caseworkers, and Life360s.

DHS will continue to discuss with DIS, the health care provider community and other state agencies our workplan for HRSN related data to support Life360 HOMEs and integration with other key HRSN across other agencies such as workforce and education.

HRSN Services

A list of the covered HRSN services (not to exceed those allowed under STC 41), with associated service descriptions and service-specific provider qualification requirements.

The Life360 HOME will ensure enrollees with identified HRSN connect with community resources and supports as permitted under the Life360 HOME STCs and Life360 provider manual. Life360s will be expected to establish an effective community referral network to include community housing and other community resource partners to obtain any resources Life360 beneficiaries would be eligible to receive. Life360s will assist individuals in applying for and accessing state and federal benefit programs, or they may also use the state's centralized benefits portal to apply on their own. For general resources, Life360s can provide referral directly or assist client with accessing resource platforms, such as 211 and FindHelp.org,Life360s HOMEs may not supplant any other available funding sources such as housing or nutrition supports available to beneficiaries through local, state or federal programs. 12 In addition to HRSN screenings and resource referrals, all Life360 HOMEs will provide care coordination and case management services to assist beneficiaries in receiving needed services. As part of that care coordination, all Life360 HOMEs will develop a Person-Centered Action Plan (PCAP) for each enrolled beneficiary as described above within the first 90 days and initial visit(s), and the process will be individualized to reflect each client's needs and preferences and recommendations for services to address HRSN The PCAP will document the needs identified through HRSN screening and through interaction with the Life360 care coordinator. The PCAP will identify the enrollee's personal goals, developed in coordination with enrollee, and the steps necessary to achieving those goals. Goals may include strengthening life and family skills, maintaining emotional and mental wellness, avoiding interaction with the criminal justice system, achieving an educational degree or career certification, and obtaining or sustaining safe housing. The PCAP will set a timeframe for meeting the goals and set milestones the enrollee should meet along the way.

Life360 HOMEs will also deliver care coordination services focused on the particular needs of the beneficiaries served in each of the three types of Life360 HOMEs. For example, Maternal Life360 HOMEs will focus on helping women with high-risk pregnancies access pre- and postnatal care and assist

_

¹² Applies to all three types of Life360 HOMEs

with newborn care, while Rural Life360 HOMEs will focus on ensuring beneficiaries with mental health needs access mental health care and needed medications. The services specific to each type of Life360 HOME are provided below.

Life360 HOME	Services Description	Provider qualifications. ¹³
Maternal Life360 HOME	Beneficiaries will receive maternal home visitation services based on one of the models recognized by the U.S. Department of Health and Human Services to be effective in improving maternal and child health. Home visiting is an evidence-based program that provides direct support and intensive care coordination of services for beneficiaries served by Maternal Life360s with the goals of improving maternal and infant health outcomes, promoting child development and school readiness, connecting families to needed community resources and supports and increasing a family's education and earning potential. ¹⁴ Life360 HOME hospitals will incorporate screening that identify needs and help inform the supports to be delivered in each of the following domains: Maternal and child health Family economic self-sufficiency Parenting practices Specific home visiting activities will include: Assessing the enrollee and her family's health-related social needs Providing beneficiaries with education and support on prenatal health, birth preparation and newborn care Helping navigate medical care and addressing barriers that could prevent regular prenatal visits and well child visits Assisting with accessing needed resources and services, including referring to community and state resources, such as food banks, WIC, and housing services. Assisting with enrollment in education or workforce training programs. This assistance is limited to case management coordination and does not include education application	A birthing hospital in the state of Arkansas or in a border state that: A. Is licensed as a general hospital; B. Provides obstetrics services; and C. Is enrolled as a provider with the Arkansas Medicaid program. The Life360 or the organization with which the Life360 contracts to provide home visiting must use an evidence- based maternal and child home visitation model. The selected model(s) must cover home visiting services from pregnancy through at least the first two (2) years of a child's life. In the Maternal Life360 HOME program, home visitors serve as the case manager/care coordinator. Home visitors must meet the following criteria: Have a high school diploma or GED and Have experience with early childhood education, childhood development, or social work, family support, maternity services, or case management services. Home visitors must have completed all training and continued education requirements of the selected home visiting model.

¹³ Life360 HOME Provider Manual community partner organization criteria Section 203.230

_

¹⁴ Life360 HOMEs Provider Manual approved December 2022.

Life360 HOME	Services Description	Provider qualifications. ¹³
	fees or other payments related to education on the person's behalf.	
Rural Life360 HOME	 Individuals with a serious mental health or substance use disorder will receive intensive care coordination ¹⁵ through the Rural Life360 hospital, including: Ensuring the PCAP establishes goals for establishing and maintaining regular care for behavioral health and medical needs; Working directly with beneficiaries to improve their skills to be healthy and thrive in their community and connecting them to identified medical services and nonmedical supports. Documenting care coordination activities including new goals and barriers/successes experienced by beneficiary. 	To be eligible to become a Rural Life360 HOME provider, hospitals must qualify as a small rural hospital, meeting the following criteria: A. Licensed as a critical access hospital or a general hospital; B. Located in a rural area, meaning an Arkansas county: • That contains a hospital designated as a critical access hospital or participant in the Small Rural Hospital Improvement Program or • Has a population of fifty-thousand (50,000) or less. C. Has fifty (50) or fewer staffed beds;
	Rural Life360 HOMEs also must operate an Acute Care Unit that provides brief crisis treatment services to persons experiencing a psychiatric and/or substance abuse-related crisis and may pose an escalated risk of harm to themselves or others. ACUs provide hospital diversion and step-down services with psychiatry and substance use disorder services available on-site as well as on-call psychiatry available 24 hours a day. The following services must be available: Ongoing assessment and observation, crisis intervention, substance use and co-occurring	 and D. Is enrolled as a provider in the Arkansas Medicaid program. In the Rural Life360 HOME program, individual care coordinators must be employees of the Life360 hospital and must meet the following criteria: Have a high school diploma or GED and Have experience working with individuals experiencing substance abuse or mental illness or providing case management services. While ACUs will be operated directly by
	intervention, substance use and co-occurring treatment and referral for independent assessment ¹⁶ and care planning as needed.	the hospital, a separate organization may be subcontracted to staff the ACUs. These organizations will have clinical

¹⁵ An umbrella term for a collaborative process in which a care coordinator or others assess, plan, implement, coordinate, monitor and evaluate the options, services and supports required to meet the beneficiary's health and HRSN needs. It is characterized by advocacy, communication, and resource management, and promotes quality interventions and outcomes. In addition to addressing medical services, care coordination coaches ensure that beneficiaries have safe housing, employment, education, financial stability, and emotional/mental wellness.

¹⁶ An assessment used to determine eligibility for PASSE program enrollment.

Life360 HOME	Services Description	Provider qualifications. ¹³
	Short-term detoxification may also be offered.	providers qualified with appropriate skills and licensure that comply with all state medical/nursing licensure and Arkansas' Medicaid ACU provider requirements.
Success Life360 HOME	Beneficiaries will receive Intensive Care Coordination services from the Success Life360, which will include: • Developing an individualized PCAP with goals that may include but are not limited to establishing and maintaining regular care for behavioral health and/or medical needs; strengthening life skills; maintaining emotional and mental wellness; applying for job training or education programs; and obtaining or sustaining safe housing. • Working directly with the beneficiary to improve their skills to be healthy and thrive in their community and connecting them to identified medical services and nonmedical supports. • Documenting care coordination activities including new goals and barriers/ successes experienced by the beneficiary.	To be eligible to become a Rural Life360 HOME provider, hospitals must qualify as: A. An acute care hospital licensed by the Arkansas Department of Health as a general hospital or a surgery and general medical care hospital; and B. Enrolled as a provider with the Arkansas Medicaid Program. The Life360 hospital or a subcontracted community organization may provide care coordination. The community partner organization must be experienced in working with young adults most at risk of long-term poverty. The partner must have experience helping individuals build life skills to be physically, socially, and emotionally healthy to live in and contribute to their communities. In the Success Life360 HOME program, case managers must meet of the following criteria: Have a high school diploma or GED and Have social work experience or experience working with veterans, corrections, homelessness, family support, workforce readiness, substance abuse or mental illness.

Life360 HOME may use its program funding to provide financial assistance to beneficiaries. Allowable expenses are those that enable a beneficiary to access services or supports to address a need identified through an HRSN screening or ongoing engagement with the beneficiary.

- 1) <u>H</u>ousing supports to include:
 - a) Pre-tenancy and tenancy sustaining services, including tenant rights education and eviction prevention.

- b) Housing transition navigation services. One-time transition and moving costs (e.g., security deposits, first-month's rent, utilities activation fees, movers, and pest eradication).
- c) Housing deposits to secure housing, including application and inspection fees and fees to secure needed identification.
- 2) Nutrition Supports, including nutrition counseling and education, such as healthy meal preparation Life360 HOMEs will be responsible for identifying program participants with food insecurity and connecting them to resources, including WIC, SNAP and food banks.

Life360 HOMEs that elect to provide financial supports for housing (not including helping with connections to housing supports) will be limited to providing such support only to individuals who are homeless or at risk of becoming homeless as defined by the U.S. Department of Housing and Urban Development (HUD) in 24 CFR 91.5. This definition serves as the social risk factor for direct receipt of housing HRSN supports from a Life360 HOMEs provider.

Life360 HOMEs that elect to provide financial nutritional supports (not including helping with connections to nutritional supports) will be limited to providing such supports only to individuals identified as meeting the <u>USDA definition</u> of low food security or very low food security:

- Low food security: Individual reports reduced quality, variety, or desirability of diet. Little or no indication of reduced food intake.
- Very low food security: Individual reports multiple indications of disrupted eating patterns and reduced food intake.

This definition serves as the social risk factor for direct receipt of nutritional HRSN supports from a Life360 HOMEs provider.

Description of how the state will ensure that HRSN screening and service delivery are provided to beneficiaries in ways that are culturally responsive and/or trauma-informed

Life 360s will be required to provide or contract to provide services that demonstrate cultural competency and are provided in the languages frequently spoken by the targeted population. Life360 provider applicants will identify the languages commonly spoken in the Life360 service area in the community assessment they submit in their initial provider application and update annually thereafter. Tools used for the program, including the HRSN screening tool and the PCAP, must be developed in the languages frequently spoken by the target population. Life360s will also be required to have adequate program staff and appropriate staff training to provide services effectively. Life360s also will be required to have a plan for monitoring beneficiary milestones and goals, collecting data on beneficiary outcomes, including demographics, and monitoring other quality improvement measures identified by DHS. DHS will monitor program's reporting of staff training received and other program data.

Infrastructure Expenditures

Proposed uses of HRSN infrastructure expenditures, including the type of entities to receive funding, the intended purpose of the funding, the projected expenditure amounts, and an implementation timeline.

Entities Receiving Infrastructure Funding

Hospitals enrolled as Life360 HOME providers will receive one or more of the five types of infrastructure funding described in the table below, depending on the type of Life360 HOME program in which they are enrolled. Hospitals can subcontract with community service providers to provide some functions of the Life360, including those categorized as infrastructure costs.

Infrastructure Funding Purpose and Allowable Uses

Туре	Life360 HOME	Amount	Allowable Expenditures
Type Startup	HOME Receiving Maternal, Rural, Success	Amount Two payments of \$50,000 for Maternal and Rural. Three payments of \$75,000 for Success.	Allowable Expenditures Startup costs necessary to develop staff capacity and the infrastructure necessary to accept and serve beneficiaries. Allowable uses include: • Salaries and fringe during the start-up phase for program staff, including program management, clerical and IT staff and home visitors, • Staff recruitment and training, • Information technology systems to allow for enrolling and case management of
			beneficiaries, Health-Related Social Needs (HRSN) screening and resource referral, tracking and monitoring program finances, reporting required program data and interfacing with community partner organization, if applicable, Program equipment and supplies, and Activities associated with the formulation of partners/subcontractors, including capacity assessments and development of business or operational policies including programmatic needs and referral flows
Technology	Success	Annual amount based on submitted and approved budget, divided by 12 and provided monthly; \$50,000 maximum	Additional costs to support data-sharing among organizations and providers that serve beneficiaries and to make coordination more efficient and effective. Allowable uses include: IT systems to allow for enrolling beneficiaries, HRSN screening and resource referral, tracking and monitoring program finances, reporting required program data and interfacing with community partner organization

Projected Infrastructure Expenditures

Infrastructure expenditures are projected based on the cost of starting up new sites and the ongoing costs for existing sites. DHS estimates infrastructure expenditures to total \$2,000,000 for the demonstration period. The chart below describes the total available infrastructure funding for each type of Life360 HOME. Each Life360 will request how much they need for their program's startup costs and other infrastructure costs up to the maximum allowable amount. However, the final amount will be based on what the state approves. The total infrastructure expenditures will not exceed the total allowable cost of \$10.5M for DY 1-DY 5 included in STC 42.

Life360 HOME Type	Year 2 (2023)	Year 3 (2024)	Year 4 (2025)	Year 5 (2026)
Maternal Life360	\$500,000	\$500,000	\$500,000	\$500,000
Total Infrastructure Expenditures	\$500,000	\$500,000	\$500,000	\$500,000

Proposed Implementation Timeline

The timeline for implementation of startup funding is provided in the table below. Each Life360 will have up to 180 days from the date of the fully executed startup agreement to complete readiness review and begin enrolling beneficiaries in the Life360 to receive supports.

Implementation	Year 2	Year 3	Year 4	Year 5
Milestone				
Maternal Life360	October 1, 2023			
providers approved				
for startup funding				
Rural Life360	October 1, 2023			
providers approved				
for startup funding				
Success Life360	December 30,			
providers approved	2023			
for startup funding				
Additional		January 2024	January 2025	January 2026
Maternal Life360				
providers approved				
for startup				
Additional Rural	_	Spring 2024	January 2025	January 2026
Life360 provider				
approved for				
startup funding				

Additional Success	January 2025	
Life360 provider		
approved for		
startup funding		

The implementation timeline also estimates starting five Life360 HOMEs of each type—Maternal, Rural and Success—in Year 2 of the ARHOME demonstration (2023). The timeline of infrastructure expenditures is based on the number of Life360 HOMEs in operation and new Life360 HOME starting operations.

		Total Life360 HOMEs	New Life360 HOMEs
	Maternal	5	5
Year Two	Rural	5	5
	Success	5	5
	Maternal	10	5
Year Three	Rural	7	2
	Success	5	0
	Maternal	15	5
Year Four	Rural	9	2
	Success	8	3
	Maternal	20	5
Year Five	Rural	11	2
	Success	8	0

PROTOCOL FOR ASSESSMENT OF BENEFICIARY ELIGIBILITY AND NEEDS: APPENDIX A

Maternal Life360 HOME: Supervision of High-Risk Diagnosis Codes

ICD-10-	
CM	History of Infertility
O0900	SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, UNSPECIFIED TRIMESTER
O0901	SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, FIRST TRIMESTER
O0902	SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, SECOND TRIMESTER
O0903	SUPERVISION OF PREGNANCY WITH HISTORY OF INFERTILITY, THIRD TRIMESTER
O09811	SUPERVISION OF PREGNANCY RESULTING FROM ASSISTED REPRODUCTIVE TECHNOLOGY, FIRST TRIMESTER
O09812	SUPERVISION OF PREGNANCY RESULTING FROM ASSISTED REPRODUCTIVE TECHNOLOGY, SECOND TRIMESTER
O09813	SUPERVISION OF PREGNANCY RESULTING FROM ASSISTED REPRODUCTIVE TECHNOLOGY, THIRD TRIMESTER
O09819	SUPERVISION OF PREGNANCY RESULTING FROM ASSISTED REPRODUCTIVE TECHNOLOGY, UNSPECIFIED TRIMESTER
	History of Ectopic or Molar Pregnancy
O0910	SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, UNSPECIFIED TRIMESTER
O0911	SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, FIRST TRIMESTER
O0912	SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, SECOND TRIMESTER
O0913	SUPERVISION OF PREGNANCY WITH HISTORY OF ECTOPIC PREGNANCY, THIRD TRIMESTER
O09A0	SUPERVISION OF PREGNANCY WITH HISTORY OF MOLAR PREGNANCY, UNSPECIFIED TRIMESTER
O09A1	SUPERVISION OF PREGNANCY WITH HISTORY OF MOLAR PREGNANCY, FIRST TRIMESTER
O09A2	SUPERVISION OF PREGNANCY WITH HISTORY OF MOLAR PREGNANCY, SECOND TRIMESTER
O09A3	SUPERVISION OF PREGNANCY WITH HISTORY OF MOLAR PREGNANCY, THIRD TRIMESTER

	History of Pre-Term Labor
O09211	SUPERVISION OF PREGNANCY WITH HISTORY OF PRE-TERM LABOR, FIRST TRIMESTER
O09212	SUPERVISION OF PREGNANCY WITH HISTORY OF PRE-TERM LABOR, SECOND TRIMESTER
O09213	SUPERVISION OF PREGNANCY WITH HISTORY OF PRE-TERM LABOR, THIRD TRIMESTER
O09219	SUPERVISION OF PREGNANCY WITH HISTORY OF PRE-TERM LABOR, UNSPECIFIED TRIMESTER
	Insufficient Reproductive Care or OB History
O09291	SUPERVISION OF PREGNANCY WITH OTHER POOR REPRODUCTIVE OR OBSTETRIC HISTORY, FIRST TRIMESTER
O09292	SUPERVISION OF PREGNANCY WITH OTHER POOR REPRODUCTIVE OR OBSTETRIC HISTORY, SECOND TRIMESTER
O09293	SUPERVISION OF PREGNANCY WITH OTHER POOR REPRODUCTIVE OR OBSTETRIC HISTORY, THIRD TRIMESTER
O09299	SUPERVISION OF PREGNANCY WITH OTHER POOR REPRODUCTIVE OR OBSTETRIC HISTORY, UNSPECIFIED TRIMESTER
O0930	SUPERVISION OF PREGNANCY WITH INSUFFICIENT ANTENATAL CARE, UNSPECIFIED TRIMESTER
O0931	SUPERVISION OF PREGNANCY WITH INSUFFICIENT ANTENATAL CARE, FIRST TRIMESTER
O0932	SUPERVISION OF PREGNANCY WITH INSUFFICIENT ANTENATAL CARE, SECOND TRIMESTER
O0933	SUPERVISION OF PREGNANCY WITH INSUFFICIENT ANTENATAL CARE, THIRD TRIMESTER
	Grand Multiparity
O0940	SUPERVISION OF PREGNANCY WITH GRAND MULTIPARITY, UNSPECIFIED TRIMESTER
O0941	SUPERVISION OF PREGNANCY WITH GRAND MULTIPARITY, FIRST TRIMESTER
O0942	SUPERVISION OF PREGNANCY WITH GRAND MULTIPARITY, SECOND TRIMESTER
O0943	SUPERVISION OF PREGNANCY WITH GRAND MULTIPARITY, THIRD TRIMESTER
	Elderly Primigravida and Multigravida
O09511	SUPERVISION OF ELDERLY PRIMIGRAVIDA, FIRST TRIMESTER
O09512	SUPERVISION OF ELDERLY PRIMIGRAVIDA, SECOND TRIMESTER
O09513	SUPERVISION OF ELDERLY PRIMIGRAVIDA, THIRD TRIMESTER
O09519	SUPERVISION OF ELDERLY PRIMIGRAVIDA, UNSPECIFIED TRIMESTER

O09521	SUPERVISION OF ELDERLY MULTIGRAVIDA, FIRST TRIMESTER
O09522	SUPERVISION OF ELDERLY MULTIGRAVIDA, SECOND TRIMESTER
O09523	SUPERVISION OF ELDERLY MULTIGRAVIDA, THIRD TRIMESTER
O09529	SUPERVISION OF ELDERLY MULTIGRAVIDA, UNSPECIFIED TRIMESTER
	Young Primigravida and Multigravida
O09611	SUPERVISION OF YOUNG PRIMIGRAVIDA, FIRST TRIMESTER
O09612	SUPERVISION OF YOUNG PRIMIGRAVIDA, SECOND TRIMESTER
O09613	SUPERVISION OF YOUNG PRIMIGRAVIDA, THIRD TRIMESTER
O09619	SUPERVISION OF YOUNG PRIMIGRAVIDA, UNSPECIFIED TRIMESTER
O09621	SUPERVISION OF YOUNG MULTIGRAVIDA, FIRST TRIMESTER
O09622	SUPERVISION OF YOUNG MULTIGRAVIDA, SECOND TRIMESTER
O09623	SUPERVISION OF YOUNG MULTIGRAVIDA, THIRD TRIMESTER

	<u></u>
O09629	SUPERVISION OF YOUNG MULTIGRAVIDA, UNSPECIFIED TRIMESTER
	Social Problems
O0970	SUPERVISION OF HIGH RISK PREGNANCY DUE TO SOCIAL PROBLEMS, UNSPECIFIED TRIMESTER
O0971	SUPERVISION OF HIGH RISK PREGNANCY DUE TO SOCIAL PROBLEMS, FIRST TRIMESTER
O0972	SUPERVISION OF HIGH RISK PREGNANCY DUE TO SOCIAL PROBLEMS, SECOND TRIMESTER
O0973	SUPERVISION OF HIGH RISK PREGNANCY DUE TO SOCIAL PROBLEMS, THIRD TRIMESTER
	In Utero Procedure During Previous Pregnancy
	SUPERVISION OF PREGNANCY WITH HISTORY OF IN UTERO PROCEDURE DURING PREVIOUS
O09821	PREGNANCY, FIRST TRIMESTER
	SUPERVISION OF PREGNANCY WITH HISTORY OF IN UTERO PROCEDURE DURING PREVIOUS
O09822	PREGNANCY, SECOND TRIMESTER
	SUPERVISION OF PREGNANCY WITH HISTORY OF IN UTERO PROCEDURE DURING PREVIOUS
O09823	PREGNANCY, THIRD TRIMESTER
	SUPERVISION OF PREGNANCY WITH HISTORY OF IN UTERO PROCEDURE DURING PREVIOUS
O09829	PREGNANCY, UNSPECIFIED TRIMESTER
	Supervision of Other High Risk Pregnancies
O09891	SUPERVISION OF OTHER HIGH RISK PREGNANCIES, FIRST TRIMESTER
O09892	SUPERVISION OF OTHER HIGH RISK PREGNANCIES, SECOND TRIMESTER
O09893	SUPERVISION OF OTHER HIGH RISK PREGNANCIES, THIRD TRIMESTER
O09899	SUPERVISION OF OTHER HIGH RISK PREGNANCIES, UNSPECIFIED TRIMESTER
O0990	SUPERVISION OF HIGH RISK PREGNANCY, UNSPECIFIED, UNSPECIFIED TRIMESTER
O0991	SUPERVISION OF HIGH RISK PREGNANCY, UNSPECIFIED, FIRST TRIMESTER
O0992	SUPERVISION OF HIGH RISK PREGNANCY, UNSPECIFIED, SECOND TRIMESTER
O0993	SUPERVISION OF HIGH RISK PREGNANCY, UNSPECIFIED, THIRD TRIMESTER

Rural Life360 HOME: Substance Abuse Disorder Diagnostic Codes

ICD-10 CM	Substance Use Disorder
F1010	ALCOHOL ABUSE, UNCOMPLICATED
F1011	ALCOHOL ABUSE, IN REMISSION
F10120	ALCOHOL ABUSE WITH INTOXICATION, UNCOMPLICATED
F10121	ALCOHOL ABUSE WITH INTOXICATION DELIRIUM
F10129	ALCOHOL ABUSE WITH INTOXICATION, UNSPECIFIED
F10130	ALCOHOL ABUSE WITH WITHDRAWAL, UNCOMPLICATED
F10131	ALCOHOL ABUSE WITH WITHDRAWAL DELIRIUM
F10132	ALCOHOL ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F10139	ALCOHOL ABUSE WITH WITHDRAWAL, UNSPECIFIED
F1014	ALCOHOL ABUSE WITH ALCOHOL-INDUCED MOOD DISORDER
F10150	ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F10151	ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F10159	ALCOHOL ABUSE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F10180	ALCOHOL ABUSE WITH ALCOHOL-INDUCED ANXIETY DISORDER
F10181	ALCOHOL ABUSE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION
F10182	ALCOHOL ABUSE WITH ALCOHOL-INDUCED SLEEP DISORDER
F10188	ALCOHOL ABUSE WITH OTHER ALCOHOL-INDUCED DISORDER
F1019	ALCOHOL ABUSE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER
F1020	ALCOHOL DEPENDENCE, UNCOMPLICATED
F1021	ALCOHOL DEPENDENCE, IN REMISSION
F10220	ALCOHOL DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F10221	ALCOHOL DEPENDENCE WITH INTOXICATION DELIRIUM
F10229	ALCOHOL DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F10230	ALCOHOL DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED
F10231	ALCOHOL DEPENDENCE WITH WITHDRAWAL DELIRIUM

F10232	ALCOHOL DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F10232	ALCOHOL DEPENDENCE WITH WITHDRAWAL WITH FERCEF TOAL DISTURBANCE ALCOHOL DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED
F10239	
	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED MOOD DISORDER
F10250	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F10251	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F10259	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1026	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER
F1027	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED PERSISTING DEMENTIA
F10280	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED ANXIETY DISORDER
F10281	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION
F10282	ALCOHOL DEPENDENCE WITH ALCOHOL-INDUCED SLEEP DISORDER
F10288	ALCOHOL DEPENDENCE WITH OTHER ALCOHOL-INDUCED DISORDER
F1029	ALCOHOL DEPENDENCE WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER
F10920	ALCOHOL USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F10921	ALCOHOL USE, UNSPECIFIED WITH INTOXICATION DELIRIUM
F10929	ALCOHOL USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F10930	ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL, UNCOMPLICATED
F10931	ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL DELIRIUM
F10932	ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F10939	ALCOHOL USE, UNSPECIFIED WITH WITHDRAWAL, UNSPECIFIED
F1094	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED MOOD DISORDER
F10950	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F10951	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS
F10959	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1096	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PERSISTING AMNESTIC DISORDER
F1097	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED PERSISTING DEMENTIA
F10980	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED ANXIETY DISORDER
F10981	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED SEXUAL DYSFUNCTION
L	

F10982	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED SLEEP DISORDER
F10988	ALCOHOL USE, UNSPECIFIED WITH ALCOHOL-INDUCED DISORDER
F1099	ALCOHOL USE, UNSPECIFIED WITH UNSPECIFIED ALCOHOL-INDUCED DISORDER
F1110	OPIOID ABUSE, UNCOMPLICATED
F11110	OPIOID ABUSE, IN REMISSION
F11120	OPIOID ABUSE, IN REMISSION OPIOID ABUSE WITH INTOXICATION, UNCOMPLICATED
F11120	OPIOID ABUSE WITH INTOXICATION, UNCOMPLICATED OPIOID ABUSE WITH INTOXICATION DELIRIUM
F11121	OPIOID ABUSE WITH INTOXICATION DELIKIOM OPIOID ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F11122	OPIOID ABUSE WITH INTOXICATION WITH TERCEL TOAL DISTURBANCE
F11129	OPIOID ABUSE WITH INTO AICATION, ONSFECIFIED OPIOID ABUSE WITH WITHDRAWAL
F1113	OPIOID ABUSE WITH WITHDRAWAL OPIOID ABUSE WITH OPIOID-INDUCED MOOD DISORDER
F1114	OPIOID ABUSE WITH OPIOID-INDUCED MOOD DISORDER OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F11150	OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F11151 F11159	OPIOID ABUSE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F11139 F11181	OPIOID ABUSE WITH OPIOID-INDUCED FST CHOTIC DISORDER, UNSFECIFIED OPIOID ABUSE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION
F11181 F11182	OPIOID ABUSE WITH OPIOID-INDUCED SEAUAL DISPUNCTION OPIOID ABUSE WITH OPIOID-INDUCED SLEEP DISORDER
F11182 F11188	OPIOID ABUSE WITH OPIOID-INDUCED SLEEP DISORDER OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDER
F1119	OPIOID ABUSE WITH OTHER OPIOID-INDUCED DISORDER OPIOID ABUSE WITH UNSPECIFIED OPIOID-INDUCED DISORDER
F1119 F1120	OPIOID ABUSE WITH UNSFECIFIED OFIOID-INDUCED DISORDER OPIOID DEPENDENCE, UNCOMPLICATED
F1120	OPIOID DEPENDENCE, UNCOMPLICATED OPIOID DEPENDENCE, IN REMISSION
F1121 F11220	
F11220	OPIOID DEPENDENCE WITH INTOXICATION, UNCOMPLICATED OPIOID DEPENDENCE WITH INTOXICATION DELIRIUM
F11222	OPIOID DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F11229	OPIOID DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F1123 F1124	OPIOID DEPENDENCE WITH WITHDRAWAL
	OPIOID DEPENDENCE WITH OPIOID INDUCED MOOD DISORDER
F11250	OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F11251	OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F11259	OPIOID DEPENDENCE WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED

F11281	OPIOID DEPENDENCE WITH OPIOID-INDUCED SEXUAL DYSFUNCTION
F11281	OPIOID DEPENDENCE WITH OPIOID-INDUCED SLEEP DISORDER
F11288	OPIOID DEPENDENCE WITH OTHER OPIOID-INDUCED DISORDER
F1129	OPIOID DEPENDENCE WITH OTHER OFIOID-INDUCED DISORDER OPIOID DEPENDENCE WITH UNSPECIFIED OPIOID-INDUCED DISORDER
F1129	OPIOID USE, UNSPECIFIED, UNCOMPLICATED
F1190	OPIOID USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F11920	OPIOID USE, UNSPECIFIED WITH INTOXICATION, UNCOMPERCATED OPIOID USE, UNSPECIFIED WITH INTOXICATION DELIRIUM
F11921 F11922	OPIOID USE, UNSPECIFIED WITH INTOXICATION BELIXION OPIOID USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F11922	OPIOID USE, UNSPECIFIED WITH INTOXICATION WITH FERCEF TOAL DISTORBANCE
F11929	OPIOID USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED OPIOID USE, UNSPECIFIED WITH WITHDRAWAL
F1193	OPIOID USE, UNSPECIFIED WITH WITHDRAWAL OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED MOOD DISORDER
F1194	OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED MOOD DISORDER OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F11950 F11951	OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F11951 F11959	OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F11939 F11981	OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED PSTCHOTIC DISORDER, UNSPECIFIED OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED SEXUAL DYSFUNCTION
F11981 F11982	OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED SEXUAL DYSFUNCTION OPIOID USE, UNSPECIFIED WITH OPIOID-INDUCED SLEEP DISORDER
F11982 F11988	
F11988 F1199	OPIOID USE, UNSPECIFIED WITH OTHER OPIOID-INDUCED DISORDER
	OPIOID USE, UNSPECIFIED WITH UNSPECIFIED OPIOID-INDUCED DISORDER
F1210	CANNABIS ABUSE, UNCOMPLICATED
F1211	CANNABIS ABUSE, IN REMISSION
F12120	CANNABIS ABUSE WITH INTOXICATION, UNCOMPLICATED
F12121	CANNABIS ABUSE WITH INTOXICATION DELIRIUM
F12122	CANNABIS ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F12129	CANNABIS ABUSE WITH INTOXICATION, UNSPECIFIED
F1213	CANNABIS ABUSE WITH WITHDRAWAL
F12150	CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH DELUSIONS
F12151	CANNABIS ABUSE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS
F12159	CANNABIS ABUSE WITH PSYCHOTIC DISORDER, UNSPECIFIED
F12180	CANNABIS ABUSE WITH CANNABIS-INDUCED ANXIETY DISORDER

F12188	CANNABIS ABUSE WITH OTHER CANNABIS-INDUCED DISORDER
F1219	CANNABIS ABUSE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER
F1220	CANNABIS DEPENDENCE, UNCOMPLICATED
F1221	CANNABIS DEPENDENCE, IN REMISSION
F12220	CANNABIS DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F12221	CANNABIS DEPENDENCE WITH INTOXICATION DELIRIUM
F12222	CANNABIS DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F12229	CANNABIS DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F1223	CANNABIS DEPENDENCE WITH WITHDRAWAL
F12250	CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH DELUSIONS
F12251	CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS
F12259	CANNABIS DEPENDENCE WITH PSYCHOTIC DISORDER, UNSPECIFIED
F12280	CANNABIS DEPENDENCE WITH CANNABIS-INDUCED ANXIETY DISORDER
F12288	CANNABIS DEPENDENCE WITH OTHER CANNABIS-INDUCED DISORDER
F1229	CANNABIS DEPENDENCE WITH UNSPECIFIED CANNABIS-INDUCED DISORDER
F1290	CANNABIS USE, UNSPECIFIED, UNCOMPLICATED
F12920	CANNABIS USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F12921	CANNABIS USE, UNSPECIFIED WITH INTOXICATION DELIRIUM
F12922	CANNABIS USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F12929	CANNABIS USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F1293	CANNABIS USE, UNSPECIFIED WITH WITHDRAWAL
F12950	CANNABIS USE, UNSPECIFIED WITH PSYCHOTIC DISORDER WITH DELUSIONS
F12951	CANNABIS USE, UNSPECIFIED WITH PSYCHOTIC DISORDER WITH HALLUCINATIONS
F12959	CANNABIS USE, UNSPECIFIED WITH PSYCHOTIC DISORDER, UNSPECIFIED
F12980	CANNABIS USE, UNSPECIFIED WITH ANXIETY DISORDER
F12988	CANNABIS USE, UNSPECIFIED WITH OTHER CANNABIS-INDUCED DISORDER
F1299	CANNABIS USE, UNSPECIFIED WITH UNSPECIFIED CANNABIS-INDUCED DISORDER
F1310	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, UNCOMPLICATED
F1311	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE, IN REMISSION

F13120 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNCOMPLICATED F13121 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION DELIRIUM F13129 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNSPECIFIED F13130 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNCOMPLICATED F13131 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL DELIRIUM F13132 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13139 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13183 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13184 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13185 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13186 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION F13220 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, WITH INTOXICATION, UNCOMPLICATED		
F13129 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNSPECIFIED F13130 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNCOMPLICATED F13131 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL DELIRIUM F13132 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13139 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED DISORDER F13189 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13120	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNCOMPLICATED
F13130 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNCOMPLICATED F13131 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL DELIRIUM F13132 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13139 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SLEEP DISORDER F13189 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED	F13121	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION DELIRIUM
F13131 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL DELIRIUM F13132 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13139 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEED DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED DISORDER F13189 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13129	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH INTOXICATION, UNSPECIFIED
F13132 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13139 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F13189 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED	F13130	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNCOMPLICATED
DISTURBANCE F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F13189 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F13190 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13131	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL DELIRIUM
F13139 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC- INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13132	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL WITH PERCEPTUAL
F1314 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		DISTURBANCE
INDUCED MOOD DISORDER F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13139	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH WITHDRAWAL, UNSPECIFIED
F13150 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F1314	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-
INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		INDUCED MOOD DISORDER
F13151 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13150	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-
INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F13159 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13151	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-
INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F13180 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED ANXIETY DISORDER F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13159	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-
F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F13181 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13180	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-
INDUCED SEXUAL DYSFUNCTION F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		
F13182 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13181	SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH SEDATIVE, HYPNOTIC OR ANXIOLYTIC-
INDUCED SLEEP DISORDER F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		
F13188 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH OTHER SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13182	
INDUCED DISORDER F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		
F1319 SEDATIVE, HYPNOTIC OR ANXIOLYTIC ABUSE WITH UNSPECIFIED SEDATIVE, HYPNOTIC OR ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F13188	
ANXIOLYTIC-INDUCED DISORDER F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		
F1320 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, UNCOMPLICATED F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION	F1319	
F1321 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE, IN REMISSION		
, , ,		
F13220 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNCOMPLICATED		
	F13220	SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNCOMPLICATED

F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH INTOXICATION, UNSPECIFIED F13231 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED F13232 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL DELIRIUM F13232 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13259 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F13259 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	
F13231 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL DELIRIUM F13232 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
F13232 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
DISTURBANCE F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
F13239 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
F1324 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
INDUCED MOOD DISORDER F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
F13250 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	TT C
F13251 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	TIC-
INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS	
	TIC-
F13259 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	
	TIC-
INDUCED PSYCHOTIC DISORDER, UNSPECIFIED	
F1326 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	TIC-
INDUCED PERSISTING AMNESTIC DISORDER	
F1327 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	TIC-
INDUCED PERSISTING DEMENTIA	
F13280 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	TIC-
INDUCED ANXIETY DISORDER	
F13281 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	TIC-
INDUCED SEXUAL DYSFUNCTION	
F13282 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH SEDATIVE, HYPNOTIC OR ANXIOLY	TIC-
INDUCED SLEEP DISORDER	
F13288 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH OTHER SEDATIVE, HYPNOTIC OR	
ANXIOLYTIC-INDUCED DISORDER	
F1329 SEDATIVE, HYPNOTIC OR ANXIOLYTIC DEPENDENCE WITH UNSPECIFIED SEDATIVE, HYPNOTIC	
ANXIOLYTIC-INDUCED DISORDER	OR
F1390 SEDATIVE, HYPNOTIC, OR ANXIOLYTIC USE, UNSPECIFIED, UNCOMPLICATED Page 1	OR

F13920	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F13921	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH INTOXICATION DELIRIUM
F13929	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F13930	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL, UNCOMPLICATED
F13931	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL DELIRIUM
F13932	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL WITH PERCEPTUAL
	DISTURBANCES
F13939	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH WITHDRAWAL, UNSPECIFIED
F1394	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED MOOD DISORDER
F13950	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F13951	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F13959	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1396	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED PERSISTING AMNESTIC DISORDER
F1397	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED PERSISTING DEMENTIA
F13980	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED ANXIETY DISORDER
F13981	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
	ANXIOLYTIC-INDUCED SEXUAL DYSFUNCTION
F13982	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH SEDATIVE, HYPNOTIC OR
71222	ANXIOLYTIC-INDUCED SLEEP DISORDER
F13988	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH OTHER SEDATIVE, HYPNOTIC OR
71200	ANXIOLYTIC-INDUCED DISORDER
F1399	SEDATIVE, HYPNOTIC OR ANXIOLYTIC USE, UNSPECIFIED WITH UNSPECIFIED SEDATIVE, HYPNOTIC
	OR ANXIOLYTIC-INDUCED DISORDER

F1410	COCAINE ABUSE, UNCOMPLICATED
F1411	COCAINE ABUSE, IN REMISSION
F14120	COCAINE ABUSE WITH INTOXICATION, UNCOMPLICATED
F14121	COCAINE ABUSE WITH INTOXICATION WITH DELIRIUM
F14122	COCAINE ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F14129	COCAINE ABUSE WITH INTOXICATION, UNSPECIFIED
F1413	COCAINE ABUSE, UNSPECIFIED WITH WITHDRAWAL
F1414	COCAINE ABUSE WITH COCAINE-INDUCED MOOD DISORDER
F14150	COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F14151	COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F14159	COCAINE ABUSE WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F14180	COCAINE ABUSE WITH COCAINE-INDUCED ANXIETY DISORDER
F14181	COCAINE ABUSE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION
F14182	COCAINE ABUSE WITH COCAINE-INDUCED SLEEP DISORDER
F14188	COCAINE ABUSE WITH OTHER COCAINE-INDUCED DISORDER
F1419	COCAINE ABUSE WITH UNSPECIFIED COCAINE-INDUCED DISORDER
F1420	COCAINE DEPENDENCE, UNCOMPLICATED
F1421	COCAINE DEPENDENCE, IN REMISSION
F14220	COCAINE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F14221	COCAINE DEPENDENCE WITH INTOXICATION DELIRIUM
F14222	COCAINE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F14229	COCAINE DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F1423	COCAINE DEPENDENCE WITH WITHDRAWAL
F1424	COCAINE DEPENDENCE WITH COCAINE-INDUCED MOOD DISORDER
F14250	COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F14251	COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F14259	COCAINE DEPENDENCE WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F14280	COCAINE DEPENDENCE WITH COCAINE-INDUCED ANXIETY DISORDER
F14281	COCAINE DEPENDENCE WITH COCAINE-INDUCED SEXUAL DYSFUNCTION

F14282	COCAINE DEPENDENCE WITH COCAINE-INDUCED SLEEP DISORDER
F14288	COCAINE DEPENDENCE WITH OTHER COCAINE-INDUCED DISORDER
F1429	COCAINE DEPENDENCE WITH UNSPECIFIED COCAINE-INDUCED DISORDER
F1490	COCAINE USE, UNSPECIFIED, UNCOMPLICATED
F14920	COCAINE USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F14921	COCAINE USE, UNSPECIFIED WITH INTOXICATION DELIRIUM
F14922	COCAINE USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F14929	COCAINE USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F1493	COCAINE USE, UNSPECIFIED WITH WITHDRAWAL
F1494	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED MOOD DISORDER
F14950	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F14951	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS
F14959	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F14980	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED ANXIETY DISORDER
F14981	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED SEXUAL DYSFUNCTION
F14982	COCAINE USE, UNSPECIFIED WITH COCAINE-INDUCED SLEEP DISORDER
F14988	COCAINE USE, UNSPECIFIED WITH OTHER COCAINE-INDUCED DISORDER
F1499	COCAINE USE, UNSPECIFIED WITH UNSPECIFIED COCAINE-INDUCED DISORDER
F1510	OTHER STIMULANT ABUSE, UNCOMPLICATED
F1511	OTHER STIMULANT ABUSE, IN REMISSION
F15120	OTHER STIMULANT ABUSE WITH INTOXICATION, UNCOMPLICATED
F15121	OTHER STIMULANT ABUSE WITH INTOXICATION DELIRIUM
F15122	OTHER STIMULANT ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F15129	OTHER STIMULANT ABUSE WITH INTOXICATION, UNSPECIFIED
F1513	OTHER STIMULANT ABUSE WITH WITHDRAWAL
F1514	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED MOOD DISORDER
F15150	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS

F15151	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH
F13131	HALLUCINATIONS
E15150	
F15159	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F15180	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED ANXIETY DISORDER
F15181	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION
F15182	OTHER STIMULANT ABUSE WITH STIMULANT-INDUCED SLEEP DISORDER
F15188	OTHER STIMULANT ABUSE WITH OTHER STIMULANT-INDUCED DISORDER
F1519	OTHER STIMULANT ABUSE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER
F1520	OTHER STIMULANT DEPENDENCE, UNCOMPLICATED
F1521	OTHER STIMULANT DEPENDENCE, IN REMISSION
F15220	OTHER STIMULANT DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F15221	OTHER STIMULANT DEPENDENCE WITH INTOXICATION DELIRIUM
F15222	OTHER STIMULANT DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F15229	OTHER STIMULANT DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F1523	OTHER STIMULANT DEPENDENCE WITH WITHDRAWAL
F1524	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED MOOD DISORDER
F15250	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH
	DELUSIONS
F15251	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS
F15259	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED PSYCHOTIC DISORDER,
	UNSPECIFIED
F15280	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED ANXIETY DISORDER
F15281	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION
F15282	OTHER STIMULANT DEPENDENCE WITH STIMULANT-INDUCED SLEEP DISORDER
F15288	OTHER STIMULANT DEPENDENCE WITH OTHER STIMULANT-INDUCED DISORDER
F1529	OTHER STIMULANT DEPENDENCE WITH UNSPECIFIED STIMULANT-INDUCED DISORDER
F1590	OTHER STIMULANT USE, UNSPECIFIED, UNCOMPLICATED
F15920	OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
113720	OTHER STIME DAM COL, SHOT LET ILD WITH INTOMERATION, SHOOM ELEKTED

F15922 OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F15929 OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION, WITH PERCEPTUAL DISTURBANCE F1593 OTHER STIMULANT USE, UNSPECIFIED WITH WITHDRAWAL F1594 OTHER STIMULANT USE, UNSPECIFIED WITH WITHDRAWAL F1595 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER F15950 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F15950 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER, F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSPUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSPUNCTION F15983 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F15999 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F16101 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE, WITH INTOXICATION, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F1614 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1615 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F1618 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED DSYCHOTIC DISORDER, UNSPECIFIED F1619 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED DSYCHOTIC DISORDER, UNSPECIFIED F1618 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED DNIED PSYCHOTIC DISORDER, UNSPECIFIED F1618 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED DNIETY DISORDER F1618 HALLUCINOGEN ABUSE WIT	T1 5001	OTHER STRUCK AND LOCK AND REPORTED WHEN REPORTED THE PROPERTY OF THE PROPERTY
F15929 OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED F1593 OTHER STIMULANT USE, UNSPECIFIED WITH WITHDRAWAL F1594 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER F15950 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F15959 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSPUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16124 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F15921	OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION DELIRIUM
F1593 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER F15950 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F15952 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER, UNSPECIFIED F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15983 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED DISORDER F15990 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, IN REMISSION F1611 HALLUCINOGEN ABUSE, IN REMISSION F1612 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F1612 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1615 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F1616 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F1616 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOSEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOSEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOSEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F1615 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F1616 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F1617 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F1618 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER		
F1594 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER F15950 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F15959 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F15999 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16161 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16160 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F15929	OTHER STIMULANT USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F15950 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS T15959 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED T15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER T15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION T15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER T15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER T1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER T1610 HALLUCINOGEN ABUSE, UNCOMPLICATED T1611 HALLUCINOGEN ABUSE, IN REMISSION T16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED T16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM T16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM T16124 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE T1614 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED T1615 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER T1616 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS T16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED T16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED T161610 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED T16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED T161610 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED T16160 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F1593	OTHER STIMULANT USE, UNSPECIFIED WITH WITHDRAWAL
F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F15959 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16139 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F161680 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F1594	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED MOOD DISORDER
F15951 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F15959 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F1612 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOSEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOSEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F161680 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED	F15950	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH
HALLUCINATIONS OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F1614 HALLUCINOGEN ABUSE WITH HINTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F161680 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED		DELUSIONS
F15959 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F1612 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F1614 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED	F15951	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER WITH
F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED		HALLUCINATIONS
F15980 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED	F15959	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED PSYCHOTIC DISORDER,
F15981 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER		
F15982 OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED	F15980	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED ANXIETY DISORDER
F15988 OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F15981	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SEXUAL DYSFUNCTION
F1599 OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F15982	OTHER STIMULANT USE, UNSPECIFIED WITH STIMULANT-INDUCED SLEEP DISORDER
F1610 HALLUCINOGEN ABUSE, UNCOMPLICATED F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F15988	OTHER STIMULANT USE, UNSPECIFIED WITH OTHER STIMULANT-INDUCED DISORDER
F1611 HALLUCINOGEN ABUSE, IN REMISSION F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F1599	OTHER STIMULANT USE, UNSPECIFIED WITH UNSPECIFIED STIMULANT-INDUCED DISORDER
F16120 HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F1610	HALLUCINOGEN ABUSE, UNCOMPLICATED
F16121 HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F1611	HALLUCINOGEN ABUSE, IN REMISSION
F16122 HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F16120	HALLUCINOGEN ABUSE WITH INTOXICATION, UNCOMPLICATED
F16129 HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F16121	HALLUCINOGEN ABUSE WITH INTOXICATION WITH DELIRIUM
F1614 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F16122	HALLUCINOGEN ABUSE WITH INTOXICATION WITH PERCEPTUAL DISTURBANCE
F16150 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F16129	HALLUCINOGEN ABUSE WITH INTOXICATION, UNSPECIFIED
F16151 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F1614	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED MOOD DISORDER
HALLUCINATIONS F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F16150	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F16159 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER	F16151	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH
F16180 HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER		HALLUCINATIONS
	F16159	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F16183 HALLUCINOGEN ABUSE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS)	F16180	HALLUCINOGEN ABUSE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER
	F16183	HALLUCINOGEN ABUSE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER (FLASHBACKS)

F16188	HALLUCINOGEN ABUSE WITH OTHER HALLUCINOGEN-INDUCED DISORDER
F1619	HALLUCINOGEN ABUSE WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER
F1620	HALLUCINOGEN DEPENDENCE, UNCOMPLICATED
F1621	HALLUCINOGEN DEPENDENCE, IN REMISSION
F16220	HALLUCINOGEN DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F16221	HALLUCINOGEN DEPENDENCE WITH INTOXICATION WITH DELIRIUM
F16229	HALLUCINOGEN DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F1624	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED MOOD DISORDER
F16250	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH
	DELUSIONS
F16251	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS
F16259	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER,
	UNSPECIFIED
F16280	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER
F16283	HALLUCINOGEN DEPENDENCE WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER
	(FLASHBACKS)
F16288	HALLUCINOGEN DEPENDENCE WITH OTHER HALLUCINOGEN-INDUCED DISORDER
F1629	HALLUCINOGEN DEPENDENCE WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER
F1690	HALLUCINOGEN USE, UNSPECIFIED, UNCOMPLICATED
F16920	HALLUCINOGEN USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F16921	HALLUCINOGEN USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM
F16929	HALLUCINOGEN USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F1694	HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED MOOD DISORDER
F16950	HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH
	DELUSIONS
F16951	HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS

F16959	HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED PSYCHOTIC DISORDER,
	UNSPECIFIED
F16980	HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN-INDUCED ANXIETY DISORDER
F16983	HALLUCINOGEN USE, UNSPECIFIED WITH HALLUCINOGEN PERSISTING PERCEPTION DISORDER
	(FLASHBACKS)
F16988	HALLUCINOGEN USE, UNSPECIFIED WITH OTHER HALLUCINOGEN-INDUCED DISORDER
F1699	HALLUCINOGEN USE, UNSPECIFIED WITH UNSPECIFIED HALLUCINOGEN-INDUCED DISORDER
F1810	INHALANT ABUSE, UNCOMPLICATED
F1811	INHALANT ABUSE, IN REMISSION
F18120	INHALANT ABUSE WITH INTOXICATION, UNCOMPLICATED
F18121	INHALANT ABUSE WITH INTOXICATION DELIRIUM
F18129	INHALANT ABUSE WITH INTOXICATION, UNSPECIFIED
F1814	INHALANT ABUSE WITH INHALANT-INDUCED MOOD DISORDER
F18150	INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F18151	INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F18159	INHALANT ABUSE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1817	INHALANT ABUSE WITH INHALANT-INDUCED DEMENTIA
F18180	INHALANT ABUSE WITH INHALANT-INDUCED ANXIETY DISORDER
F18188	INHALANT ABUSE WITH OTHER INHALANT-INDUCED DISORDER
F1819	INHALANT ABUSE WITH UNSPECIFIED INHALANT-INDUCED DISORDER
F1820	INHALANT DEPENDENCE, UNCOMPLICATED
F1821	INHALANT DEPENDENCE, IN REMISSION
F18220	INHALANT DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F18221	INHALANT DEPENDENCE WITH INTOXICATION DELIRIUM
F18229	INHALANT DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F1824	INHALANT DEPENDENCE WITH INHALANT-INDUCED MOOD DISORDER
F18250	INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F18251	INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS

E10050	BULLI ANT DEPENDENCE WITH BULLI ANT DIDLIGED DOVOLOTIC DICODDED ANGREGIER
F18259	INHALANT DEPENDENCE WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1827	INHALANT DEPENDENCE WITH INHALANT-INDUCED DEMENTIA
F18280	INHALANT DEPENDENCE WITH INHALANT-INDUCED ANXIETY DISORDER
F18288	INHALANT DEPENDENCE WITH OTHER INHALANT-INDUCED DISORDER
F1829	INHALANT DEPENDENCE WITH UNSPECIFIED INHALANT-INDUCED DISORDER
F1890	INHALANT USE, UNSPECIFIED, UNCOMPLICATED
F18920	INHALANT USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F18921	INHALANT USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM
F18929	INHALANT USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F1894	INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED MOOD DISORDER
F18950	INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F18951	INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PSYCHOTIC DISORDER WITH
	HALLUCINATIONS
F18959	INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1897	INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED PERSISTING DEMENTIA
F18980	INHALANT USE, UNSPECIFIED WITH INHALANT-INDUCED ANXIETY DISORDER
F18988	INHALANT USE, UNSPECIFIED WITH OTHER INHALANT-INDUCED DISORDER
F1899	INHALANT USE, UNSPECIFIED WITH UNSPECIFIED INHALANT-INDUCED DISORDER
F1910	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED
F1911	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, IN REMISSION
F19120	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION, UNCOMPLICATED
F19121	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION DELIRIUM
F19122	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION WITH PERCEPTUAL
	DISTURBANCES
F19129	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH INTOXICATION, UNSPECIFIED
F19130	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH WITHDRAWAL, UNCOMPLICATED
F19131	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH WITHDRAWAL DELIRIUM
F19132	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH WITHDRAWAL WITH PERCEPTUAL DISTURBANCE
F19139	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH WITHDRAWAL, UNSPECIFIED
-	· · · · · · · · · · · · · · · · · · ·

F1914	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED MOOD
	DISORDER
F19150	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PSYCHOTIC DISORDER WITH DELUSIONS
F19151	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PSYCHOTIC DISORDER WITH HALLUCINATIONS
F19159	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PSYCHOTIC DISORDER, UNSPECIFIED
F1916	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PERSISTING AMNESTIC DISORDER
F1917	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PERSISTING DEMENTIA
F19180	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED ANXIETY
	DISORDER
F19181	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SEXUAL
	DYSFUNCTION
F19182	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH PSYCHOACTIVE SUBSTANCE-INDUCED SLEEP
	DISORDER
F19188	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH OTHER PSYCHOACTIVE SUBSTANCE-INDUCED
	DISORDER
F1919	OTHER PSYCHOACTIVE SUBSTANCE ABUSE WITH UNSPECIFIED PSYCHOACTIVE SUBSTANCE-
	INDUCED DISORDER
F1920	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE, UNCOMPLICATED
F1921	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE, IN REMISSION
F19220	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNCOMPLICATED
F19221	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION DELIRIUM
F19222	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION WITH PERCEPTUAL
	DISTURBANCE
F19229	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH INTOXICATION, UNSPECIFIED
F19230	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNCOMPLICATED

F19231	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL DELIRIUM
F19232	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL WITH PERCEPTUAL
119232	DISTURBANCE DISTURBANCE
F19239	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNSPECIFIED
F19239 F1924	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH WITHDRAWAL, UNSFECIFIED OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
F1924	
F10250	MOOD DISORDER
F19250	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
F10051	PSYCHOTIC DISORDER WITH DELUSIONS OTHER PRINCIPLE ACTIVE CHECK PRINCIPLE WITH PRINCIPLE ACTIVE CHECK PRINCIPLE PRIN
F19251	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PSYCHOTIC DISORDER WITH HALLUCINATIONS
F19259	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PSYCHOTIC DISORDER, UNSPECIFIED
F1926	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PERSISTING AMNESTIC DISORDER
F1927	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	PERSISTING DEMENTIA
F19280	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	ANXIETY DISORDER
F19281	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	SEXUAL DYSFUNCTION
F19282	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH PSYCHOACTIVE SUBSTANCE-INDUCED
	SLEEP DISORDER
F19288	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH OTHER PSYCHOACTIVE SUBSTANCE-
	INDUCED DISORDER
F1929	OTHER PSYCHOACTIVE SUBSTANCE DEPENDENCE WITH UNSPECIFIED PSYCHOACTIVE
	SUBSTANCE-INDUCED DISORDER
F1990	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED, UNCOMPLICATED
F19920	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION, UNCOMPLICATED
F19921	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM
F19921	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION WITH DELIRIUM

F19922	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION WITH PERCEPTUAL
	DISTURBANCE
F19929	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH INTOXICATION, UNSPECIFIED
F19930	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL, UNCOMPLICATED
F19931	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL DELIRIUM
F19932	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL WITH PERCEPTUAL
	DISTURBANCE
F19939	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH WITHDRAWAL, UNSPECIFIED
F1994	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED MOOD DISORDER
F19950	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED PSYCHOTIC DISORDER WITH DELUSIONS
F19951	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED PSYCHOTIC DISORDER WITH HALLUCINATIONS
F19959	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED PSYCHOTIC DISORDER, UNSPECIFIED
F1996	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED PERSISTING AMNESTIC DISORDER
F1997	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED PERSISTING DEMENTIA
F19980	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED ANXIETY DISORDER
F19981	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED SEXUAL DYSFUNCTION
F19982	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTIVE SUBSTANCE-
	INDUCED SLEEP DISORDER
F19988	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH OTHER PSYCHOACTIVE SUBSTANCE-
	INDUCED DISORDER
F1999	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH UNSPECIFIED PSYCHOACTIVE
	SUBSTANCE-INDUCED DISORDER Page 134 of 146

Rural Life360 Serious Mental Illness Diagnostic Codes List

ICD-10-	Serious Mentai fililess Diagnostic Codes List
CM	Schizophrenia
F200	PARANOID SCHIZOPHRENIA
F201	DISORGANIZED SCHIZOPHRENIA
F202	CATATONIC SCHIZOPHRENIA
F203	UNDIFFERENTIATED SCHIZOPHRENIA
F205	RESIDUAL SCHIZOPHRENIA
F2081	SCHIZOPHRENIFORM DISORDER
F2089	OTHER SCHIZOPHRENIA
F209	SCHIZOPHRENIA, UNSPECIFIED
F21	SCHIZOTYPAL DISORDER
F22	DELUSIONAL DISORDERS
F23	BRIEF PSYCHOTIC DISORDER
F24	SHARED PSYCHOTIC DISORDER
F250	SCHIZOAFFECTIVE DISORDER, BIPOLAR TYPE
F251	SCHIZOAFFECTIVE DISORDER, DEPRESSIVE TYPE
F258	OTHER SCHIZOAFFECTIVE DISORDERS
F259	SCHIZOAFFECTIVE DISORDER, UNSPECIFIED
F28	OTHER PSYCHOTIC DISORDER NOT DUE TO A SUBSTANCE OR KNOWN PHYSIOLOGICAL CONDITION
F29	UNSPECIFIED PSYCHOSIS NOT DUE TO A SUBSTANCE OR KNOWN PHYSIOLOGICAL CONDITION
	Bipolar and Related Disorders
F310	BIPOLAR DISORDER, CURRENT EPISODE HYPOMANIC
F3110	BIPOLAR DISORDER, CURRENT EPISODE MANIC WITHOUT PSYCHOTIC FEATURES, UNSPECIFIED
F3111	BIPOLAR DISORDER, CURRENT EPISODE MANIC WITHOUT PSYCHOTIC FEATURES, MILD
F3112	BIPOLAR DISORDER, CURRENT EPISODE MANIC WITHOUT PSYCHOTIC FEATURES, MODERATE
F3113	BIPOLAR DISORDER, CURRENT EPISODE MANIC WITHOUT PSYCHOTIC FEATURES, SEVERE

F312	BIPOLAR DISORDER, CURRENT EPISODE MANIC SEVERE WITH PSYCHOTIC FEATURES
F3130	BIPOLAR DISORDER, CURRENT EPISODE DEPRESSED, MILD OR MODERATE SEVERITY, UNSPECIFIED
F3131	BIPOLAR DISORDER, CURRENT EPISODE DEPRESSED, MILD
F3132	BIPOLAR DISORDER, CURRENT EPISODE DEPRESSED, MODERATE
F314	BIPOLAR DISORDER, CURRENT EPISODE DEPRESSED, SEVERE, WITHOUT PSYCHOTIC FEATURES
F315	BIPOLAR DISORDER, CURRENT EPISODE DEPRESSED, SEVERE, WITH PSYCHOTIC FEATURES
F3160	BIPOLAR DISORDER, CURRENT EPISODE MIXED, UNSPECIFIED
F3161	BIPOLAR DISORDER, CURRENT EPISODE MIXED, MILD
F3162	BIPOLAR DISORDER, CURRENT EPISODE MIXED, MODERATE
F3163	BIPOLAR DISORDER, CURRENT EPISODE MIXED, SEVERE, WITHOUT PSYCHOTIC FEATURES
F3164	BIPOLAR DISORDER, CURRENT EPISODE MIXED, SEVERE, WITH PSYCHOTIC FEATURES
F3170	BIPOLAR DISORDER, CURRENTLY IN REMISSION, MOST RECENT EPISODE UNSPECIFIED
F3171	BIPOLAR DISORDER, IN PARTIAL REMISSION, MOST RECENT EPISODE HYPOMANIC
F3172	BIPOLAR DISORDER, IN FULL REMISSION, MOST RECENT EPISODE HYPOMANIC
F3173	BIPOLAR DISORDER, IN PARTIAL REMISSION, MOST RECENT EPISODE MANIC
F3174	BIPOLAR DISORDER, IN FULL REMISSION, MOST RECENT EPISODE MANIC
F3175	BIPOLAR DISORDER, IN PARTIAL REMISSION, MOST RECENT EPISODE DEPRESSED
F3176	BIPOLAR DISORDER, IN FULL REMISSION, MOST RECENT EPISODE DEPRESSED
F3177	BIPOLAR DISORDER, IN PARTIAL REMISSION, MOST RECENT EPISODE MIXED
F3178	BIPOLAR DISORDER, IN FULL REMISSION, MOST RECENT EPISODE MIXED
F3181	BIPOLAR II DISORDER
F3189	OTHER BIPOLAR DISORDER
F319	BIPOLAR DISORDER, UNSPECIFIED
F340	CYCLOTHYMIC DISORDER
F0633	MOOD DISORDER DUE TO KNOWN PHYSIOLOGICAL CONDITION WITH MANIC FEATURES
F0634	MOOD DISORDER DUE TO KNOWN PHYSIOLOGICAL CONDITION WITH MIXED FEATURES
F3010	MANIC EPISODE WITHOUT PSYCHOTIC SYMPTOMS, UNSPECIFIED

	<u>, </u>
F3011	MANIC EPISODE WITHOUT PSYCHOTIC SYMPTOMS, MILD
F3012	MANIC EPISODE WITHOUT PSYCHOTIC SYMPTOMS, MODERATE
F3013	MANIC EPISODE, SEVERE, WITHOUT PSYCHOTIC SYMPTOMS
F302	MANIC EPISODE, SEVERE WITH PSYCHOTIC SYMPTOMS
F303	MANIC EPISODE IN PARTIAL REMISSION
F304	MANIC EPISODE IN FULL REMISSION
F308	OTHER MANIC EPISODES
F309	MANIC EPISODE, UNSPECIFIED
	Depressive Disorders
F320	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, MILD
F321	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, MODERATE
F322	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, SEVERE WITHOUT PSYCHOTIC FEATURES
F323	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, SEVERE WITH PSYCHOTIC FEATURES
F324	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, IN PARTIAL REMISSION
F325	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, IN FULL REMISSION
F3281	PREMENSTRUAL DYSPHORIC DISORDER
F3289	OTHER SPECIFIED DEPRESSIVE EPISODES
F329	MAJOR DEPRESSIVE DISORDER, SINGLE EPISODE, UNSPECIFIED
F32A	DEPRESSION, UNSPECIFIED
F341	DYSTHYMIC DISORDER
F348	OTHER PERSISTENT MOOD [AFFECTIVE] DISORDERS
F3481	DISRUPTIVE MOOD DYSREGULATION DISORDER
F3489	OTHER SPECIFIED PERSISTENT MOOD DISORDERS
F349	PERSISTENT MOOD [AFFECTIVE] DISORDER, UNSPECIFIED
F330	MAJOR DEPRESSIVE DISORDER, RECURRENT, MILD
F331	MAJOR DEPRESSIVE DISORDER, RECURRENT, MODERATE
F332	MAJOR DEPRESSIVE DISORDER, RECURRENT SEVERE WITHOUT PSYCHOTIC FEATURES

F333	MAJOR DEPRESSIVE DISORDER, RECURRENT, SEVERE WITH PSYCHOTIC SYMPTOMS
F3340	MAJOR DEPRESSIVE DISORDER, RECURRENT, IN REMISSION, UNSPECIFIED
F3341	MAJOR DEPRESSIVE DISORDER, RECURRENT, IN PARTIAL REMISSION
F3342	MAJOR DEPRESSIVE DISORDER, RECURRENT, IN FULL REMISSION
F338	OTHER RECURRENT DEPRESSIVE DISORDERS
F339	MAJOR DEPRESSIVE DISORDER, RECURRENT, UNSPECIFIED
	Anxiety Disorder
F930	SEPARATION ANXIETY DISORDER OF CHILDHOOD
F938	OTHER CHILDHOOD EMOTIONAL DISORDERS
F939	CHILDHOOD EMOTIONAL DISORDER, UNSPECIFIED
F940	SELECTIVE MUTISM
F941	REACTIVE ATTACHMENT DISORDER OF CHILDHOOD
F942	DISINHIBITED ATTACHMENT DISORDER OF CHILDHOOD
F948	OTHER CHILDHOOD DISORDERS OF SOCIAL FUNCTIONING
F949	CHILDHOOD DISORDER OF SOCIAL FUNCTIONING, UNSPECIFIED
F4000	AGORAPHOBIA, UNSPECIFIED
F4001	AGORAPHOBIA WITH PANIC DISORDER
F4002	AGORAPHOBIA WITHOUT PANIC DISORDER
F4010	SOCIAL PHOBIA, UNSPECIFIED
F4011	SOCIAL PHOBIA, GENERALIZED
F40210	ARACHNOPHOBIA
F40218	OTHER ANIMAL TYPE PHOBIA
F40220	FEAR OF THUNDERSTORMS
F40228	OTHER NATURAL ENVIRONMENT TYPE PHOBIA
F40230	FEAR OF BLOOD
F40231	FEAR OF INJECTIONS AND TRANSFUSIONS
F40232	FEAR OF OTHER MEDICAL CARE

F40233	FEAR OF INJURY
F40240	CLAUSTROPHOBIA
F40241	ACROPHOBIA
F40242	FEAR OF BRIDGES
F40243	FEAR OF FLYING
F40248	OTHER SITUATIONAL TYPE PHOBIA
F40290	ANDROPHOBIA
F40291	GYNEPHOBIA
F40298	OTHER SPECIFIED PHOBIA
F408	OTHER PHOBIC ANXIETY DISORDERS
F409	PHOBIC ANXIETY DISORDER, UNSPECIFIED
F410	PANIC DISORDER [EPISODIC PAROXYSMAL ANXIETY]
F411	GENERALIZED ANXIETY DISORDER
F413	OTHER MIXED ANXIETY DISORDERS
F418	OTHER SPECIFIED ANXIETY DISORDERS
F419	ANXIETY DISORDER, UNSPECIFIED
	Obsessive-Compulsive Disorder
F422	MIXED OBSESSIONAL THOUGHTS AND ACTS
F423	HOARDING DISORDER
F424	EXCORIATION (SKIN-PICKING) DISORDER
F428	OTHER OBSESSIVE-COMPULSIVE DISORDER
F429	OBSESSIVE-COMPULSIVE DISORDER, UNSPECIFIED
F63	IMPULSE DISORDERS
F630	PATHOLOGICAL GAMBLING
F631	PYROMANIA
F632	KLEPTOMANIA
F633	TRICHOTILLOMANIA

F638	OTHER IMPULSE DISORDERS
F6381	INTERMITTENT EXPLOSIVE DISORDER
F6389	OTHER IMPULSE DISORDERS
F639	IMPULSE DISORDER, UNSPECIFIED
	Trauma Stressor related disorders
F430	ACUTE STRESS REACTION
F4310	POST-TRAUMATIC STRESS DISORDER, UNSPECIFIED
F4311	POST-TRAUMATIC STRESS DISORDER, ACUTE
F4312	POST-TRAUMATIC STRESS DISORDER, CHRONIC
F438	OTHER REACTIONS TO SEVERE STRESS
F439	REACTION TO SEVERE STRESS, UNSPECIFIED
	Dissociative Disorders
F440	DISSOCIATIVE AMNESIA
F441	DISSOCIATIVE FUGUE
F442	DISSOCIATIVE STUPOR
F4481	DISSOCIATIVE IDENTITY DISORDER
F4489	OTHER DISSOCIATIVE AND CONVERSION DISORDERS
F449	DISSOCIATIVE AND CONVERSION DISORDER, UNSPECIFIED
F481	DEPERSONALIZATION-DEREALIZATION SYNDROME
	Somatic Symptom and Related Disorders
F444	CONVERSION DISORDER WITH MOTOR SYMPTOM OR DEFICIT
F445	CONVERSION DISORDER WITH SEIZURES OR CONVULSIONS
F446	CONVERSION DISORDER WITH SENSORY SYMPTOM OR DEFICIT
F447	CONVERSION DISORDER WITH MIXED SYMPTOM PRESENTATION
F450	SOMATIZATION DISORDER
F451	UNDIFFERENTIATED SOMATOFORM DISORDER
F4520	HYPOCHONDRIACAL DISORDER, UNSPECIFIED

F4521	HYPOCHONDRIASIS
F4522	BODY DYSMORPHIC DISORDER
F4529	OTHER HYPOCHONDRIACAL DISORDERS
F4541	PAIN DISORDER EXCLUSIVELY RELATED TO PSYCHOLOGICAL FACTORS
F4542	PAIN DISORDER WITH RELATED PSYCHOLOGICAL FACTORS
F458	OTHER SOMATOFORM DISORDERS
F459	SOMATOFORM DISORDER, UNSPECIFIED
	PSYCHOLOGICAL AND BEHAVIORAL FACTORS ASSOCIATED WITH DISORDERS OR DISEASES
F54	CLASSIFIED ELSEWHERE
F6810	FACTITIOUS DISORDER IMPOSED ON SELF, UNSPECIFIED
	FACTITIOUS DISORDER IMPOSED ON SELF, WITH PREDOMINANTLY PSYCHOLOGICAL SIGNS AND
F6811	SYMPTOMS
	FACTITIOUS DISORDER IMPOSED ON SELF, WITH PREDOMINANTLY PHYSICAL SIGNS AND
F6812	SYMPTOMS
	FACTITIOUS DISORDER IMPOSED ON SELF, WITH COMBINED PSYCHOLOGICAL AND PHYSICAL SIGNS
F6813	AND SYMPTOMS
F688	OTHER SPECIFIED DISORDERS OF ADULT PERSONALITY AND BEHAVIOR
F68A	FACTITIOUS DISORDER IMPOSED ON ANOTHER
	Feeding and Eating Disorders
F5000	ANOREXIA NERVOSA, UNSPECIFIED
F5001	ANOREXIA NERVOSA, RESTRICTING TYPE
F5002	ANOREXIA NERVOSA, BINGE EATING/PURGING TYPE
F502	BULIMIA NERVOSA
F508	OTHER EATING DISORDERS
F5081	BINGE EATING DISORDER
F5082	AVOIDANT/RESTRICTIVE FOOD INTAKE DISORDER
F5089	OTHER SPECIFIED EATING DISORDER

F509	EATING DISORDER, UNSPECIFIED
	Personality Disorders
F600	PARANOID PERSONALITY DISORDER
F601	SCHIZOID PERSONALITY DISORDER
F602	ANTISOCIAL PERSONALITY DISORDER
F603	BORDERLINE PERSONALITY DISORDER
F604	HISTRIONIC PERSONALITY DISORDER
F605	OBSESSIVE-COMPULSIVE PERSONALITY DISORDER
F606	AVOIDANT PERSONALITY DISORDER
F607	DEPENDENT PERSONALITY DISORDER
F6081	NARCISSISTIC PERSONALITY DISORDER
F6089	OTHER SPECIFIC PERSONALITY DISORDERS
F609	PERSONALITY DISORDER, UNSPECIFIED
	Attention Deficit Hyperactivity Disorders
F900	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, PREDOMINANTLY INATTENTIVE TYPE
F901	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, PREDOMINANTLY HYPERACTIVE TYPE
F902	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, COMBINED TYPE
F908	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, OTHER TYPE
F909	ATTENTION-DEFICIT HYPERACTIVITY DISORDER, UNSPECIFIED TYPE

Attachment J CENTERS FOR MEDICARE & MEDICAID SERVICES Amendments to Expenditure Authorities and Special Terms and Conditions Effective December 27, 2024

NUMBER: 11-W-00379/6

TITLE: Arkansas Health and Opportunity for Me Section 1115

Demonstration

AWARDEE: Arkansas Department of Human Services

This Attachment J is appended to the STCs effective December 27, 2024.

This Attachment J amends this demonstration, as approved on December 21, 2021 and as amended and restated on November 1, 2022, by adding the following language to the expenditure authorities and STCs, as further specified herein, for the remaining period of this demonstration from December 27, 2024 through December 31, 2026. Except to extent amended herein, existing expenditure and waiver authorities and Special Terms and Conditions (STCs) currently approved and set forth in this demonstration remain in full force and effect.

Amendment to Expenditure Authorities

This Attachment J hereby amends the expenditure authorities, as approved on December 21, 2021 and as amended and restated on November 1, 2022, to add the following authority. The following expenditure authority must only be implemented consistent with the approved STCs and shall enable Arkansas to implement the section 1115 demonstration amendment.

5. Expenditures for Non-Medical Transportation. Expenditures for non-medical transportation (NMT) not otherwise covered under title XIX of the Act for qualifying individuals, as described in STC 41 as well as other applicable STCs.

AMENDMENTS TO SPECIAL TERMS AND CONDITIONS

This Attachment J hereby amends the STCs, as approved on December 21, 2021 and as amended and restated on November 1, 2022, as follows.

- 1. This Attachment J amends STC 41, entitled "Allowable HRSN Services," by adding the following language as STC 41.d.
- d. Non-medical transportation (NMT) services may be provided to Medicaid beneficiaries who qualify for HRSN services under this demonstration. The NMT services transport the qualifying beneficiary to and from HRSN services which they are authorized to receive under this demonstration. Both the NMT services and the HRSN services for which NMT services are authorized must be described in the beneficiary's care plan. All NMT services must be provided in alignment with the technical specifications, and safeguards applicable to NMT authorized under 1915(c) waiver or under 1915(i) state plan authorities.
 - 2. This Attachment J amends STC 78, entitled "Medicaid Expenditure Groups," by adding a row to Table 3 as specified below. The remainder of STC 78 and Table 3 remains in full force and effect.

Table 3: Master MEG Chart							
MEG	Which BN Test Does Applies?	WOW Per Capita	WOW Aggregate	ww	Brief Description		
NMT	Нуро 1	X		X	Non-medical transportation for Medicaid beneficiaries eligible for HRSN services authorized under ARHOME whose care plan includes HRSN services.		

BN – budget neutrality; MEG – Medicaid expenditure group; WOW – without waiver; WW – with waiver

3. This Attachment J amends STC 79, entitled "Reporting Expenditures and Member Months," by adding a row to Table 4 as specified below. The remainder of STC 79 and Table 4 remains in full force and effect.

Table 4. MEG Detail for Expenditure and Member Month Reporting										
MEG (Waiver Name)	Detailed Description	Exclusions	CMS-64.9 or 64.10 Line(s) To Use	How Expend. Are Assigned to DY	MAP or ADM	Report Member Months (Y/N)	MEG Start Date	MEG End Date		
NMT	Report all expenditures for approved HRSN related transportation	See STC #41.d	Follow standard CMS 64.9 or CMS 64.10 Category of Service Definitions	Date of Service	MAP	Y	12/27/24	12/31/26		

4. This Attachment J amends STC 90, entitled "Hypothetical Budget Neutrality Test 1," by adding a row to Table 6 as specified below. The remainder of STC 90 and Table 6 remains in full force and effect.

Table 6. Hypothetical Budget Neutrality Test 1									
MEG	PC or Agg	WOW Only, WW Only, or Both	Base Year	Trend Rate	DY 01	DY 02	DY 03	DY 04	DY 05
NMT	PC	Both	2025	5.0%	-	-	-	\$35.30	\$37.07